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Abstract 
Lentiviral vectors (LVs) are successfully used in clinical trials showing long term therapeutic 
benefits. Studying the role of cellular proteins during replication of lentivirus HIV-1 helped to 
understand virus assembly and budding. Knowing what cellular proteins interact with viral 
proteins and identifying interactions that promote formation of functional particles can be 
valuable for improving LV production in Gene Therapy. 
The cellular protein composition of LVs produced by two different methods was compared, the 
transient transfection system producing vectors pseudotyped with the VSV-G envelope and a 
stable producer cell system producing vectors pseudotyped with the non-toxic retroviral 
envelope, RDpro.  
Lentiviral vectors were purified using size exclusion chromatography (SEC). The number of 
purified LVs produced by transient transfection was six fold higher compared to stably 
produced particles. For linear ion trap-orbitrap tandem mass spectrometry (LTQ-MS/MS) a 
comparable amount of SEC purified LVs was analysed, detecting a smaller number of cellular 
protein species in stably compared to transiently produced vector samples.   
The greater numbers of host proteins in purified transiently produced samples may due to the 
presence of co-purified VSV-G vesicles. On the other hand, a large number of proteins we 
identified had also been detected in studies of wild type viruses and HIV-1 derived vectors 
indicating a role in vector formation, such as viral protein transport to the assembly site in 
producer cells. The potential role in LV particle production of selected identified proteins was 
assessed. Whilst some proteins that have been detected in studies on wild type HIV-1 were 
found in all our samples, such as ALIX, AHNAK was unique to stably produced, RDpro 
pseudotyped vector samples, and thus selected for further investigation. In summary, knock 
down of ALIX, AHNAK and TSG101 host cell proteins in vector producer cells did not result in a 
significant difference in vector production.  
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1. Introduction 
1.1. General Introduction 
Gene therapy is defined by the American Society of Gene and Cell Therapy as a set of 
strategies that modify the expression of an individual’s genes or that correct abnormal genes. 
Each strategy involves the administration of a specific DNA (or RNA). The first gene therapy 
trial in humans was approved by the US Food and Drug Administration (FDA) in 1990 in which a 
retroviral vector was used to treat two children suffering from adenosine deaminase 
deficiency (ADA-SCID) (Bordignon et al., 1995). 
As of January 2014, over 60% of ongoing clinical trials are attempted to treat cancer, followed 
by monogenic disorders (9%) and cardiovascular diseases (8%). Most commonly is the use of 
adenoviral vectors (23.5%), retroviral vectors (19.1%) and naked plasmid DNA (17.7%). 
Lentiviral vectors have been used in 3.3% of all trials and are being used increasingly in newly 
started trials (The Journal of Gene Medicine, January, 2014).  
Increasing demands for the supply of lentiviral vector require improvements in the large scale 
vector production, which in turn calls for a detailed understanding of vector formation in 
producer cells such as interactions of host proteins with viral protein and viral RNA during 
assembly or budding. This thesis characterises lentiviral vector associated host proteins 
comparing two different vector production systems. This chapter is an introduction to basic 
lentivirology and the development of HIV-1 based lentiviral vectors including the pioneers of 
retroviral vector, gammaretroviral vectors, as well as transient and stable production systems 
of lentiviral vectors. 
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1.2. Biology of Lentiviruses 
1.2.1. Classification of Retroviruses 
Retroviruses are a family of enveloped viral particles containing two copies of positive (+) 
strand RNA that is reverse transcribed and integrated into the host cell genome. According to 
the International Committee on Taxonomy of Viruses (Lefkowitz et al., 2013) the family of 
Retroviridae is divided into two subfamilies Orthoretrovirinae and Spumaretrovirinae. The 
latter consist of only one genus, Spumaviruses, including various species of Foamy Viruses, for 
example Simian Foamy Virus.  
Orthoretrovirinae include the genera alpha-, beta-, gamma-, delta- and epsilonretroviruses as 
well as lentiviruses.  Lentiviruses consist of human immunodeficiency virus-1 (HIV-1) and HIV-
2, simian immunodeficiency virus (SIV) as well as equine infectious anaemia virus (EIAV) along 
with other non-primate viruses, for example feline immunodeficiency virus (FIV), bovine 
immunodeficiency virus (BIV) and caprine arthritis encephalitis virus (CAEV). 
As the lentiviral vectors used in this study are based on the lentivirus HIV-1, this introduction 
will focus on HIV-1 and HIV-1 derived lentiviral vectors as well as the, to this project related, 
retrovirus RD114, a replication-competent feline endogenous gammaretrovirus (Reeves and 
O'Brien, 1984). 
 
1.2.2. HIV-1 Genome and Life Cycle 
Human immunodeficiency virus-1 (HIV-1) evolved from a simian immunodeficiency virus (SIV) 
and emerged in the late 20th century. It is the causative agent of acquired immunodeficiency 
syndrome (AIDS) (Gojobori, et al., 1990).   
The viral genome of HIV-1 is a single-stranded RNA genome of approximately 9.7 kilobases and 
consists of nine genes that code for 15 proteins (Petropoulos, 1997). The three largest open-
reading frames are common to all retroviruses and code for the major structural proteins Gag 
polyprotein [matrix (MA), capsid (CA), p2, nucleocapsid (NC), p1 and p6], Pol polyprotein 
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[protease (PR), reverse transcriptase (RT) and integrase (IN)], as well as Env [subunits: surface 
glycoprotein (SU) and transmembrane protein (TM)]. In contrast to gammaretroviral vectors 
(see section 1.3.1), LVs are complex retroviruses as their genome carries six additional genes, 
the regulatory genes tat and rev that are essential for virus replication and genes encoding 
accessory proteins Vif, Vpr, Vpu and Nef thought to modulate immune functions (Swanson and 
Malim, 2008). The viral genome is flanked on either side with a long terminal repeat (LTR), in 
particular the 5’LTR being promoter for transcription and the 3’LTR ensuring polyadenylation. 
 
 
 
Figure 2: Integrated provirus of a HIV-1 (simplified). Adapted from (Swanson and Malim, 2008).  
Shown are: the long terminal repeats, 5’LTR and 3’LTR, each composed of U3, R and U5; open 
reading frames (light grey boxes) for Gag, Pol and Env proteins with their processed subunits, 
above or below, respectively. Att: integration attachment site, E: enhancer, P: promoter, cap: 
5’capping site, pA: polyadenylation site, PBS: primer binding site, Ψ: packaging signal, MA: 
matrix, CA: capsid, NC: nucleocapsid, PR: protease, RT: reverse transcriptase, IN: integrase, SU: 
surface, TM: transmembrane, cPPT: central polypurine tract, RRE: Rev responsive element, 
PPT: polypurine tract. Regulatory genes (black boxes) rev: regulator of expression of viral 
proteins and tat: trans-activator of transcription. Accessory genes (dark grey boxes) vif: virion 
infectivity factor, vpr: viral protein R, vpu: viral protein U, Nef: negative factor. Figure is not to 
scale. 
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1.2.3. HIV-1 Virus Structure 
HIV-1 virions contain the viral RNA genome, which is enclosed in a core structure surrounded 
by the envelope layer. Virions are on average 130 nm in diameter and contain approximately 
1500 to 2500 Gag molecules determined by scanning transmission electron microscopy (STEM) 
of HIV-1 virions (Zhu et al., 2003, Carlson et al., 2008). The core which is a homomultimer of 
capsid (CA) proteins lined by matrix protein (MA) encases two single stranded RNAs, the viral 
genome. The RNA genome is coated by the nucleocapsid (NC) and associates with the proteins 
reverse transcriptase (RT) integrase (IN), protease (PR) and the viral accessory protein Vpr 
(Briggs and Krausslich, 2011). The envelope membrane made of cellular lipoproteins is studded 
with about 8 to 10 glycoproteins, each formed of three heterodimers of the surface 
glycoprotein (SU, gp120) and transmembrane protein (TM, gp41) (Zhu et al., 2003).  
 
1.2.4. HIV-1 Entry 
In vivo HIV-1 infects predominantly CD4+ T cells and monocytes as well as macrophages. The 
surface glycoprotein gp120 determines this cell tropism and TM gp41 is responsible for 
merging of the viral and host membrane. Upon binding of gp120 to the CD4 receptor and its 
secondary receptor CCR5 or CXCR4, gp41 changes into its extended conformation revealing its 
ectodomain. The fusion peptide FP on the N-terminus of gp41 inserts into the host membrane 
followed by folding of gp41 into a hairpin and formation of a fusion pore with subsequent cell 
entry of the virus (Ashkenazi and Shai, 2011). Virions can enter the cell via clathrin-mediated 
endocytosis and low pH fusion with the endosomal membrane as documented by live cell 
imaging (Miyauchi et al., 2009).  
The cellular restriction factor rhesus macaque Trim5-α has been identified to reduce HIV-1 
infection of retroviruses in multiple ways, for example by acceleration of CA uncoating and 
thus prevention of reverse transcription (Black and Aiken, 2010). It has also been shown that 
Trim5-α can bind to CA of incoming retroviral cores and it was concluded that 
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autoubiquitinylation of Trim5-α results in subsequent degradation of the complex in the 
proteasome (Stremlau et al., 2004, Towers, 2007).  The exact mechanisms are not completely 
understood and Trim5-α can possibly execute its anti-retroviral activity in several redundant 
ways (Malim and Bieniasz, 2012).  
 
1.2.5. HIV-1 Reverse Transcription 
After entering the cell, the reverse transcription complex (RTC) containing the viral RNA 
genome and proteins travels via microtubules and actin filaments to the nucleus (McDonald et 
al., 2002) during which the viral genomic RNA (gRNA) is converted by reverse transcription into 
double stranded DNA. Reverse transcriptase (RT) synthesises DNA from the viral RNA genome 
and duplicates the LTRs to create the full proviral DNA genome.  
The HIV-1 gRNA is encompassed by the repeat region (R) on its 5’ and 3’ end, containing only 
one copy of each, U5 at the 5’ and U3 at the 3’ end. Minus strand DNA synthesis is initiated by 
binding of host cell primer tRNAlysine3 to the primer binding site (PBS) in the gRNA (Figure 2A) 
(Petropoulos, 1997). Viral genomic RNA (gRNA) is copied up to the 5’ end of the genomic RNA 
(also known as “minus strand strong stop DNA”) (Figure 2B). The RNase H activity of RT cleaves 
the 5’ end of the viral RNA and the short minus DNA strand is then transferred to the 3’ end of 
the gRNA to continue synthesis up to the 5’PBS (Figure 2C to E). The primer for the synthesis of 
the plus strand is generated by cleavage of the gRNA of the RNA-DNA hybrid and is derived 
from the polypurine tract region (PPT). A second plus-strand DNA synthesis is initiated at the 
central PPT (cPPT) (Figure 2F). Initially the plus strand DNA, originating at the PPT, is 
synthesised up to the methylated base, 1-methyl-adenosine, of the tRNA, followed by the 
removal of the PPT and tRNA primer by RNase H cleavage (referred to as “plus strand strong 
stop DNA”) (Figure 2G).  This initiates the second strand transfer of the “plus strands strong 
stop DNA” and plus and minus strand elongation continue until both strands are copied 
completely (Figure 2H to I). 
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Apart from host cell primer tRNAlysine3 cyclophilin A (CypA) is another host factor required for 
reverse transcription. CypA is a peptidyl prolyl cis/trans isomerase that catalyses the switch 
between cis and trans conformations of proline residue (Takahashi et al., 1989). In the context 
of the HIV-1 life cycle it has been shown that high amounts of CypA are packaged into virions 
during assembly in late stages of the replication cycle by binding to HIV-1 Gag (Franke et al., 
1994). Initially it was thought that CypA incorporated during assembly could influence HIV-1 
infectivity. Mutations in Gag lead to the loss of interaction of Gag with CypA in producer cells, 
resulting in reduced CypA incorporation but did not affect particle assembly and packaging of 
viral proteins or viral RNA (Braaten et al., 1996). T cells infected with CypA deficient virions 
contained lower levels of full length viral DNA compared to T cells infected with wild type Gag 
containing virions, hence a role of CypA in early stages of infection was suggested (Braaten et 
al., 1996). Later it was documented that CA interaction with CypA, originating in the infected 
cells, is more important, as knock down of CypA expression in producer cells did not affect HIV-
1 virion infection (Sokolskaja and Luban, 2006). APOBEC3G (apolipoprotein B mRNA editing 
enzyme-catalytic polypeptide-like 3G) was shown to be another cellular restriction factor. 
APOBEC3G deaminates C nucleotides of the minus-strand of viral DNA during vif-negative HIV-
1 replication (Harris et al., 2003). Recently it has been shown that eukaryotic elongation 
factors 1A and 1G (EEF1A1 and EEF1G) co-immunoprecipitate with RT and IN. SiRNA induced 
silencing resulted in lower reverse transcription levels as well as reduced levels of RTCs in 
those cells. It was suggested that EEF1A1 and EEF1G stabilise the RTC and stimulate late 
reverse transcription (Warren et al., 2012). 
Formation of a triple DNA strand during reverse transcription, the central DNA flap, a 99 
nucleotide overlap at the cPPT, (Zennou et al., 2000) has been shown to be involved in 
uncoating of CA from the newly formed DNA (Arhel et al., 2007). Recent data also suggests 
that uncoating and reverse transcription proceed in parallel potentially influencing each other 
(Hulme et al., 2011). The double stranded DNA complex is referred to as the pre-integration 
complex (PIC) and enters the nucleus via a nuclear pore.  
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Figure 3: HIV-1 reverse transcription.  Adopted from Onafuwa-Nuga et al. 2009. (A) The 
tRNAlys3 is bound to complementary sequences at the primer binding site (PBS) on the HIV-1 
genomic RNA (gRNA). (B) DNA minus-strand synthesis [(-)strand DNA] is initiated from primer 
tRNA and halts when it reaches the 5’ end of gRNA, resulting in “minus-strand strong-stop 
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DNA.” (C) RNase H degrades the template RNA strand. (D) First strand transfer: minus strand 
anneals to the 3’end of gRNA, complementary sequence in the R-region. (E) RNase H degrades 
gRNA up to PPT, minus-strand DNA synthesis continues. (F) Plus-strand DNA [(+) strand DNA] 
synthesis is initiated from oligoribonucleotides at PPT and cPPT. The plus-strand strong stop 
DNA results after synthesis stops at the first modified base in primer tRNA. (G) RNase H 
mediates removal of the tRNA primer. (H) Second strand transfer: plus-strand strong-stop DNA 
anneals at the 3’ end of plus-strand strong-stop DNA to complementary sequences at the end 
of the minus-strand DNA. (I) DNA synthesis is completed; double-stranded DNA with long 
terminal repeats and a central flap at the central PPT (cPPT) is generated. The continuous line 
represents viral genomic RNA, dotted lines represent viral DNA. Primer tRNA is shown as beta-
shaped form. 
 
1.2.6. HIV-1 Nuclear Entry and Integration 
Most gamma-retroviruses need the host cell to be in the cell cycle stage of mitosis to gain 
access to the nucleus through the dissolved nuclear membrane (Lewis and Emerman, 1994). 
Lentiviruses can infect both dividing and non-dividing cells and use the nuclear pore to enter 
the nucleus and access the chromatin (Suzuki and Craigie, 2007).  
The PIC associates with and actively enters the nucleus through the nuclear pore complex 
(NPC) (Arhel et al., 2007). Generally, import of a molecule into the nucleus through the NPC 
involves specific transport receptors such as importin (Kutay et al., 1997). The subunit of 
importin-α first recognises the nuclear localisation signal (NLS) on the molecule requiring 
nuclear import (cargo). After binding to importin-ß, the whole complex locates to the NPC. 
After translocation of PIC into the nucleus, the small Ran GTPase (RanGTP) associates with 
importin-β inducing the release of the cargo from the receptor complex into the nucleus 
(Suzuki and Craigie, 2007). The exact molecular mechanisms that determine how HIV-1 crosses 
the nuclear membrane are still under debate; however, it has been documented that several 
host factors can mediate nuclear import. Depletion of the nuclear pore protein nucleoporin 
(Nup) 358 decreased HIV-1 infection suggesting that Nup358 helps HIV-1 to dock at the nuclear 
pore (Schaller et al., 2011). A genome wide screen was performed using siRNA to knock down 
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protein expression in target cells. Knock down of Nup358, Nup153 and the nuclear transport 
factor transportin 3 (Tnpo3) in HeLa cells reduced HIV-1 infectivity (König et al., 2008). Other 
factors identified to promote nuclear import of HIV-1 are tRNAs (Zaitseva et al., 2006) as well 
as importin-7 (imp7) (Fassati et al., 2003).  
In the nucleus the viral DNA is integrated into the host cell DNA by the viral enzyme integrase 
(IN) that is associated to the viral DNA. IN binds to the attachment sites of the viral DNA LTRs, 
followed by an endonucleotide cleavage of the viral DNA 3’ends, called 3’ processing which 
allows cutting of the genomic cellular DNA and simultaneous joining of the viral DNA to the 5’ 
end of the target DNA (Krishnan and Engelman, 2012). It has been demonstrated that HIV-1 
favours integration within transcribed genes (Schröder et al., 2002) and that viral gene 
expression levels differ significantly between different integration sites (Jordan et al., 2001).  
 
1.2.7. HIV-1 Transcription 
Viral gene expression from proviral DNA is initiated by cellular transcription factors that allow 
low level expression of short RNA transcripts including an RNA loop at the R-U5 region in the 
5’LTR called the trans-activating response (TAR) element. These cellular transcription factors 
include nuclear factor kappa B (NF-kB) and transcription factor Sp1. NF-kB forms a complex 
with Sp1 by binding to the viral promoter in the U3 region of the 5’LTR. The short RNA 
transcripts are synthesised by the cellular RNA polymerase II (RNAPII) which pauses due to 
binding of negative elongation factors after transcription of the TAR loop and are not further 
elongated in the absence of Tat. Tat is a trans-activating provirus encoded protein interacting 
with TAR and can be expressed from a few fully elongated proviral transcripts in which RNAPII 
evaded pausing. As soon as sufficient amounts of Tat accumulate it can bind together with the 
cellular positive transcription elongation factor (P-TEFb) to TAR stem loop. This interaction 
allows P-TEFb to phosphorylate RNAPII, un-pausing the elongation and continuing the full RNA 
synthesis (Wu, 2004, Van Lint et al., 2013). 
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A combination of three reverse transcriptase inhibitors is the current treatment of HIV-1 
infections, called combination antiretroviral therapy (cART) (World_Health_Organization, 
2014). It is not fully effective in every patient and therapy interruption leads often to re-
emergence of detectable viral replication. This re-emergence has been accounted to 
transcriptionally silent proviruses forming a latent reservoir that is thought to be caused 
mainly by blockage of provirus transcription post-integration. The main reservoir of latent 
proviruses are resting memory CD4+ T cells, but macrophages and haematopoietic progenitor 
cells are also thought to contribute (Van Lint et al., 2013). 
 
1.2.8. HIV-1 RNA processing, Nuclear Export and Translation 
The HIV-1 genome has four splice donor sites close to the 5’ end of the genome (5’ splice sites) 
and eight splice acceptor sites (3’ splice sites). More than 40 different mRNAs are produced 
from the pre-mRNA whilst associated with the spliceosome. These mRNAs include four 
incompletely spliced mRNAs encoding Vpu and Env as well as incompletely spliced mRNAs 
encoding Vif, Vpr and a truncated form of Tat. Completely spliced mRNAs encode Rev, Nef and 
full length Tat. All mRNAs include the non-coding 5’cap to the first splice donor site (5’ss D1). 
To facilitate nuclear export of intron containing unspliced and incompletely spliced mRNAs the 
HIV-1 regulatory protein Rev is required. Rev interacts with the Rev-responsive element (RRE) 
in the env gene followed by binding of additional monomers of Rev leading to oligomerisation 
of Rev at RRE. For nuclear export through the nuclear pore Rev interacts with karyopherin 
family member exportin 1 (Crm1) in the presence of GTP-bound form of the Ran GTPase. Rev is 
released from the mRNA and re-enters the nucleus by binding to importin-ß. After 3’ 
processing and polyadenlyation translation of viral mRNAs is initiated. To allow translation of 
gag as well as pol, a -1 reading frame shift occurs at the ‘slippery’ sequence 200 nucleotides 
upstream of the gag termination sequence, shifting from the gag to the pol reading frame. 
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This occurs in 5% of translations of the unspliced mRNA resulting in one Gag-Pol precursor 
(Pr160Gag-Pol) for every 20 Gag precursors (Karn and Stoltzfus, 2012).      
1.2.9. HIV-1 Assembly 
The Gag polyprotein Pr55Gag mediates HIV-1 particle assembly. It has four structural domains 
that all contribute to the assembly process, matrix (MA), capsid (CA), nucleocapsid (NC) and 
p6. MA facilitates targeting Gag to the assembly site and binding of Gag to the plasma 
membrane (PM). Gag dimerisation is then provided by the Gag dimerisation domain in CA 
followed by multimerisation of Gag through binding to viral RNA, serving as a scaffold, and 
followed by encapsulation of the viral genomic RNA both mediated by NC. These events and 
incorporation of the viral Env glycoprotein and Gag-Pol precursor protein into the viral particle 
can take place simultaneously along with budding of the immature viral particle from the 
infected cell. The latter is stimulated by p6 recruiting the endosomal sorting complex required 
for transport (ESCRT) (Balasubramaniam and Freed, 2011). 
The identity of the HIV-1 assembly site is still under debate. Gag trafficking and the site of virus 
assembly, appear to be cell type dependent and are influenced by cell-cell interactions. It has 
been proposed that in macrophages HIV-1 particles accumulate in neutral-pH compartments 
(Jouve et al., 2007) connected to the PM by microchannels and are in fact invaginations of the 
macrophage PM (Deneka et al., 2007). Via these microchannels virions can be secreted into 
the cell surrounding or delivered to uninfected T cells via the virological synapse (Gousset et 
al., 2008). Another study suggests that the virions are assembled on late endocytic membranes 
(Pelchen-Matthews et al., 2003). During HIV-1 formation in tissue culture cell lines such as 
293T cells GFP-tagged Gag has shown to localise at the PM (Jouvenet et al., 2006).  
For targeting of Gag to the PM it binds to the highly basic region (HBR) at the surface of MA. 
This exposed the myristoyl moiety at the N- terminus of MA allowing it to be inserted into the 
lipid bilayer and stabilising the interaction between Gag and the cell membrane. The PM is rich 
in the anionic lipids, mainly phosphatidylserine (PS) and phosphoinositides (Saad et al., 2006) 
31 
 
resulting in an acidic cytoplasmid surface, allowing the basic residues in MA-HBR to interact 
with the acidic phospholipid PI(4,5)P2, a member of the phosphoinositides.  
Viral genomic RNA associates with NC of Gag during budding to be package into particles. The 
NC region also catalyses dimerisation of the viral gRNA as well as annealing of the cellular tRNA 
primer to the PBS of viral RNA, which happens possibly during particle assembly but the exact 
time point is not known (Feng et al., 1999).  
Unlike Gag and Gag-Pol, Env is not translated in the cytosol. It contains an endoplasmic 
reticulum (ER) signal sequence at its N-terminus and is synthesised on the rough ER (RER) 
being treated in the same way as proteins that are going to be secreted or membrane bound. 
After synthesis and glycosylation in the RER as a 160-kDa precursor protein (gp160) it 
oligomerises into trimers. Oligomers are transported to the Golgi and the trans-Golgi network 
(TGN), where they are cleaved by cellular proteases into mature SU glycoprotein gp120 and 
TM glycoprotein gp41. Noncovalently bound together they go through the secretory pathway 
to the PM where three molecules of each gp120 and gp41 form a heterohexameric HIV-1 
glycoprotein spike and incorporate into the virus particle, with about 8 to 10 spikes per virion 
(Checkley et al., 2011). 
The exact mechanism of how the Env glycoprotein complex is incorporated into the viral 
particle is under debate and currently there are four models. 1) The passive incorporation 
model suggesting that Env and Gag arrive independently at the PM and Env is incorporated 
due to its presence at the cell surface; 2) the direct Gag-Env interaction model in which gp41 of 
Env binds to the MA domain of Gag mediating Env incorporation; 3) the ‘Gag-Env co-targeting’ 
model suggesting a cellular structure such as the PM to which Gag and Env are both recruited; 
4) the indirect Gag-Env interaction model saying that Gag and Env interact with host cell 
proteins that serve as linkers or adapters helping to incorporate Env (Checkley et al., 2011). As 
many studies have shown that cellular proteins do interact with Gag and Env during HIV-1 
assembly these host proteins will be described in the next section. 
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1.2.9.1. Host Protein Interaction with HIV-1 during Assembly 
In addition to virus encoded elements, several cellular proteins have been identified that can 
increase or decrease the efficiency of viral assembly.  Gag and Env are recruited to the same 
PM site (for example a lipid raft) possibly by being connected at MA and gp41 C-terminus by a 
host protein. Several cellular proteins have been reported to interact with either or both Gag 
and Env proteins. Clathrin-associated heterotetrameric adaptor protein (AP) complexes assist 
normally in sorting and transporting of cellular cargo (Ohno 2006). AP-1 and AP-2 regulate the 
subcellular location of Env by binding to gp41 C-terminus (Berlioz-Torrent et al., 1999). AP-1u 
also binds Gag and silencing AP-1u by RNA interference showed a reduced Gag release in 
transfected cells (Camus et al., 2007). AP-3δ has been shown to help Gag trafficking to late 
endosomal compartments (Dong et al., 2005). The ATP-binding cassette protein family 
member 1 (ABCE-1) interacts with NC of Gag promoting its multimerisation at the PM (Dooher 
et al., 2007). TIP47, a protein involved in lipid droplet metabolism, was also shown to interact 
with Gag and Env and is required for their co-localisation in virus assembly (Bauby et al., 2012). 
Human discs large protein (Dlg1) is important in the assembly of multiprotein complexes. By 
binding to Gag Dlg1 modulates the subcellular distribution of Gag and HIV-1 infectivity (Perugi 
et al., 2009). Calmodulin can bind gp41 (Miller et al., 1993) however a clear role in HIV-1 
biology has not been established yet as calmodulin also binds MA of Gag inducing the 
exposure of the myristoyl moiety as seen in binding Gag to the cell membrane (Tang et al., 
2004). 
Env gp41 also interacts with a range of other proteins. So far the following have been 
described: α-cantenin (Kim et al., 2002), involved in actin filament assembly; the prohibitin 
family members Phb1 and Phb2 (Emerson et al., 2010), associated with mitochondrial 
functions and cell proliferation; Luman (Blot et al., 2006), a transcription factor involved in ER 
stress response and prenylated Rab acceptor (PRA1), mediating trafficking of Rab proteins in 
vesicles (Evans et al., 2002). Further analysis is necessary to decipher implications of these 
interactions on HIV-1 replication. 
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1.2.10. HIV-1 Budding 
The last phase of the virus assembly is budding from the cellular membrane involving 
membrane scission and particle release. The p6 domain in Gag recruits the endosomal sorting 
complexes required for transport (ESCRT). ESCRT serves in eukaryotes to deliver 
transmembrane proteins into the interior of endosomes for their eventual degradation 
(Raiborg and Stenmark, 2009). The ESCRT machinery consists of five heterooligomeric 
complexes: ESCRT-0, ESCRT-I, ESCRT-II, ESCRT-III and VPS4. The p6 domain in Gag has two 
binding domains for ESCRT complexes that are functionally equivalent in all retroviruses and 
referred to as “late assembly “or L domains. In HIV-1 the highly conserved PTAP motif within 
the C-terminus of p6 binds the TSG101 (Garrus et al., 2001) component of ESCRT-I and a 
second L domain in p6, LYPxnL binds ALIX (Strack et al., 2003) resulting in recruitment of ESCRT-
III that mediates membrane scission after bud formation (Weiss and Göttlinger, 2011).  
The plasma membrane contains microdomains that are enriched in sphingolipid, cholesterol 
and membrane anchored proteins, so called lipid rafts (Lingwood and Simons, 2010). Assembly 
and particle release of retroviruses including HIV-1 has been shown to take place at these 
microdomains (Ono, 2010). They compartmentalise cellular processes and are known to be 
involved in protein sorting, membrane trafficking and signal transduction (Simons and Ikonen, 
1997). It was demonstrated that cholesterol depletion in HIV-1 and SIV virions harvested from 
T cell lines resulted in permeabilisation of virion membrane and reduced infectivity indicating 
that cholesterol is needed for viral membrane integrity (Graham et al., 2003). 
1.2.11.  HIV-1 Maturation 
As viral particles are budding from the infected cell the viral protease (PR) cleaves polyproteins 
Gag and Gag-Pol into mature proteins. This leads to the formation of the conical core 
composed of the RNA dimer coated by the nucleocapsid. Nucleocapsids are encased in a 
capsid formed of a homomultimer of CA protein along with the enzymes RT and IN as well as 
Vpr (Briggs and Krausslich, 2011). 
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1.2.12. HIV-1 Cell-to-Cell Transmission  
HIV-1 virion transmission from cell to cell has been shown to be more efficient than infection 
by cell-free virions (Sattentau, 2008) and can help to evade an immune response such as 
neutralising antibodies or complement. In HIV-1 cell-to-cell transmission, the formation of 
structures such as virological synapses (VS) (Pearce-Pratt et al., 1994, Jolly, 2010) and 
nanotubes (Sowinski et al., 2008) between retroviral producing cells and target cells have been 
described. VS are similar to the immunological synapse formed during antigen presentation by 
antigen presenting cells (APCs) to T cells and are created  between APCs and CD4+ T cells but 
also between CD4+ T cells. Env glycoprotein is expressed on the infected cell and can interact 
with CD4 receptor and co-receptor CCR5 or CXCR4 on the target cell. Intercellular adhesion 
molecule 1 (ICAM1) and lymphocyte function-associated antigen 1 (LFA1) stabilise the bond. 
Recruitment of lipid rafts and polarisation of the secretary pathway, particularly the 
microtubule organising centre (MTOC) allows directing viral budding towards the target cell 
(Sattentau, 2008, Jolly, 2010).  
1.2.13. Association of Host cell Proteins with Released HIV-1 Virions 
Cellular proteins have been found to interact with viral proteins during particle formation. 
Some of these proteins can then be detected on the surface of the virus or within virions after 
they have been released from the infected cell. Studies that investigated proteins associated 
with HIV-1 virions can be used to identify new host cell proteins that could play a role in HIV-1 
replication.  
One approach to understand host cell protein and virus interactions is to purify secreted 
viruses and identify cellular proteins that are incorporated or on the virus surface. In density-
purified HIV virions vesicles have been detected that were similar in size and composition to 
co-purified HIV-particles (Bess et al., 1997, Gluschankof et al., 1997). Treatment of virus 
preparations with subtilisin can remove almost all of these vesicles. However this procedure 
also removes all other surface proteins leaving only proteins inside the particles intact. As 
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vesicles contain the protein CD45 but not HIV-1 virions, vesicles can be depleted by treatment 
with anti-CD45 antibodies and only HIV-1 particles remain in the sample (Ott, 2008).   
Biochemical analyses can only give total protein amounts, the distribution of proteins on 
individual particles cannot be measured as well as quantifying the population of virions that 
carries a specific protein. Studies to identify cellular proteins in HIV-1 have used also liquid 
chromatography-linked tandem mass spectrometry (LC-MS/MS) (Chertova et al., 2006, Saphire 
et al., 2006b). However the absence of a protein is not conclusive as an abundant protein can 
mask proteins present at a low level. Only sequences of statistical significance are considered 
which means that post-translational modifications, such as glycosylation that are highly 
variable can prevent detection by LC-MS/MS. A long list of proteins has been identified in HIV-
1 particles over the last years by various techniques. The AIDS and Cancer Virus Program 
within the National Cancer Institute (USA) published a web-based database 
(http://web.ncifcrf.gov/research/avp/) containing all cellular proteins that have been 
identified in HIV-1 virions with the methods mentioned above and can be continuously 
updated by the scientific community. Cellular proteins found in secreted HIV-1 virions with a 
defined role in HIV-1 assembly are described below.  
Certain proteins have been identified on the surface of virus particles. ICAM-1 (CD54), is 
known to interact with Gag shown by immunoprecipitation of the cellular protein on virus 
particles produced in 293T cells (Beauséjour et al., 2004). It is thought to stabilise HIV-1 
binding to target cells promoting virus binding. Other proteins on the HIV-1 surface are HLA-II, 
Galectin-1, CD80 and CD86 as well as LFA-1 which have been shown to increase infectivity (Ott, 
2008). Proteins that have been found inside HIV-1 virions include thioltransferase that 
removes glutathione from glutathionylated cysteine residues and can regulate protease 
glutathionylation of HIV-1 in vitro preventing its inactivation (Davis et al., 1997). The protein 
INI1/HSNF5 of the BAF (SWI/SNF) complex, normally responsible for remodelling of chromatin 
has been shown to be important for virion formation and infectivity (Sorin et al., 2006). 
Members of the heat shock protein (Hsp) 70 family, such as Hsp 70 and Hsp 90, have been 
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found in virion membranes produced by 293T cells by antibody detection and are thought to 
be integrated by Gag (Gurer et al., 2002) 
Some proteins are known to play an active role in HIV-1 replication such as ubiquitin that is 
taking part in particle budding and release. Members of the actin cytoskeleton and actin-
binding proteins have also been shown to be important in HIV replication. Experiments using 
fixed cell immunofluorescence labelling and confocal microscopy after inhibition of actin and 
tubulin could show reduced Gag release, infectivity and Env incorporation (Jolly et al., 2007). 
Another protein found to be integrated in purified virions is Staufen (Ott, 2002). Staufen is a 
cellular protein that is normally involved in cellular RNA localisation and was shown to interact 
with Gag during assembly (Chatel-Chaix et al., 2007). Staufen was also shown to bind to 
genomic HIV-1 RNA in virus producing cells (Mouland et al., 2000). When overexpressed in 
infected 293T cells its packaging into viral particles was increased as well as the amount of RNA 
encapsidation in each particle, however infectivity was not improved. In vivo Staufen 
potentially helps to incorporate RNA into viruses (Mouland et al., 2000). Cyclophilin A is 
incorporated into HIV-1 virions (Franke et al., 1994). CypA originating in the target cell is bound 
to CA and potentially determines the nuclear import pathway of HIV-1 post-infection (Schaller 
et al., 2011b). Members of the ESCRT pathway have been detected in HIV-1 virions and are 
known to help particle budding (see 1.2.10). Interestingly the HIV restriction factor, 
APOBEC3G, is actively excluded from particle packaging by the viral protein Vif (Mariani et al., 
2003). 293T cells, commonly used in viral vector production (see section 1.5) do not express 
APOBEC3G therefore there is no need to include Vif in vector production systems (Sheehy et 
al., 2002). 
 
1.2.14. Association of Host cell Proteins with Enveloped Viruses 
Several cellular proteins that have been identified in HIV-1 replication or are incorporated HIV-
1 virions have also been found in other enveloped viruses. Studies have been undertaken that 
37 
 
used mass spectrometry for protein detection. Analysed viruses include human 
cytomegalovirus (HCMV) (Varnum et al., 2004), Epstein-Barr virus (EBV) (Johannsen et al., 
2004), karposi’s sacromas-associated virus (KSHV or HHV-8) (Zhu et al., 2005) and influenza 
virus (Shaw et al., 2008).  Members of the annexin family and heat shock protein family were 
detected in all of these viruses as well as cyclophilin A (not in EBV) and actin. The actin binding 
protein cofilin was found in HCMV, EBV and influenza virus and its expression has shown to be 
modified in KSHV-infected endothelial cells (McAllister et al., 2004). Another actin-binding 
protein moesin was detected in HCMV and EBV. These studies are further discussed in chapter 
4. 
 
1.2.15. Brief Molecular Biology of Vesicular Stomatitis Virus and RD114 
Virus 
In this thesis the envelope protein from VSV and the modified form of the RD114 virus 
envelope protein, RDpro, have been used to pseudotype lentiviral vectors (see section 1.4.5) 
and a brief background of their life cycles as well as known cellular proteins in VSV and RD114 
is given. The envelope protein of the rhabdovirus vesicular stomatitis virus (VSV), VSV-
glycoprotein (VSV-G), is commonly used in lentiviral vector pseudotyping (see section 1.4.5), as 
it has a high transduction efficiency and can infect a wide range of host cells (Burns et al., 
1993). VSV encodes five proteins: the nucleocapsid protein (N), the phosphoprotein (P), the 
matrix protein (M), the glycoprotein (G), and the large polymerase protein (L). The viral core 
contains nucleocapsid (NC) enclosing the viral single stranded genomic RNA associated with 
the viral RNA polymerase (Barr et al., 2002). The low density lipoprotein (LDL) receptor has 
been identified as a receptor for VSV (Finkelshtein et al., 2013). The solubilised membrane 
phospholipid phosphatidylserine from Vero cells, kidney epithelial cells from African green 
monkey, was shown to saturate the binding site of VSV (Schlegel et al., 1983). Other 
investigators however did not see a correlation of phosphatidylserine cell surface levels and 
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VSV binding for various cell types (Coil and Miller, 2004). VSV enters cells by clathrin-mediated 
endocytosis, involving endocytic adaptor protein AP-2, Actin and Dynamin-2 (Johannsdottir et 
al., 2009, Cureton et al., 2009). The viral core is released into the cytoplasm after low pH-
dependent fusion of the viral envelope with the endosomal membrane. The viral RNA-
dependent RNA polymerase (RdRP) then transcribes copies of the viral RNA genome which are 
translated and new NCs are formed. NCs are transported towards the cell periphery along 
microtubules (Das et al., 2006). At the plasma membrane viral components assemble and bud 
from the cell. In a study on wild type VSV host cell proteins that are involved in virus infection 
were identified by genome wide RNA interference assay. Coatomer complex I (COPI), a protein 
complex involved in vesicular transport from the Golgi apparatus to the endoplasmic reticulum 
(ER) was identified and it was hypothesised that depletion of COPI negatively influences VSV-G 
protein transport  to the PM (Panda et al., 2011). Hence expression levels of this protein could 
influence vector production of VSV-G pseudotyped viral vectors. Cyclophilin A was shown to be 
required for VSV life cycle; overexpression of a mutant form of Cyclophilin A in infected cells 
resulted in reduced virus replication (Bose et al., 2003).  
RD114 is a replication-competent feline endogenous gamma-retrovirus. The receptor for RD-
114-type viruses in humans has been identified as sodium-dependent neutral amino acid 
transporter-type 2 (Tailor et al., 1999) and is also highly expressed on CD34+CD38- cells 
(Brenner et al., 2003) making RD114 glycoprotein suitable for pseudotyping of viral vectors 
targeting multipotential haemopoietic stem cells (HSC). It has been suggested that RD114-Gag 
recruits the ESCRT machinery to the PM for viral assembly similar to other retroviruses 
including HIV-1 (Votteler and Sundquist, 2013). RD114 budding was greatly inhibited by 
alanine substitution of the PPPY L-domain in pp15 of RD114-Gag (Fukuma et al., 2011). 
Literature search indicates that RD114 virion-associated host proteins have not been studied 
to date.  
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1.3. Gammaretroviral Vectors 
1.3.1. Gammaretroviral Genome and Particle Structure 
The integrated gammaretroviral provirus is flanked by two LTRs, composed of U3, R and U5. 
Viral transcription is initiated from the 5’U3 region containing the enhancer and promoter. 
Thus the viral RNA starts with the 5’R region, followed by U5, the primer binding site (PBS), the 
major splice donor (SD), the packaging and RNA dimerisation signal (Ψ). The latter is located 
upstream of viral protein encoding genes gag, pol and env and splice acceptor (SA) in pol. 
Downstream of env are the polypurine tract (PPT) and the 3’U3 and 3’R region. The 3’R region 
contains the polyadenylation site which gives the viral RNA a poly A tail resembling a cellular 
mRNA (Figure 3).  
Unspliced viral RNA will be packaged into particles along with viral proteins encoded by the 
open reading frames. These included the structural proteins matrix (MA), p12, capsid (CA) and 
nucleocapsid (NC) encoded by gag, proteins for virus replication, protease (PR), reverse 
transcriptase (RT) and integrase (IN) encoded by pol and the envelope protein. Proteins 
encoded by gag and pol are cleaved during virion maturation by the viral protease whereas 
Env is cleaved into surface (SU) and transmembrane (TM) by a cellular protease during 
transport to the assembly site in the Golgi apparatus (Maetzig et al., 2011). Compared to the 
complex lentiviral RNA genome, gammretroviruses have a simple RNA genome only encoding 
for Gag-Pol and Env and lacking genes encoding for accessory and regulatory proteins. Only 
one spliced mRNA encoding Env and no multiple spliced mRNAs are produced (Coffin et al., 
1997). 
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Figure 4: Integrated provirus of a gammaretrovirus (example MLV, simplified). Adapted from 
(Baum et al., 2006).  Depicted are the long terminal repeats 5’LTR and 3’LTR composed of U3, 
R and U5 and open reading frames (filled boxes) for Gag, Pol and Env proteins with their 
processed subunits shown below. Att: integration attachment site, E: enhancer, P: promoter, 
cap: 5’capping site pA: polyadenylation site, PBS: primer binding site, SD: splice donor, Ψ: 
packaging signal, SA: splice acceptor, PPT: polypurine tract, MA: matrix, CA: capsid, NC: 
nucleocapsid, PR: protease, RT: reverse transcriptase, IN: integrase, SU: surface, TM: 
transmembrane. Figure is not to scale. 
 
1.3.2. Development of Gammaretroviral Vectors 
1.3.2.1. Split Packaging Design 
Retroviruses insert their viral genome into cells they infect followed by expression of the viral 
proteins, hence they can be exploited as a delivery vehicle for therapeutic genes to target cells. 
The therapeutic gene is also referred to as the gene of interest (GOI) and is inserted into the 
viral genome. Research on retroviruses for their use as gene therapy vectors started in the 
early 1980s (Mann et al., 1983) and since then several modifications to the original viral 
genome have been made. The development of retroviral vectors as a gene delivery system has 
been especially focused on increasing their safety for their use in clinical trials. To avoid 
generation of replication competent retroviruses (RCR) by homologous recombination or 
template switching during reverse transcription the split packaging design was developed. The 
viral genome is divided and expressed from three separate DNA plasmids. Two plasmids 
express the viral genes gag-pol and env, respectively, from a promoter. The third plasmid, the 
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transfer vector, expresses the therapeutic gene flanked by LTRs harbouring the PBS. The Gag-
Pol backbone is devoid of the packaging signal Ψ and vector coding sequences and only the 
vector genome RNA that contains the packaging signal Ψ is packaged into vector particles. 
 
1.3.2.2. Further Improvements in Vector Safety and Efficiency  
The conventional transfer vector contains a transgene cassette flanked by two LTRs.  
Expression from RNA transcripts in producer cells starts and ends with R regions as 
transcription termination is ensured by a polyadenylation in the 3’R region. After transduction 
of target cells with the produced vectors the 3’U3 region is copied to the 5’LTR during reverse 
transcription (section 1.2.5).  
Several potential scenarios using this vector design raised safety issues. If transduced cells are 
infected with wild-type retroviruses, after transduction with a retroviral vector with full length 
LTRs, the HIV-1 wild-type virus could act as a helper virus and package the integrated vector 
into new viral particles spreading them beyond the target cells. Another issue can be the 
activation of cellular genes including oncogenes from the strong enhancer and promoter in 
5’U3 region. These concerns led to the first development of an MLV based self-inactivating 
(SIN) vector containing a deletion of 299 base pairs in the 3’U3 region, including the enhancer 
and promoter sequences (Yu et al., 1986). Later on problems with this design were identified. 
The deletion of this large part of the 3’U3 region increased the probability of read-through of 
transcription in MLV-SIN  and HIV-1 -SIN vectors beyond the R’ region, suggesting that U3 
contains termination enhancer motifs in addition to enhancer and promoter sequences (Zaiss 
et al., 2002). To circumvent this safety risk the heterologous polyadenylation enhancer 
element derived from simian virus 40 (SV40) was introduced in the 3’ deletion to act as a 
termination enhancer (Schambach et al., 2007). Furthermore SIN-gammaretroviral vectors 
were of lower titers compared to those with full length LTRs (Schambach et al., 2006) 
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In order to find the optimal gene expression level and produce high titer vectors several other 
modifications have been made. Early γ-RVs expressed the transgene from the 5’LTR, 
harbouring enhancer and promoter sequences in the U3 region. In improved variants the 
gammaretroviral U3 region was replaced with those of spleen-focus forming virus (SFFV) 
showing higher transgene expression (Baum et al., 1995). The introduction of a minimal splice 
acceptor oligonucleotide into the HIV leader sequence creates an artificial intron, downstream 
of the 5’LTR and upstream of the transgene, which was also shown to increase GOI expression 
(Hildinger et al., 1999). Retroviral vectors can be combined with envelope proteins of other 
viruses, so called pseudotyping, mediating target cell specificity. A more detailed description is 
outlined in the context of lentiviral vector pseudotyping in section 1.4.5.  
 
1.3.3. Gammaretroviral Vectors in Gene Therapy Trials 
1.3.3.1. Severe Combined Immunodeficiency (SCID)  
1.3.3.1.1. ADA-SCID  
ADA-SCID is caused by mutations in the enzyme adenosine deaminase (ADA). Ubiquitously 
expressed in all tissues of the body, ADA converts the toxic metabolites deoxyadenosine and 
adenosine from broken down DNA and RNA, respectively. ADA deficiency leads to the 
accumulation of these toxic metabolites resulting in impaired development of functional T, B 
and natural killer (NK) cells. The symptoms of the resulting severe combined 
immunodeficiency (SCID) are repeated and persistent infections from early childhood onwards 
and can ultimately lead to death when left untreated. Besides allogenic haematopoietic stem 
cell transplantation (HSCT), enzyme replacement therapy (ERT) in the form of PEG-ADA 
intramuscular injections is the treatment of choice. Alternatively gene therapy treatment was 
first tested in the early 1990s. 
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In early trials a γ-RV was used encoding an ADA-minigene in the 3’ LTR to result in two 
expression cassettes per integrated vector after duplication of the 3’LTR U3 during reverse 
transcription (Hantzopoulos et al., 1989). Autologous bone marrow (BM) cells and peripheral 
blood lymphocytes (PBL) were transduced and injected intravenously. One year after the 
treatment PBL-derived cells containing the vector declined and were progressively replaced by 
BM derived gene-marked cells (Bordignon et al., 1995). In this patient, PEG-ADA treatment was 
continued so that clinical benefits due to gene therapy treatment were difficult to determine. 
Another trial showed that PEG-ADA discontinuation led to preferential expansion of gene-
marked T cells containing the ADA gene (Bordignon et al., 1995). 
In a later trial two patients, for whom PEG-ADA was financially not available, were treated with 
the γ-RV GIADAl encoding ADA cDNA under the control of the LTR. Transduction of autologous 
HSC after mild pre-conditioning resulted in reconstituted T cell proliferative response and 
normalised serum immunoglobulin levels in both patients with no respiratory infection up to 
12 months after treatment (Aiuti et al., 2002). Eight additional patients were treated. Follow 
up studies showed that a high percentage of transduced T, B and NK cells between 54% and 
88% showed successful reconstitution of the immune system one year after treatment. After a 
median follow up of four years, eight out of a total of ten treated patients did not need PEG-
ADA therapy any longer. A polyclonal T cell receptor repertoire implied that no clonal 
dominance had occurred that is normally caused by vector insertions near cellular proto-
oncogenes (Aiuti et al., 2009). Five more patients have been treated with this protocol and all 
fifteen patients were well with only two patients requiring ERT after gene therapy (Ferrua et 
al., 2010). 
In a trial in the UK six patients were treated with nonmyeloablative conditioning and γ-RVs 
delivering human ADA cDNA driven by the SFFV LTR. These vectors also contained woodchuck 
hepatitis virus (WHP) posttranscriptional regulatory element (WPRE) for increased transgene 
expression. After a median follow up of 43 months, metabolic detoxification in three patients 
with sustained ADA expression from different haematopoietic lineages and functional gene-
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marked T cell levels were observed. Two patients had to restart ERT permanently due to graft 
failure. Similar insertions into the MDS1 and EVI1 complex (MDS-EVI1) locus, encoding a 
transcriptional regulator and oncoprotein, like in the CGD trial (see section 1.3.3.2) were seen 
(Stein et al., 2010). So far adverse effects such as the development of leukaemia due to vector 
mediated insertional mutagenesis have not been seen in any of the patients (Gaspar et al., 
2006, Gaspar et al., 2011).  
To date all of the ADA-SCID gene therapy patients worldwide survived the treatment and an 
overall efficacy shown by cessation of ERT in more than 70% of patients (Gaspar, 2012) has 
been documented. Nevertheless, all the conducted trials used γ-RVs with intact viral 
promoters that are known to have caused insertional mutagenesis in other gene therapy trials 
(Stein et al., 2010, Hacein-Bey-Abina et al., 2008) and therefore treated individuals will need to 
be closely monitored in the future. To reduce the possibility of γ-RVs insertional mutagenesis 
SIN lentiviral vectors are tested as an alternative. A multicentre trial is ongoing using a SIN-LV 
under the control of the short form of the elongation factor1α promoter (EFS) (Mukherjee and 
Thrasher, 2013). 
 
1.3.3.1.2. X-linked SCID 
X-linked SCID accounts for 50% to 60% of all reported SCID cases and is caused by mutations in 
the common gamma chain (yc) gene a subunit shared by several cytokine receptors (IL2, 4, 7, 
9, 15, and 21R, located on the X-chromosome. Patients are unable to develop T and NK cells 
and have defective B cells (Fischer, 2000) resulting in recurrent infection of the respiratory and 
gastrointestinal tracts and the failure to thrive (Buckley et al., 1997). Bone marrow 
transplantation is the only available treatment providing a partially or fully matched donor is 
available. 
The first clinical trial for X-linked SCID in Paris included 10 patients treated with autologous 
bone marrow derived CD34+ cells transduced with a moloney murine leukaemia retroviral 
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vector (MLV-RV) delivering yc cDNA driven by the MLV LTRs (MFGyc vector) (Hacein-Bey et al., 
1996, Cavazzana-Calvo et al., 2000, Hacein-Bey-Abina et al., 2002). No adverse events were 
observed up to one year after gene therapy. T cell levels were normal in six patients, however 
four patients developed T-cell acute lymphoblastic leukaemia (T-ALL), of which one patient 
died. Insertional analysis showed that cells of those four patients harboured vectors at 
predominant integration sites near the transcription start site of the proto-oncogenes LIM 
domain only 2 (LMO2), G1/S-specific cyclin-D2 (CCND2) or Polycomb complex protein (BMI1) 
(Hacein-Bey-Abina et al., 2008). The latest follow up study 8 to 11 years after treatment on 
eight of the patients shows that all are well including one individual that had received HSCT 
(Hacein-Bey-Abina et al., 2010). 
A second trial was conducted in London with ten patients receiving autologous bone marrow 
derived CD34+ cells transduced with the same vector used in the Paris trial but pseudotyped 
with gibbon-ape leukaemia virus (GALV) envelope instead of amphotropic MLV. Twelve to 29 
months after treatment of the first four treated patients all had normal T cell counts, 
detectable but low levels of NK cells and no adverse effects were observed (Gaspar et al., 
2004). Within two years of gene therapy one out of a total of ten treated patients developed T 
cell acute lymphoblastic leukaemia (T-ALL). Peripheral blood cell analysis identified a single 
insertion near the transcription start of the proto-oncogene LMO2 resulting in its 
overexpression as well as that of neighbouring genes. Expression changes of other genes were 
also observed, such as down-regulation of tumour suppressors p14(ARF1) and p16(INK4a) and 
overexpression of leukaemia associated NOTCH1 suggesting that a combination of genetic 
changes additionally to insertional mutagenesis contributes to the development of leukaemia 
in this patient (Howe et al., 2008). The same vectors (MFGyc pseudotyped with GALV or 
amphotrophic MLV) were used in separate trials in London and Paris as well as the USA in five 
older patients (10 to 20 years) but did not show any clinical benefits (Thrasher et al., 2005, 
Chinen et al., 2007).   
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In summary, X-linked SCID can be successfully treated by gene therapy however the 
development of leukaemia required further vector development and a shift to using lentiviral 
vectors (see section 1.4.1). 
 
1.3.3.2. Chronic granulomatous disease (CGD)  
Chronic granulomatous disease (CGD) is a rare primary immunodeficiency characterised by 
severe and life-threatening bacterial and fungal infections and tissue granuloma formation 
caused by deficient antimicrobial activity of phagocytes. This defect is caused by mutations in 
any of the five genes encoding phagocytic oxidase forming the nicotinamide dinucleotide 
phosphate (NADPH) oxidase complex.  
In the USA a total of thirteen patients with CGD was treated with γ-RVs encoding phagocytic 
oxidase with or without pre-conditioning however only 0.13% of CD34+ cells were gene-
corrected and enzyme activity declined after 8 months resulting in no long-term clinical 
benefits (Malech et al., 1997, Malech, 2000, Kang et al., 2010, Mukherjee and Thrasher, 2013). 
In another two trials in Germany and Switzerland, pre-conditioning with busulfan was used 
before gene therapy in two patients per trial with X-linked CGD (Ott et al., 2006, Stein et al., 
2010, Bianchi et al., 2009, Bianchi et al., 2011). In one trial up to 50% of total neutrophils in 
patients peripheral blood contained the integrated γ-RV encoding the gp91phox gene driven by 
spleen focus forming virus (SFFV) derived LTR. This was found to be caused by clonal expansion 
of cells with vectors inserted into oncogenic loci MDS-EVI1, PRDM-16 and SETBP1 (Ott et al., 
2006) and both patients developed myelodysplasitic syndrome (MDS), characterised by the 
ineffective production (or dysplasia) of the myeloid cell lineage. Furthermore methylation of 
the retroviral promoter caused loss of oxidase function (Stein et al., 2010). In the second trial 
one patient developed MDS and the second patient showed clonal expansion of transduced 
neutrophils (Mukherjee and Thrasher, 2013). 
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In patients treated in London less than 10% of neutrophils carrying the transduced gene were 
detected and became undetectable by day 42 post treatment (Mukherjee and Thrasher, 2013). 
Two patients treated in Seoul had only 0.2 to 0.9 % of gene corrected cells in peripheral blood 
one year after treatment (Kang et al., 2011). A clinical benefit after treatment in some of the 
patients is encouraging for the use of gene therapy in CGD patients however apart from 
improvements in the level of gene-marked cells, improvements in vector design need to be 
undertaken to avoid integration into sites near to or within transcription starts of proto-
oncogenes.  As an alternative to γ-RV lentiviral vectors are being tested in a currently ongoing 
trial of CGD sponsored by Genethon, for the treatment of 20 patients over 4 different sites, 
including the UK, Germany, Switzerland and France (Genethon, 2013, ClinicalTrials.gov, 2013).  
 
1.3.3.3. Wiskott Aldrich Syndrome (WAS) 
Wiskott-Aldrich syndrome (WAS) is a primary immunodeficiency with mutations in the WAS 
gene. WAS regulates the cytoskeleton and WAS-deficiency deregulates proliferation and 
activation of immune cells leading to recurrent infections, autoimmunity, thrombocytopenia 
(low platelet count) and lymphoid malignancies. Ten patients were treated using a GALV-
pseudotyped γ-RV with full length LTRs following preconditioning. An initial report showed 
restored gene expression and a proportion of corrected lymphocytes as well as reduced 
frequency and severity of infections  (Boztug et al., 2010) however seven patients developed 
leukaemia and insertional integration and transactivation of proto-oncogenes MDS1-EVI1, 
PRDM16, LMO2 and CCND2 was observed (Braun et al., 2014).  
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1.4. Lentiviral Vectors 
1.4.1. Advantages of Lentiviral over Gammaretroviral Vectors 
In recent clinical trials LVs are being used preferentially over γ-RVs as they have several 
advantages. Integration profile analysis of patient’s samples treated with γ-RVs showed that 
they tend to integrate close to the transcription start site and near or into proto-oncogenes as 
shown by analysis of integration sites by linear-amplification mediated PCR (LAM-PCR), 
sequencing unknown DNA flanking sequences, in CGD patients (Ott et al., 2006). It is generally 
accepted that the enhancers and promoter sequences in 5’U3 region of the integrated provirus 
in target cells in these vectors transactivate these oncogenes leading to clonal expansion that 
resulted in leukaemia in some patients. Integration site analysis results of the latest clinical 
trial using LVs in patients with Wiscott-Aldrich syndrome (WAS) showed that these vectors 
cluster in gene-rich regions and integrate within transcriptional units but integration sites 
covered a wide variety of biological categories and did not dominate proto-oncogenes (Aiuti et 
al., 2013). Follow up of patients showed similar integration site profiles compared to results of 
an earlier X-linked adrenoleukodystrophy (ALD)-trial using LVs (Cartier et al., 2009) without 
clonal expansion or leukaemia. Furthermore γ-RVs can only infect cells that are going through 
mitosis, hence are proliferating (Lewis and Emerman, 1994). When using γ-RVs HSCs need to 
be induced using a cocktail of cytokines and other growth factors to enter cell cycling prior to 
transduction (Cornetta et al., 2008). In contrast LVs can transduce non-dividing cells (Naldini et 
al., 1996) by entering through the nuclear pore. Additionally LVs have a larger transgene 
capacity and are suitable to deliver large therapeutic genes. Insert with a size of up to 14 kb 
have been tested however titers reduce with increased insert size (Kumar et al., 2001). 
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1.4.2. Lentiviral Vectors in Gene Therapy Trials 
1.4.2.1. Acquired Immunodeficiency Syndrome (AIDS) 
Lentiviral vectors have been used the first time in a clinical trial for the treatment of Acquired 
Immunodeficiency Syndrome (AIDS) starting in 2003. Autologous CD4+ T cells from AIDS-
patients were transduced with a lentiviral vector, named VRX496, carrying an antisense 
sequence of HIV env (Lu et al., 2004) in order to decrease viral load and increase the number of 
CD4+ T cells (MacGregor, 2001). In a follow up study, one year after treatment, transduced 
cells could engraft in all five patients resulting in an increased number of CD4+ T cells in four 
patients and a decrease in viral load in one out of five patients (Levine et al., 2006). By 2013 
another 60 patients have been treated with VRX496. Clinical follow up results of eight patients 
of whom records of viral loads before treatment with combination antiretroviral therapy 
(cART) were available were published. Following infusion of VRX496 transduced autologous T 
cells patients were taken off cART and as expected the viral load increased, but stayed below 
levels before cART treatment in six out of eight patients. A high variability in persistence of 
gene-modified PBMCs was seen with a maximum of 10% in two patients (Tebas et al., 2013). 
For a more informative outcome follow up results of all patients need to be seen. 
1.4.2.2. X-linked Adrenoleukodystrophy (ALD) 
Lentiviral vectors were also used for the treatment of X-linked adrenoleukodystrophy (ALD), a 
severe brain demyelinating disease. Mutations in the ABCD1 gene lead to a deficiency in ALD 
protein, an adenosine triphosphate–binding cassette transporter that helps to degrade very 
long chain fatty acids (VLCFAs) in oligodendrocytes and microglia. In patients with mutations in 
the ABCD1 gene VLCFAs accumulate in the peroxisomes of these cells disrupting myelin 
maintenance. In a clinical trial two patient’s autologous CD34+ haematopoietic progenitor cells 
were transduced with lentiviral vectors delivering the wild type ABCD1 cDNA expressed from 
the MND promoter (myeloproliferative sarcoma virus enhancer) (Cartier et al., 2009). Twenty 
months post-transplantation of the transduced CD34+ cells VCLFA levels were reduced 20% 
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and 28% in patient 1 and 2 respectively. Of all peripheral blood mononuclear cells (PBMCs) 
10% and 15% still expressed vector delivered ALD after 30 months of treatment. Integration 
site analysis by linear amplification mediated (LAM)–PCR showed insertions into the same 
gene or genomic region in two or more individual cell clones, termed common integration sites 
(CIS) however no haematopoietic clones dominated.   
1.4.2.3. Beta-Thalassaemia 
Another clinical trial with clear therapeutic benefits after using lentiviral vector gene therapy 
has been undertaken in two patients with beta-thalassaemia. Beta-thalassaemia is a group of 
blood disorders caused by mutation of the HBB gene encoding human ß-globin. These 
mutations can be hetero- or homozygous resulting in reduced or absent levels of ß-globin 
polypeptide chains in red blood cells leaving them unable to bind α-globin chains to ß-globin 
chains to form haemoglobin A. The current treatment options for beta-thalassaemia are 
regular blood transfusions or HSC transplantation. In the gene therapy trial patients were 
transplanted with autologous CD34+ cells carrying a ß-globin gene variant, βA(T87Q) which had 
been delivered by lentiviral vector transduction. Beta-globin protein derived from the gene 
variant will be distinguishable in the patients’ blood during treatment follow up studies. One 
patient failed to engraft the transplanted CD34+ cells due to the technical handling of the cells 
(Cavazzana-Calvo et al., 2010). The follow up study of the second patient up to three years 
after treatment showed that nucleated blood cells increased to 11% and left him transfusion 
independent with stable levels of haemoglobin one year post-treatment. Clonal expansion of 
cells with vector integrated into the cell genome at the high mobility group protein locus, 
HMGA2 had been observed without evidence of leukaemia development (Cavazzana-Calvo et 
al., 2010). However, six years after the trial this clone is not dominant anymore and ß-globin 
expression is still sufficient for the patient to remain transfusion independent (Leboulch, 
2013). 
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1.4.2.4. Metachromatic Leukodystrophy (MLD)  
Metachromatic leukodystrophy (MLD) is an early onset neurodegenerative lysosomal storage 
disorder caused by mutations in the ARSA gene, resulting in a deficiency of the enzyme 
arylsulfatase. The enzyme substrate sulfatide accumulates in cells of the central nervous 
system (CNS) and Schwann cells and macrophages of the peripheral nervous system (PNS). In 
2010, a clinical trial phase I/II was undertaken treating 10 children with ARSA deficiency with 
gene therapy (Verma, 2013). The results of three patients are reported.  A third generation 
lentiviral vector (LV) (see section 1.4.3) delivering the correct form of the human ARSA cDNA 
under the control of phosphoglycerate kinase (PGK) promoter (Biffi et al., 2013) was used. 
After pre-conditioning treatment using myeloablative bulsufan autologous bone marrow 
derived CD34+ cells transduced with the LVs were re-administered. A high-level of stable 
engraftment was achieved with 40% to 80% of bone-marrow derived haematopoietic colonies 
containing the vector. Common insertion sites were found to be the same as in the ALD HSC-
GT trial (Cartier et al., 2009) confirming a preference for integration within transcriptional 
units. However, no clonal dominance was seen in these patients. Gene expression of functional 
ARSA was reconstituted to above normal levels. Follow up from 18 to 24 months showed that 
two patients remained asymptomatic and the third patient’s pre-existing severe peripheral 
neuropathy improved after the therapy (Biffi et al., 2013).  
1.4.2.5. Wiskott Aldrich Syndrome (WAS) 
As described in section 1.3.3.3, Wiskott-Aldrich syndrome (WAS) is a primary 
immunodeficiency with mutations in the WAS gene. Coordinated by the same institute that 
undertook the MLD trials, gene therapy using lentiviral vectors was applied in six patients with 
WAS, the results of three patients are reported. After pre-conditioning to deplete endogenous 
HSCs, LV-transduced autologous CD34+ cells were re-administered. LVs were self-inactivating 
(see section 1.3.2.2) delivering the correct form of human WAS under the control of the WAS 
promoter (Aiuti et al., 2013). Engraftment levels of 25% to 50% in HSC in the bone marrow 
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were achieved. WAS protein expression was restored to normal levels as well as 
immunological responses such as T cell proliferation and NK cell cytotoxic activity. Analysis of 
IS showed a preference for transcriptional units and gene dense regions and similar CIS in 
comparison to the ALD trial. No clonal dominance was detected 6 to 18 month after 
treatment. Pre-treatment eczema dissolved after 6 to 12 months of treatment and frequent 
infections decreased.    
1.4.2.6. Acute Lymphoid Leukaemia 
Two children with acute lymphoblastic leukaemia (ALL) were treated with T cells transduced 
with LVs delivering the chimeric antigen receptor CTL019 including a CD137 (4-1BB) signalling 
domain. Transduced T cells expressed a modified receptor able to kill CD19 expressing tumour 
cells. Complete remission of ALL and robust expansion of CTL019 expressing T cells was 
observed in both patients without clonal expansion of a dominant T cell receptor clone and 
was ongoing in one patient up to 11 month follow up. The third patient had a relapse of 
leukaemia with CD19 negative tumour cells showing that in some patients more than one 
target molecule needs to be delivered to decrease the likelihood of emergence of CD19 
negative escape cells (Grupp et al., 2013). 
1.4.2.7. Parkinson’s Disease  
Recently the result of a first clinical trial using a lentiviral vectors for the treatment of 15 
patients with Parkinson’s disease have been published (Palfi et al., 2014).  A VSV-G 
pseudotyped tricistronic EIAV-based vector, named ProSavin (Oxford BioMedica, Oxford, UK), 
was administered in vivo into the striatum of the brain targeting postmitotic neurons. Vectors 
delivered the rate-limiting dopamine biosynthetic enzymes tyrosine hydroxylase, aromatic L-
amino acid decarboxylase (AADC) and cyclohydrolase driven from CMV and two IRES, 
respectively.  Sustained transgene expression was reported. Follow up studies at 12 months 
showed mild drug-related adverse events, with the majority being increased dyskinesias 
(involuntary muscle movements), which resolved after reduction of the oral dopaminergic 
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medication suggesting an efficacious dopaminergic therapy. No severe adverse events were 
reported. Twelve month post-treatment significant improvement in motor function was seen 
in all patients and follow up for up to four years after treatment showed long-term tolerability. 
However these results need to be treated with caution as no placebo group was included in 
this trial and all positive effects of this study were within the placebo range that has been 
reported in other clinical trials for Parkinson’s disease using surgical techniques (Palfi et al., 
2014). 
 
1.4.3. Development of Lentiviral Vectors 
In the early 1990s studies on HIV-1 viruses were carried out in which HIV-1 produced from viral 
genes expressed from two separate DNA plasmids, one plasmid encoding HIV-1 provirus with a 
deletion in env and a second DNA plasmid encoding Env protein. These early vectors could 
transfer non-viral genes that were inserted into the proviral plasmid. The viral nef gene was 
replaced by the chloramphenicol acetyltransferase (CAT) gene conferring drug resistance to 
the target cell (Helseth et al., 1990). Since then a range of other improvements have been 
designed making LVs not only more efficient and safer but allowing them to be used in a wider 
range of therapeutic applications, as described below. 
The first generation of lentiviral vectors split the viral genome into three plasmids. The 
packaging plasmid contains gag-pol and regulatory as well as accessory genes expressed from 
a strong viral promoter. Vpu and env genes were deleted. HIV-1 gp120 was replaced by VSV-G 
or amphotropic MLV Env and expressed from a separate plasmid. The 3’LTR in the packaging 
and Env plasmids were replaced by the polyadenylation site of the insulin gene. The transfer 
vector contained, as opposed to the other two plasmids, a packaging signal as well as both 
LTRs and RRE, the latter for increased export of mRNA mediated by Rev binding to RRE. Only 
the transgene is expressed from this construct and no viral genes (Naldini et al., 1996). In the 
second generation LV system most accessory genes, including vif, vpr, vpu and nef were 
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deleted from the packaging construct as they were shown not to be necessary for vector 
production in 293T cells (Zufferey et al., 1997, Kim et al., 1998). In the third generation LV 
packaging system tat was removed and rev provided from a separate, fourth, DNA plasmid. Tat 
independence was achieved by replacing the enhancer and promoter sequences in the 5’U3 
region with a strong viral promoter, such as the RSV or CMV promoter. This increased vector 
safety considerably by reducing the number of viral genes to three and lowering the likelihood 
of generation of replication-competent HIV-1 like viruses as for this at least three 
recombination events were necessary (Dull et al., 1998, Kim et al., 1998). 
Vector production and performance can be improved by further modifications of the DNA 
sequences used in vector packaging systems. Transduction efficiency can be increased when 
the central polypurine tract (cPPT) derived from pol is included into the transfer vector 
upstream of the transgene expression cassette and it was suggested to have a positive 
influence on vector nuclear translocation (Follenzi et al., 2000). Insertion of the woodchuck 
hepatitis virus posttranscriptional regulatory element (WPRE) downstream of the transgene in 
HIV-1 as well as MLV-derived vectors increases transgene expression by increasing the amount 
of unspliced RNA in target cells. The exact mode of action of WPRE has not been fully 
elucidated but is likely to be at the posttranscriptional stage such as nuclear export of viral 
mRNAs (Zufferey et al., 1999). The HIV-1 genome contains AU rich sequences that destabilise 
the viral mRNA and was first found in HIV-1 gag (Schwartz et al., 1992). Codon optimisation of 
HIV-1 Gag-Pol eliminates AU-rich sequences increasing Gag-Pol expression, resulting in a Rev 
independent packaging system (Kotsopoulou et al., 2000). 
A problem for the efficiency of gene therapy is the silencing of provirus expression caused by 
epigenetic changes, such as CpG methylation, rather than mutations in the vector genome 
DNA (Ellis, 2005). It was suggested that vector silencing can either occur immediately after 
integration and takes place in the majority of proviruses or occurs long term after stable vector 
expression (Mok et al., 2007). To circumvent potential silencing events insulators have been 
used. An insulator is a DNA sequence that is able to block the activation of a promoter by an 
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enhancer when placed between the two, preventing gene activation or silencing as described 
for the 250 bp sequence of the 5’ end of the chicken hypersensitive site-4 (cHS4) insulator. To 
avoid effects of the enhancers around the LV integration site on transgene expression an 
insulator has been introduced into the 3’LTR of the transfer vector increasing transgene 
expression (Chung et al., 1997). A minimal sequence of 400 bp of the 3′cHS4 sequence was 
shown to increase transgene expression levels by two-fold in murine hematopoietic stem cells 
(HSCs) compared to vectors without insulators (Arumugam et al., 2007). Aside from the 
problem that HS4 integration into transfer vectors reduces vector titers, in human HSCs only 
minimal effects on transgene expression could be seen (Uchida et al., 2011). Nevertheless, 
minimal HS4 sequences have been used in LVs for transduction of CD34+ cells in the ß-
thalassemia-trial. No dominant clones were present after long term follow up (Leboulch, 2013) 
although there is no evidence that this absence is due to the barrier function of HS4 insulators. 
In another study a 650 bp HS4 sequence (a combination of the 250 and 400 bp sequence 
described above) and synthetic scaffold attachment regions (SARs) combined in the 3’LTR of 
SIN-LVs have been tested. These insulated LVs were used to transduce human embryonic stem 
cells (hESCs) and increased and prolonged transgene expression as well as reduced expression 
variability compared to LVs without the chimeric insulator were seen with minimal effects on 
vector titers (Benabdellah et al., 2014). 
Locus control regions (LCRs) and ubiquitously acting chromatin-opening elements (UCOEs) are 
genetic regulatory elements that have been exploited to increase transgene expression in LVs. 
The LCR within the human ß-globin gene (HBB) specifically regulates the HBB family. In LVs for 
the treatment of ß-thalassemia, ßLCR segments have been used to enhance gene expression of 
the mini-HBB gene (May et al., 2000). UCOEs were identified in the human housekeeping 
HNRPA2B1-CBX3 locus and consist of 5’ dual divergently transcribed promoters separated by a 
methylation-free CpG island. A2UCOEs, derived from the human HNRPA2B1-CBX3 locus, can 
be employed to drive expression of transgenes and have been shown to be superior to SFFV- 
or CMV promoter driven GFP expression within cells of peripheral blood cell lineages as well as 
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bone marrow derived HSCs after ex vivo transduction and transplantation in mice. 
Furthermore it was shown that A2UCOEs can express therapeutic levels of the IL2RG gene 
delivered by ex vivo transduction of HSCs and transplantation in the mouse X-linked SCID 
model (Zhang et al., 2007). A follow-up study documented that A2UCOEs can prevent 
transgene silencing in murine pluripotent embryonic carcinoma stem cells up to 44 days 
compared to SFFV-driven expression which was silenced after 17 days (Zhang et al., 2010). In a 
recent study aberrant splicing of LV-initiated transcripts driven from A2UCOE has been 
described that can potentially cause insertional mutagenesis. Clones were selected in which 
LVs, driving GFP from A2UCOE, integrated into the cellular growth hormone receptor gene 
(Ghr) in order to study effects of A2UCOE on the expression of the neighbouring gene Ghr. 
Fusion mRNAs of A2UCOE and Ghr were detected and were shown to be derived from the 
native or cryptic splice donor sites within the A2UCOE and Ghr. Point mutations in the A2UCOE 
splice donor sites could abolish the aberrant splicing potentially preventing this insertional 
mutagenesis effect (Knight et al., 2012). 
To reduce the risk of insertional mutagenesis integration-deficient lentiviral vectors (IDLVs) 
have been developed. Typically they have mutations in the integrase gene (IN) with mutations 
in the catalytic core residues of IN gene resulting in integration deficient viral DNA (Leavitt et 
al., 1996). Mutations in the 5’LTR-U3 and 3’LTR-U5 attachment sites have also resulted in 
integration deficient vectors (Masuda et al., 1998). A study using IDLVs showed that these 
vectors can transduce post-mitotic cells such as retinal pigment epithelium (RPE) and neuronal 
cells in rodents in vivo and showed similar transduction efficiencies compared to integrase-
proficient vectors. Furthermore functional rescue in an in vivo mouse model of retinitis 
pigmentosa was achieved by subretinal injection of IDLV making them attractive for 
application in clinical trials (Yanez-Munoz et al., 2006). Zinc-finger nucleases (ZFNs) are hybrid 
restriction enzymes linking a cleavage domain (FokI) to a designed zinc-finger protein (ZFP). 
ZFN heterodimers, made from two different ZFNs, can be used for site specific double-strand 
break by binding to the target site followed by homology-directed repair (HDR) through the 
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presence of a donor sequence delivered to the cell alongside two different ZFNs (Miller et al., 
2007). IDLVs have been used to deliver ZFNs and a donor DNA sequence in the same vector. 
The donor sequence contains a silent point mutation resulting in the insertion of a novel 
restriction site and correction of the endogenous sequence with the donor-encoded sequence 
by HDR. This was shown in different human including haematopoietic progenitors targeting 
the human IL-2 receptor common gamma-chain (IL2RG) locus. This study proved that delivery 
and correction of a transgene in a specific genomic site of non-dividing cells can be achieved 
eliminating the risk of insertional mutagenesis (Lombardo et al., 2007). Potential off-target ZFN 
activity and long term re-population and differentiation studies will be required to assess its 
safety.  
So far, no replication competent lentiviruses (RCLs) have been reported from using second or 
third generation packaging systems, however there is a risk of formation of replication RCLs 
caused by homologous recombination of sequences that are shared in transfer and packaging 
plasmid (Sakuma et al., 2012). One of these sequences is the encapsidation signal extending 
from Ψ into the 5’ part of gag. The first 40 nucleotides of gag are introduced upstream of the 
transgene expression cassette in transfer vectors for its optimal packaging (Luban and Goff, 
1994). Other homologous sequences in transfer and packaging plasmids include cPPT derived 
from pol and RRE, both being potential sites for homologous recombination. 
Other developments in lentiviral vector design widen the range of their potential clinical 
application. The concept of using LVs as a vaccine has been reported in mice challenged with 
an Ova-tumour cell line. LVs transduced murine dendritic cells (DCs) deliver the SFFV driven 
OVA antigen (Ova-LVs). Targeting the MHC II presentation pathway the transduced DCs were 
shown to stimulate Ova-specific CD8+ T cells. Ova-LVs could also activate Ova-specific CD4+ and 
CD8+ T cells after direct injection (Rowe et al., 2006). Furthermore maturation of DCs through 
NF-κB activation in mice could be induced by LVs delivering the adjuvant vFLIP from kaposi's 
sarcoma-associated herpesvirus (Rowe et al., 2009). Using lentiviral vectors as a vaccine means 
vectors will be applied in larger group of patients than in currently treated small cohorts of 
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patients with comparably rare diseases. To meet supply demands large scale vector production 
needs to be established. In search of a non-toxic alternative to VSV-G Env (see section 1.4.5) 
other envelope proteins need to be found. Lentiviral vectors pseudotyped with the envelope 
protein of alphavirus Ross river virus (RRV-LVs) were characterised in terms of their suitability 
to infect murine and human DCs in vitro and immunise mice in vivo. RRV-LVs could transduce 
murine and human DCs as well as stimulate human T cells, however a 50 fold higher dose of 
RRV-LVs than of LVs pseudotyped with VSV-G was required to generate a comparable T cell 
response (Lopes et al., 2011). Other envelope proteins for pseudotyping of LVs are described in 
section 1.4.5. 
 
1.4.4. Non-HIV-1 Lentiviral Vectors 
Efficient gene transfer into dividing and non-dividing cells of HIV-2- (Poeschla et al., 1998) and 
simian immunodeficiency virus (SIV)-derived vectors (Negre et al., 2000) has been reported as 
safer alternatives to HIV-1 vectors. HIV-2 is less pathogenic in humans. Replication and 
encapsidation deficient HIV-2 based vectors with a deletion in the packaging and env sequence 
as well as replacement of the 3’LTR with the bovine growth hormone poly A sequence were 
produced. It was shown that these vectors could transduce non-dividing cells such as 
terminally differentiated human macrophages and human neuronal cell culture model neurons 
(NTN2) but did not show ß-galactosidase or GFP transgene expression in human CD34+ CD38- 
hematopoietic progenitor cells (Poeschla et al., 1998). VSV-G pseudotyped-SIV-based LVs were 
constructed that were comparable to a third-generation HIV-1 packaging system, being tat-
independent, devoid of env accessory genes vif, vpx and vpr as well as the 3’LTR, which was 
replaced with SV40 polyA. These vectors were able to transduce human 293 as well as mature 
and immature DCs (Negre et al., 2000). In another study gene transfer and expression of SIV-
based vectors were tested on X-CGD patients’ cells. SIV-derived RD114/TR pseudotyped 
vectors, equivalent to the vector design of third generation HIV-1 based vectors were shown to 
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transduce ex vivo CD34+ PBMCs from X-CGD patients delivering the human gp91phox  (Naumann 
et al., 2007). These vectors could be a potential safer alternative to HIV-1 based LVs once their 
application in other diseases has been further investigated. 
Further developed towards clinical applications are non-primate lentiviral vectors derived from 
equine infectious anaemia virus (EIAV) or feline immunodeficiency virus (FIV). Non-primate 
lentiviral vectors have been proposed to be a safer alternative to HIV-1 based LVs as they 
cannot replicate in human cells in case of the development of replication competent viruses. 
For example the functional receptor of FIV is feline CD134 on CD4+ T cells but not human 
CD134 (Shimojima et al., 2004). Non-primate lentiviral vectors have been developed including 
EIAV-based vectors pseudotyped with various envelopes such as VSV-G or RVG (Mitrophanous 
et al., 1999).  Preclinical safety studies of VSV-G pseudotyped EIAV-based Tat independent LVs 
for the treatment of age-related macular degeneration and juvenile macular dystrophy 
showed that these vectors were well tolerated and localised to the site of administration 
(Binley et al., 2012, Binley et al., 2013). Recently published results of the first clinical phase 1/2 
trial have been published using VSV-G pseudotyped EIAV-based vectors for the treatment of 
Parkinson’s disease (Palfi et al., 2014) (see section 1.4.2.7). 
 
1.4.5. Viral Vector Pseudotyping  
Pseudotyped lentiviral vectors, like other retroviral vectors, have been developed in 
combination with heterologous envelope proteins. Envelope proteins from different viruses 
recognises each a specific cellular receptor hence the pseudotype of a retroviral vector 
determines the cell type it can transduce, also called the vector tropism. The vesicular 
stomatitis virus glycoprotein (VSV-G) has been the most commonly used envelope for lentiviral 
vectors due to its high stability, wide host range and cell tropism (see section 1.2.14). 
Disadvantages of VSV-G for the use in vector pseudotyping were reported in comparison with 
other envelopes including amphotropic murine leukaemia virus (MLV-A) Env, a modified 
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gibbon ape leukaemia virus (GALV+) Env and two modified RD114 envelope proteins.  VSV-G 
Env was sensitive to inactivation by human complement and of lower resistance to freeze-
thawing when harvested in serum-free media (Strang et al., 2004). VSV-G is also known to be 
cytotoxic at high concentrations and during long-term expression, hence not suitable for the 
use in a stable producer cell line (Sakuma et al., 2012).  
Targeting a specific cell type can be achieved by using alternative envelope proteins. Relander 
et al. (2005) tested pseudotyped lentiviral vectors for the transduction of haematopoietic stem 
cells (HSC) with various gammaretroviral envelopes including amphotropic MLV 4070 A, the 
modified envelope RDpro derived from feline endogenous virus RD114, and the GALV Env with 
an MLV cytoplasmic tail (GALV+) produced by the STAR cell line. Vectors bearing RDpro gave 
the best transduction efficiency in CD34+ cells compared to the other retroviral envelopes. 
RDpro is an improved form of the RD114 envelope, when used in vector packaging, producing 
higher titers of vectors compared to its wild type form. To create RDpro the R peptide cleavage 
site was replaced by a matrix-capsid cleavage site from HIV-1 Gag (Ikeda et al. 2003) which was 
predicted to increase R peptide cleavage by HIV-1 protease, thought to be a crucial condition 
for viral host cell entry.  
LVs incorporating Edmonston measles virus (MV) glycoproteins haemagglutinin (H) and fusion 
protein (F) (H/F-LVs) could transduce completely resting B (Frecha et al., 2009) and T cells 
(Frecha et al., 2008) without prior stimulation. Certain envelope proteins can also alter 
intracellular behaviour of viral vectors. Pseudotyping EIAV derived vectors with rabies virus 
glycoprotein (RVG) allows retrograde transport of vectors along motor neuron cell axons 
(Mazarakis et al., 2001). Transduction efficiency could be improved by about 25-fold in using a 
chimeric RVG-VSV-G envelope in comparison to RVG pseudotyped HIV-1 derived LV. The 
chimeric envelope is comprised of the RVG receptor-binding domain by replacing the 
cytoplasmic, transmembrane and extracellular stalk regions of RVG with the corresponding 
regions from VSV-G (Carpentier et al., 2012). 
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1.5. Viral Vector Production: Transient Transfection 
For the production of lentiviral vectors 293T cells are most commonly used as they are highly 
transfectable (Pear et al., 1993). They are derived from human embryonic kidney (HEK) cells 
transformed with sheared adenovirus type 5 DNA (Graham et al., 1977). The modified form 
293T cells, stably expressing the SV40 T-large antigen (T-Ag) facilitate the replication of 
plasmids containing a SV40 replication origin. Depending on which viral vector generation is 
used transient transfection involves adding DNA plasmids at a defined ratio for most efficient 
transfection. Plasmids include the transfer vector, packaging and envelope constructs as well 
as plasmids for regulatory genes (in third generation systems) to the packaging cells in 
combination with a transfection reagent such as calcium-phosphate or lipid-based reagents.  
Traditionally calcium-phosphate precipitation (Ca2PO4) has been used during which 
precipitates of calcium-phosphate bind to DNA plasmids. However, this method has several 
disadvantages as the transfection efficiency can vary depending on factors such as the density 
and general condition of the cells influencing transfection efficiency. Factors easier to control 
during transfection with Ca2PO4 precipitation is the formation of calcium phosphate 
precipitates. The concentration of calcium and phosphate as well as the pH of the transfection 
buffer affects the size of formed precipitates which in turn defines their capacity to bind DNA. 
Precipitate stability after addition to the culture medium is dependent on the pH of the culture 
medium (Jordan and Wurm, 2004).  
Alternatively to Ca2PO4 precipitation the polyethylenimine (PEI) based transfection method can 
be used and gives higher yields of infectious particles compared to Ca2PO4 precipitation 
(Segura et al., 2007, Toledo et al., 2009) but optimisation of PEI ratio to DNA amounts is 
required in order to form PEI-DNA complexes (Reed et al., 2006). Commercially available lipid-
based transfection reagents, such as Fugene®, have been used in lentiviral vector production 
(Kosaka et al., 2004) and allow reproducible and efficient transfections as they are less pH 
dependent. They also require less than one-third of the DNA amounts compared to the Ca2PO4 
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method (Coleman et al., 2003). Transient transfection results in temporary or transient 
expression of viral genes and vector particles are normally produced over a short period of five 
to six days before cells begin to detach and die (Segura et al., 2013). Cell factory systems 
(Nunc, ThermoScientific) or HYPERFlaskTM (Corning) have been used to scale up vector 
production. Alternatively transient transfection using PEI in a suspension-growing clone of 293 
cells (293E) can produce lentiviral vectors in bioreactors with a capacity of 3 litre (Segura et al., 
2007). This method however, requires large amounts of reagents as well as DNA plasmids and 
consistency between production batches is less easily to control than in stable producer cells. 
On the other hand transient transfection provides flexibility in vector particle construction 
avoiding the development of a stable producer cell line which can take several months. 
 
1.6. Stable Vector Production Systems 
Currently most lentiviral vectors used in clinical trials are produced by transient transfection. 
However, cell lines that have viral components stably integrated into their genome, stable 
producer cells, would be preferable for large scale vector production. Large batches of vectors 
with high reproducibility and of consistent quality at low costs can be generated. The use of 
virus producing cell lines (VPCLs) or packaging cell lines (PCLs) can avoid: 1) the risk of 
recombination between transfected plasmids, 2) medium contamination with DNA plasmids 
that can co-purify with vectors and need to be removed during downstream processing and 3) 
variability between batches in transient transfection. Producer cell lines stably express trans-
acting vector elements including Gag-Pol, Env and, if the third generation LV production 
system is used, Rev.  
Production of high amounts of infectious vector particles for clinical trials by a PCL has shown 
to be difficult as a sufficient level of constitutive HIV gag-pol expression is hampered due to its 
toxicity to producer cells (Kräusslich 1992). Other components such as Rev (Miyazaki et al. 
1995) and vesicular stomatitis virus-G protein (VSV-G) (Burns et al. 1993) have also been 
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shown to be cytotoxic to producer cells if over-expressed. This promoted the development of 
cell lines with inducible expression of viral elements, for example tetracycline-regulated 
promoters. In the Tet-off system the expression of more than one viral gene can be controlled. 
In a study using this system the vector genome was transduced with transiently produced LVs 
(Klages et al., 2000). 293G cells express tetracycline transactivator protein (tTA) constitutively 
as well as VSV-G Env under the control of a tetracycline-inducible promoter. To allow indirect 
controlled expression of Gag-Pol, 293G cells were stably co-transfected with HIV-1 Gag-Pol and 
Rev. Rev expression is driven by the tet operator (tet O) fused to a minimal CMV promoter 
forming the tetracycline response element (TRE). In the absence of tetracycline or its 
derivative doxycycline tTA binds to tetO activating transcription of Rev. Rev expression in turn 
controls the expression of Gag-Pol since Gag-Pol transcripts are exported from the nucleus 
only in the presence of Rev and otherwise degraded in the nucleus. Hence, removal of 
tetracycline (or doxycycline) from the cell culture medium induced Gag-Pol expression. The 
Tet-off system for expression of Gag-Pol as well as VSV-G Env by tetracycline induction was 
also used in another PCL with introduction of the transfer vector by several rounds of infection 
(Farson et al., 2001).  
A disadvantage of inducible systems is that they require the removal of tetracycline or 
doxycycline from the culture medium which is not practical in large scale vector production. 
Other inducible transcription systems, like the Tet-on and the cumate switch, have been 
applied that require addition of an inducer to the growth medium (Broussau et al. 2008). In 
this stable producer cell line regulation of VSV-G env is achieved by using a Tet-on system that 
requires the addition of doxycycline (Dox) for expression. Rev expression is regulated by using 
the cumate switch inducible system derived from the p-cym operon of Pseudomonas putida 
based on the addition of the inducer cumate to the culture medium. A disadvantage of this 
system is that Dox and cumate remain in the vector containing cell supernatant and their 
removal during downstream vector purification is required. On the other hand this PCL can 
also grow in medium without the addition of serum and was cultivated in suspension for large 
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scale vector production. Avoiding serum in the vector production systems has the advantage 
of cost reduction and removal of fewer impurities during vector purification. An inducible 
lentiviral packaging cell line based on equine infectious anemia virus (EIAV) for Parkinson’s 
disease was developed successfully based on VSV-G env and EIAV gag-pol expression induction 
by the addition of Dox to the cell culture medium producing vectors with stable titer for 7 
weeks (Stewart et al., 2009) and up to 16 weeks (Stewart et al., 2011). None of the inducible 
lentiviral vector producer cell lines have been used in clinical trials so far. Transient 
transfection allowed production of adequate amounts of vectors for the treatment of small 
patient groups.  In other cell lines shortcomings of the induction system have been 
documented including high basal expression of uninduced promoter and insufficient levels of 
activation of the inducible promoter (Ni et al., 2005). 
Using an alternative approach for stably introducing vector packaging components the 
continuous HIV-1 packaging cell line STAR has been developed in the laboratory at UCL (Ikeda 
et al. 2003). In 293T cells high expression of HIV-1 Gag-Pol was achieved by introducing a 
codon optimised gag-pol expression cassette (Kotsopoulou et al. 2000) into the cells by 
retroviral vector transduction and selection of a high expression locus. Stable expression tat 
and rev, was achieved by the same method, transduction with MLV gammaretroviral vectors 
with full 3’LTR and internal CMV promoters driving expression of the viral gene. As described 
in section 1.4.5, VSV-G Env is not suitable for stable expression in a producer cell line. For 
selection of an alternative viral envelope several gammaretroviral envelopes were compared, 
including amphotrophic MLV 4070A (Ampho), RDpro and GALV+. GALV+ is a GALV Env with an 
MLV cytoplasmic tail and RDpro a modified form of RD114 glycoprotein with the R cleavage 
site replaced by the HIV-1 protease cleavage site (Ikeda et al., 2003) increasing efficiency of 
envelope processing during maturation of vector particles. Titers of up to 8.5x106 transducing 
units per ml could be achieved when transducing STAR-RDpro cells with the non-self-
inactivating (non-SIN) vector genome HV delivered by a HIV-1-VSV-G pseudotyped vector, 
creating STAR-RDpro-HV cells. Among vectors pseudotyped with different envelope proteins 
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GALV+ or Ampho MLV vectors pseudotyped with RDpro Env showed the best transduction 
efficiency. In comparison to transiently produced vector particles pseudotyped with VSV-G 
Env, STAR-RDpro produced less infectious particles per p24 ng, however titers are still 
sufficiently high for producing lentiviral vectors for clinical trials. STAR-RDpro cells require 
further improvement before they can be used for clinical grade production. The two main 
problems with the current design are 1) the 293T clone used for production of these cells is 
non-traceable and 2) HIV gag-pol is packaged into virions (Ikeda et al., 2003). Currently an 
improved form of STAR cells is under development considering these aspects. Generally, the 
development of STAR-RDpro has shown that LVs can be stably produced without the need for 
an inducible system for HIV-1 gag-pol or viral envelope expression. 
The above described cell lines generate non-SIN LVs are not suitable for many clinical 
applications (see section 1.4.3). Transduction of a SIN-vector genome into the producer cell 
genome is not applicable since the duplication of the deletion in the 3’LTR region during 
reverse transcription would leave the integrated provirus promoterless preventing the 
expression and packaging of the vector genome into vector particles. Transient transfection of 
a SIN-vector genome does result in lower vector titers compared to vectors produced by 
transduction of a non-SIN-vector genome (Ikeda et al., 2003). To circumvent this problem a 
conditional SIN (cSIN) vector was designed. In cSIN vectors the 3’U3 region enhancer and 
promoter sequence is deleted and replaced by a tetracycline response element (TRE) initiating 
transcription of the vector genome RNA upon tTa binding. However improvement of the cSIN 
vector genome sequence is required as a basal expression of the full vector genome RNA was 
detected even in the absence of tTa in target cells (Xu et al., 2001).  
To achieve high transgene expression the vector genome can also be introduced by site 
specific integration. This system allows the stable integration of the SIN vector genome 
construct into a predefined locus. Using the FRT-flp system, a high expression locus in the 
producer cells is tagged followed by RMCE with a targeting vector (Schucht et al., 2006). This is 
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achieved by co-transfection of the Flp-tagged cells with a targeting vector encompassed by FRT 
sites (the SIN-vector genome) and a DNA plasmid expressing the tagging site specific 
recombinase flipase. 
In the LV packaging cell line GPRG-TL20-GFP, the introduction of the SIN vector genome (see 
section 1.4.3) into producer cells was achieved by concatemeric array transfection technique 
(Throm et al., 2009). Vector components, Gag-Pol, Rev and Env were introduced sequentially 
by transduction with γ-RVs, in which rev expression was controlled by the tet-off system. 
Finally, the vector genome was transfected using a concatemeric array. These arrays are two 
linked vector genome expression cassettes and are regulated by doxycycline allowing 
increased transgene expression in combination with the safety of a SIN vector genome design. 
The concatemeric array transfection technique was also used by others confirming that this 
system can produce SIN-LVs of high titers with ~107 transducing units per ml cell supernatant 
(Lee et al., 2012). 
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1.7. Aim of Thesis 
The project outlined in this thesis was aimed to identify possible protein-protein interactions 
between host and lentiviral vectors (LVs) in an attempt to elucidate which of these proteins 
might be important for vector particle production, focusing on particle assembly and budding 
from the producer cell. LVs are being used for the treatment of relatively rare diseases, 
including primary immunodeficiencies and neurodegenerative diseases but also increasingly 
for applications such as cancer therapy that will target diseases with a higher prevalence. 
Furthermore promising results of early clinical trial stages will allow the use of LVs in larger 
cohorts of patients in clinical trial stages III and IV. This development is leading to an increased 
demand in vector material and requires improvement in vector production methods to 
produce large batches of vectors with high infectious titers. This in turn would benefit from a 
good understanding of vector particle formation within the producer cell.  
Characterisation of cellular protein interactions with viral proteins, in particular identifying 
interactions that promote production of functional particles, could potentially help advance 
viral vector production. This investigation set out to contribute to a better understanding of 
vector biology. LV samples were produced by the transient transfection method, currently 
used for vector preparation in clinical trials, pseudotyped with the widely applied VSV-G. 
Alternatively stably produced RDpro-pseudotyped vectors were prepared by the packaging cell 
line STAR-RDpro. Following vector purification by size exclusion chromatography (SEC), 
subsequent protein content analysis by liquid-chromatography mass spectrometry (LC-MS/MS) 
was applied in order to find differences and similarities in host cell protein composition 
between vector samples. To identify proteins that might be involved in vector assembly in 
293T or 293T-derived STAR-RDpro cells selected proteins were knocked down in producer cells 
by siRNA for further analysis of their function on vector production.  
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2. Materials and Methods 
2.1. Cell Culture 
HEK293T (293T) cells are derived from 293 human embryonic kidney cells and express the 
SV40 large T-antigen (Graham et al., 1977). The stable producer cell line, STAR-RDpro-pHV 
(Ikeda et al., 2003), is derived from 293T cells by transduction with MLV vectors delivering the 
codon optimised HIV-1 gag/pol (Kotsopoulou et al., 2000), tat and rev each driven by a 
cytomegalovirus (CMV) promoter and stably transfected with the gammaretroviral envelope 
RDpro. The vector genome encoding a green fluorescent protein (GFP) expression cassette 
driven by the spleen focus-forming virus (SFFV) promoter and is stably integrated in the STAR-
RDpro-pHV cells after transduction with a HIV-1 derived vector (Ikeda et al., 2003). For stable 
production of LVs without genomic RNA, the STAR cell line STAR-RDpro is used which does not 
contain a vector genome. All cell lines were maintained in Dulbecco’s modified Eagle medium 
(DMEM) (Sigma-Aldrich, Gillingham, UK) completed by the addition of 10% fetal calf serum 
(Appleton Woods, Birmingham, UK), 2 mM L-glutamine, 100 units/ml penicillin, 100 μg/ml 
streptomycin (all by Sigma-Aldrich). Cells were usually passaged every 48 or 72 hours at a ratio 
of 1:10 or 1:20, respectively. 
 
2.2. Amplification and Purification of DNA plasmids 
2.2.1. Preparation of Chemically Competent Bacteria Cells 
Chemically competent Escherichia coli (E.coli) XL1-Blue (Stratagene, Santa Clara, CA, USA) were 
prepared for transformation with DNA plasmids. Bacteria were streaked on an LB agar plate 
containing 12.5 µg/ml tetracycline (both by Sigma-Aldrich) and incubated overnight at 37°C. 
The next day a single colony was picked and grown overnight in 4 ml Luria Bertani (LB) medium 
(Lennox) (Sigma-Aldrich) with 12.5 µg/ml tetracycline. After 8 hours incubation on a shaker 
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(300 rpm) at 37°C 100 ml of LB medium (without antibiotics) were inoculated with 1 ml of the 
overnight culture and incubated on a shaker at 37°C for approximately 2.5 hours or until OD600 
was between 0.3-0.6. After cooling of the culture on ice for 5 minutes and centrifugation at 
6000 x g for 10 minutes (4°C) the bacteria pellet was resuspended in 50 ml TBF-1 (30 mM of 
potassium acetate, 100 mM potassium chloride, 10 mM calcium chloride, 50 mM manganese 
chloride, 15% glycerol; all by Sigma-Aldrich). The suspension was incubated on ice for 5 
minutes  and centrifuged at 500 x g  for 10 minutes (4°C) followed by re-suspension in 4 ml 
TBF-2 (10 mM MOPS, 75 mM calcium chloride, 10 mM potassium chloride, 15% glycerol; all 
supplied by Sigma-Aldrich) and incubation for 15 minutes on ice. Aliquots of 50 µl were 
prepared on ice and stored at 80°C.   
 
2.2.2. Transformation of Competent Cells with Plasmid DNA 
Transformation efficiency of the competent XL1-Blue E.coli was determined. An aliquot of cells 
was thawed on ice and 0.1 ng of control DNA (1 µl of 0.1 ng/µl serially diluted pHV plasmid 
DNA) added. After incubation for 20 minutes on ice cells were transferred to a water bath at 
42°C and incubated for 2 min. This was followed by incubation for 2 minutes on ice and then 
bacteria were mixed with 950 µl of LB medium (without antibiotics) and incubated at 37°C on a 
shaker for 1 hour. 10 µl of the culture were diluted in 990 µl of LB medium and 100 µl spread 
on an LB agar plate with 100 µg/ml of ampicillin (Sigma-Aldrich) and incubated overnight at 
37°C. To calculate the transformation efficiency colonies on the plate were counted. For 
example if 100 colonies were counted, the transformation efficiency is: number of colonies on 
plate/ ng of DNA plated x 1000 ng/µg, hence 100 transformants/0.0001 μg x 1000 ng/µg = 1 x 
109 transformants/µg. 
For transformation of competent cells with DNA 10 to 50 ng of plasmid DNA were added to the 
thawed cells and the above described procedure was followed, with the difference that 200 µl 
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of the 1 ml culture were spread on the agar plate before incubation of the plate at 37°C 
overnight. 
 
2.2.3. DNA Plasmid Preparation   
Plasmid DNA was purified from transformed E.coli using a DNA plasmid kit (Qiagen, Limburg, 
Netherlands) following the manufacturer’s protocol. A single colony of transformed bacteria 
from a LB agar plate was picked and used to inoculate 5 ml of LB medium containing the 
respective antibiotic. After 8 hours shaking incubation at 37°C the required volume of LB 
medium containing the respective antibiotics were inoculated at a dilution of 1:500 with the 
starter culture and incubated on a shaker overnight at 37°C. Following plasmid DNA extraction 
by alkaline lysis of bacteria and plasmid DNA purification, DNA pellets were resuspended in 1 
to 2 ml of TE buffer (10 mM Tris-HCl, pH 8.0; 1 mM EDTA, supplied in kit). Plasmid DNA 
concentration was quantified using the NanoDrop™ 1000 Spectrophotometer (Thermo Fisher 
Scientific, Hemel Hampstead, Herts, UK) measuring the absorbance A260 and aliquots kept at -
20°C or -80°C for long term storage. 
 
2.2.4. DNA Plasmids 
DNA plasmids were used to make transiently produced LVs (chapter 3) and GIPZ-LVs (chapter 
4). Transient transfection is described in sections 2.3.1 and 2.5.1. Plasmid pHV is the third 
generation lentiviral genome vector. The 3’ and 5’ long terminal repeats (LTRs) of pHV were 
derived from pH7G (provided by Oxford Biomedica, Oxford, UK; (Ikeda et al., 2003). The U3 
region, containing enhancer and transcription regulatory signals, of the 5’LTR was replaced by 
a CMV promoter. Internally, pHV encodes enhanced GFP (eGFP) under the control of the SFFV 
promoter and the packaging sequence psi (Ψ), central polypurine tract (cPPT) upstream as well 
as the woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) downstream 
of eGFP (Ikeda et al., 2003). The transfer vector pRRLSIN.cPPT.PGK-GFP.WPRE is a self-
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inactivating (SIN) vector genome plasmid with a deletion in the U3 of the 3’LTR encoding eGFP 
driven by the promoter of the human phosphoglycerate kinase gene (PGK), and contains cPPT, 
Ψ as well as WPRE. Plasmids p8.91 and pMDLg/pRRE contain wild type HIV-1 gag-pol under 
the control of the CMV promoter. Plasmids pMDG and pMDG.2 contain VSV-G envelope under 
the control of a CMV promoter. Plasmid pRSV-Rev encodes Rev driven by rous sarcoma virus 
(RSV) U3. The DNA plasmid RDpro encodes the RD114 envelope, where the R-peptide cleavage 
site is replaced with a HIV-1 protease cleavage site, driven by MLV LTR (Ikeda et al., 2003). The 
DNA plasmid pGIPZ is a SIN-LV genome containing the elements of cPPT, Ψ and WPRE with a 
shRNA as transgene. The shRNA is based on the endogenous miRNA 30 (mir-30). To mark 
shRNA expression the reporter gene turbo GFP (tGFP) driven by the CMV promoter is included 
and placed upstream of an internal ribosome entry site (IRES) that drives the expression of an 
antibiotic selection marker, puromycin as well as expression of the shRNA (Thermo Fisher 
Scientific). An overview of all plasmids including their source is given in the appendix (Table 2 
and Figure 4). 
 
2.3. Lentiviral Vector Preparation and Characterisation 
2.3.1. Vector Production 
Transiently produced LVs (in chapter 3 and Table 1) were prepared by calcium-phosphate four-
plasmid co-transfection of 293T cells using third generation HIV-1 vector plasmids (adopted 
method by (Kutner et al., 2009). On the day before the transfection, 8x106 293T cells were 
plated per 15 cm dish in 18 ml complete DMEM. The DNA plasmids used to transfect cells of 
one 15 cm plate were 7 µg pMD2.G encoding VSV-G, 7 µg pRSV-Rev encoding Rev, 14 µg 
pMDLg/pRRE encoding HIV-1 Gag-Pol and 21 µg pRRLSIN.cPPT.PGK-GFP.WPRE encoding a SIN-
LV genome including the marker protein eGFP driven by a PGK promoter; representing a ratio 
of 1:1:2:3. The day after transfection, the supernatant was changed to 18 ml fresh complete 
DMEM per plate, followed by the first harvest 48 hours post-transfection. For the second 
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harvest, fresh DMEM was added to the cells and collected 72 hours post-transfection (day 4 
and 5 after plating). First and second supernatants were filtered through 0.45 µm cellulose 
acetate (Schleicher & Schwell Micro Science, NJ, USA) pooled and centrifuged at 19000 rpm 
for 2 hours at 4°C (Beckman Coulter, L-90K, SW28). Vector supernatants from one 15 cm dish 
were concentrated from 18 ml to 900 μl. For preparations of vector samples up to batch #54 
pellets were soaked for 1 hour in complete DMEM at 4°C and resuspended to a final 
concentration factor of 40. Pellets of vector samples from batch #55 onwards, including those 
that were analysed by LC-MS/MS analysis, were soaked for 1 hour in Opti-MEM® Reduced 
Serum Medium, GlutaMAX™ (Invitrogen, Carlsbad, CA, USA) at 4°C and resuspended to a final 
concentration factor of 40.  Aliquots were stored at -80°C. The sample at this stage is referred 
to as ‘crude sample’. 
For lentiviral vector production by stable producer cells, STAR-RDpro-pHV cells (Ikeda et al., 
2003) were seeded at a density of 8x106 cells per 15 cm dish. After 48 hours the medium was 
changed to 18 ml complete DMEM per plate for the first harvest. This was followed by the first 
and second harvest 24 hours and 48 hours later (day 4 and 5 after plating). Filtration of harvest 
was carried out as described above and LVs concentrated  at a reduced speed of 8500 rpm and 
spin time of 1.5 hours at 4°C (Beckman Coulter, L-90K, SW28), according to (Strang et al., 
2004). 
 
2.3.2. Lentiviral Vector Purification using Size Exclusion Chromatography 
For vector purification, a Gilson liquid chromatography system was used, consisting of a pump 
(model 306), an autosampler (model 231XL) as well as a fraction collector (model FC203B) 
connected to a temperature controlled rack. Sample injection was controlled by the software 
Trilution LC 2.1 and sample elution and detection were controlled by Unipoint 5.11 (all parts 
and software by Gilson, Middleton, WI, USA). Samples were separated by a cooling jacked 
XK16/70 column packed with Sephacryl-500–HR medium (both by GE Healthcare, Little 
73 
 
Chalfont, UK). Sephacryl-500–HR medium consists of cross-linked copolymer beads of 
allyl dextran and N,N’-methylene bisacrylamide with an average particle size of 47 µm, 
allowing the separation of macromolecules in the range of 4x104 to 2x107 relative molecular 
mass (Mr). TEN buffer containing 150 mM NaCl, 1 mM EDTA, 10 mM Tris-HCl pH 7.4 was used 
as sample running buffer (Sigma-Aldrich). 
For size exclusion chromatography, 900 µl of crude vector sample were purified per column at 
a flow rate of 0.8 ml/minutes with a bed volume of 140 ml for a run time of 350 min, allowing 
the flow through of buffer equivalent to two column volumes. One 4ml fraction, the void peak 
fraction, was collected per run. Three columns were used in this project, depending on the 
exact volume of medium in each column, the elution time ranged from 64 to 68 min. To set up 
a newly packed column for SEC, the elution time of the void peak was determined and the 
collection start of the first fraction was set.  Fractions were collected in a cooled rack and 
stored at -80°C for further processing. 
 
2.3.3. Purified Lentiviral Vector Sample Preparation for Mass Spectrometry  
To prepare SEC purified viral vectors for LC-MS/MS analysis, 4 ml void peak fractions from a 
total of 8 runs of 900 µl crude vector samples were pooled and dialysed to exchange the 
sample buffer TEN to 10 mM ammonium bicarbonate (ABC; Sigma-Aldrich), pH 8.0. 
Slide-A-Lyzer dialysis cassettes (3 to 12 ml capacity, molecular cut-off 10 000 Da, Thermo 
Fisher Scientific) were hydrated for 2 minutes in 10 mM ABC and filled with 2x 4ml SEC void 
peak fractions through one of the cassettes injection ports using a 10 ml syringe and 18 Gauge 
needle. Samples were dialysed overnight in 3 litres of 10 mM ABC, pH 8.0. Dialysed samples 
were freeze-dried using an Edwards E2M2 High Vacuum Pump. Lyophilised samples were 
resuspended in distilled water and stored at -80°C. 
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2.3.3.1. Purified Lentiviral Vector Quantification using Bradford Protein Assay 
For total protein quantitation samples were measured in triplicate by mixing 5 µl of sample (in 
10 mM ABC; pH 8.0), 10 µl of HCl (0.1 N; Sigma-Aldrich) and 785 µl dH2O. A standard curve 
was generated using BSA protein standard (Thermo Fisher Scientific) in the range of 0.125-
 0.875 µg/ml, in duplicates. After 5 minutes incubation at room temperature with 200 µl of 
concentrated Bradford dye (BioRad, Hercules, CA, USA), absorbance was measured using 
Lambda 800 UV/Vis Spectrometer (PerkinElmer, Waltham, MA, USA) at the wavelength 
595 nm. 
 
2.3.3.2. Purified Lentiviral Vector Characterisation using LC-MS/MS  
LC-MS/MS analysis was performed by Jun Wheeler, in the proteomics facility, NIBSC. In brief, 
purified and concentrated lentiviral vector samples were digested with trypsin in the presence 
of 1% Rapigest (an enzyme-compatible detergent to ensure solubilisation of membrane 
proteins; Waters, Milford, MA, USA) and 50 mM ammonium bicarbonate, pH 8.5 for 3 hours at 
37oC. HCl was added to terminate digestion and ensure breakdown of Rapigest. 
LC-MS/MS was carried out using a mass spectrometry system (Thermo Fisher Scientific,  Hemel 
Hampstead, Herts, UK) equipped with a nano-electrospray ion source and two mass detectors 
including linear trap (LTQ) and orbitrap, coupled with an Ultimate 3000 nano-LC system, 
comprising a solvent degasser, a loading pump, a nano-pump, and a thermostated 
autosampler. After an automated injection, the extracted peptides from each digestion were 
desalted in a trapping cartridge (PepMap reversed phase C18, 5 μm 100 Ǻ, 300μ id x 5 mm 
length; Thermo Fisher Scientific), eluted on to a C18 reversed phase nano-column (3 μm, 100Ǻ, 
5 cm length; Thermo Fisher Scientific) followed by a 60 minutes separation under a column 
flow rate of 0.3 µl/minutes using linear gradient of 5 to 70% acetonitrile and 0.1% formic acid 
(both by Sigma-Aldrich). Separated and eluted peptides were ionised by electrospray 
ionisation (ESI) followed by a MS survey scan (mass-to charge-ratio, m/z 400 – 2000) in the 
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LTQ, sequentially selecting the five most abundant ions of peptides eluting  from the LC at that 
time, before being  passed on to the Orbi-trap. The total cycle time for each MS/MS was 
approximately 30 milliseconds. The Orbi-trap took accurate mass measurement with the 
resolution of 30,000 parts per million (ppm) and ions were then fragmented in the linear ion 
trap by collision induced dissociation (CID) at collision induced energy of 35%. Subsequently, 
fractionated ions were separated according to their m/z ratio. Data was collected in data 
dependent MS/MS mode with dynamic exclusion set to 2 counts. Data analysis including mass 
spectra processing and database searching was carried out using Thermo Proteome Discoverer 
1.2. with built-in Sequest (Thermo Fisher Scientific). Initial mass tolerances for protein 
identification by MS were set to 10 ppm. Up to two missed tryptic cleavages were considered 
and methionine oxidation was set as dynamic modification. Peptide sequences by MS/MS 
were only included when Xcorrelation scores were greater than 1.5, 2 or 2.2 for charge states 
1, 2 and 3, respectively. An unambiguous identification was considered when at least two 
peptides matched to the protein. The protein FASTA databases were downloaded from 
www.uniprot.org, release 2012-03 including the complete entries from Homo Sapiens (taxon 
identifier 9606), Bos Taurus (9913), human immunodeficiency virus type 1 group M subtype B 
(isolate HXB2) (HIV-1) (11706), vesicular stomatitis indiana virus (strain San Juan) (VSIV) 
(11285), RD114 virus (11834), RDpro Env (Ikeda et al., 2003) AA sequence: (Bell et al., 2010, 
Ikeda et al., 2003), and GFP (P42212). 
 
2.4. Lentiviral Vector Characterisation 
2.4.1. Vector Titration by Fluorescence Activated Cell Sorting (FACS) 
The vector transduction titer was measured after concentration by ultracentrifugation and 
after SEC purification of vector particles. 293T cells were plated in 6-well dishes at a density of 
2x105 cells per well in 2ml complete DMEM and allowed to grow overnight. Cells were 
transduced with concentrated vector after serial dilution in complete DMEM containing 8 
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µg/ml polybrene (Sigma-Aldrich). Concentrated vector samples were serially diluted and final 
amounts of 2.5 µl, 0.5 µl and 0.1 µL in 1 ml complete DMEM were added to cells of each well. 
Five hours later the medium was taken off and 2 ml of complete DMEM added. 72 hours post 
transduction cells were analysed by FACS for percentage of GFP expressing cells.  
To titrate SEC purified samples, 1.5 ml of a 4 ml void peak fraction was 0.2 µm filtered 
(cellulose acetate; Schleicher & Schwell Micro Science) and cells transduced with 400 µl, 100 µl 
and 50 µl of filtered SEC fractions and processed like crude samples above. After 4 to 5 hours 
incubation, the culture medium was exchanged with 2 ml of complete DMEM. After 72 hours 
the cells were analysed by FACS for percentage of GFP expressing cells.  
Lentiviral vector particles carrying the pGIPZ vector genome (concentrated LV-GIPZ) used in 
knock-down of host cell proteins experiments were titered in a similar way. 293T cells were 
plated in 24 well plates at a density of 4x104 cells per well in 500 µl of complete medium. The 
next day serial dilutions of LV-GIPZ preparations were prepared and cells transduced with final 
amounts of 50 µl, 10 µl and 2 µl vector sample in 250 µl complete DMEM containing 8 µg/ml 
polybrene per well. The medium was changed 5 hours following transduction and GFP 
expressing cells were counted by FACS  using a BD FACSCantoTM II (BD Biosciences, San Jose, 
CA, USA) 72 hours after transduction. 
Unconcentrated LV harvests produced by STAR-GIPZ and 293T-GIPZ cells were titered on 24 
well plates with 4x104 293T cells per well. Cells were transduced with serially diluted harvests 
in DMEM containing 8 µg/ml polybrene; 250 µl, 50 µl and 10 µl of harvests were applied in a 
final amount of 250 µl per well. Five hours later the medium was changed and GFP positive 
cells counted by FACS 72 hours post transduction.  
The number of transducing units per ml (TU/ml) was calculated using the equation:  TU/ml = 
(no. of cells at time of transduction x [% of GFP positive cells/100])/input volume of vector 
sample in ml. 
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2.4.2. Vector Titration by p24 ELISA (Chapter 3) 
SEC fractions of lentiviral vector samples were analysed by p24 ELISA (chapter 3). On day one, 
a 96 well plate (High Binding, Corning, by Fisher Scientific, Gillingham, UK) was prepared by 
coating each well with 10 µg/ml of capture antibody, affinity-purified sheep anti-HIV-p24 Gag 
(ARP410, CFAR, NIBSC, UK). Plates were in a closed container and left to incubate at room 
temperature overnight. On day two, wells were washed six times with 200 μl per well of TBS 
(50 mM Tris, 150 mM NaCl, pH 7.5, media facility, NIBSC), followed by blocking each well with 
200 μl of 2% skimmed milk (Marvel, Original Dried Semi Skimmed Milk Powder) in TBS solution 
and incubated for 30 minutes at room temperature in a closed container to prevent drying out. 
Another wash with TBS (6x200 µl per well) followed and the p24 protein standard (ARP620, 
CFAR, NIBSC, UK) was added to each well in a serial dilution in phosphate buffered saline (PBS; 
137 mM NaCl, 2.7 mM KCL and 10 mM phosphate buffer, pH 7.4, media facility, NIBSC) 
containing 0.1% Empigen (Millipore, Billerica, MA, USA) and 10% sheep serum (Sigma-Aldrich) 
(PBS/E/S), giving a p24 detection range of 78 pg to 5 ng. To 100 µl vector sample (SEC fraction) 
11 µl of 1% Empigen were added, mixed, heated at 56°C for 30 minutes and added to each 
well. The plate was incubated overnight at room temperature in a closed container. The 
following day, wells were washed with TBS (6x200 µl per well) with subsequent antigen 
detection. The detection antibody, biotinylated monoclonal mouse anti-HIV-p24 Gag (ARP454, 
CFAR, NIBSC, UK), was diluted to a working concentration of 1 µg/ml in TBS containing 2% 
skimmed milk, 20% sheep serum and 0.5% Tween 20. 100μl diluted detection antibody were 
added to each well and incubated for 2 hours at room temperature. This was followed by a 
wash with TBS (6x200 µl per well). Extravidin (Sigma-Aldrich) was diluted 1:2000 in PBS-0.5% 
Tween 20, 100 µL added per well, followed by an incubation of 1 hour at room temperature. 
Wells were washed again and p-nitrophenyl phosphate (Sigma-Aldrich), dissolved as per 
manufacturer’s instructions in reaction buffer (10mM ethanolamine, 0.5mM MgCl², pH 9.8; 
Sigma-Aldrich), added to each well in aliquots of 100 µl. The absorbance at 405 nm was 
recorded directly after addition of the substrate as chromogenesis starts immediately. 
78 
 
Readings were taken every 5 minutes for 20 minutes using an absorbance microplate reader 
(SpectraMax 340PC, Molecular Devices, Sunnyvale, CA, USA). 
 
2.4.3. Vector Titration by p24 ELISA (Chapter 5) 
The p24 ELISA kit ‘Lenti-X p24 Rapid Titer Kit’ (Clontech, Mountain View, CA, USA) was used to 
measure p24 protein levels in vector harvests from STAR, transiently transfected 293T cells 
and STAR-GIPZ and 293T-GIPZ LV producer cells presented in chapter 5. The manufacturers’ 
protocol was followed. The assay principle is based on the binding of p24 of vectors in cell 
samples to anti-p24 antibodies coated on a microwell plate. This is followed by incubation with 
a secondary biotin-labelled antibody against HIV-1 p24. Subsequently samples are exposed to 
a streptavidin-horse radish peroxidase (HRP) conjugate. In the next step the soluble 
colorimetric substrate solution 3,3’,5,5’- tetramethylbenzidine (TMB) is added and reacts with 
HRP to form a blue by-product whose intensity is proportional to the amount of HRP, which in 
turn is directly proportional to the amount of p24 in the samples. After addition of sulfuric or 
phosphoric acid stop solution (not specified) the sample colour changes to yellow. The 
absorbance was read immediately at 450 nm using an absorbance microplate reader 
(SpectraMax 340PC, Molecular Devices, Sunnyvale, CA, USA). Standard curve dilutions of the 
kit supplied p24 control were prepared in complete DMEM and samples measured in one or 
two dilutions (in complete DMEM) depending on levels of infectious titer (1:4 up to 1:5000).  
 
2.4.4. Vector Genome Titration by Quantitative Reverse Transcription 
Polymerase Chain Reaction (Q-RT-PCR) 
Q-RT-PCR was used to quantify copies of the vector genome RNA in LV producer cells and in LV 
harvests made in experiments studying effects of producer cell shRNA treatment on vector 
production (chapter 5). 
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2.4.4.1. Vector Genome RNA Extraction for Q-RT-PCR in LV Producer Cells 
For Q-RT-PCR of vector genome RNA from producer cells, cell pellets of 5 to 10 x106 cells were 
trypsinised (Sigma-Aldrich) from wells of 6-well plates and pelleted by centrifugation at 300 x g 
at 4°C for 3 min. The RNAeasy mini kit (Qiagen, Limburg, Netherlands) was used to extract total 
cellular RNA by adding 350 µl lysis buffer RLT in the presence of ß-mercaptoethanol (Sigma-
Aldrich) to each cell pellet. Cells were disrupted by freezing at -80 °C and subsequent thawing 
of the sample on ice. One volume of 70% ethanol (HAYMAN Speciality Products, Witham, UK) 
was added to each tube followed by RNA purification using Qiagen spin tubes that contain a 
silica-based membrane. The concentration of eluted RNA was determined by measuring the 
sample’s absorbance at 260 nm using a NanoDrop™ 1000 Spectrophotometer (Thermo Fisher 
Scientific) and RNA concentration was normalised to 100 ng/µl with nuclease free water. 
 
2.4.4.2. Vector Genome RNA Extraction for Q-RT-PCR in LV harvests  
For Q-RT-PCR from vector harvests (producer cell supernatants) the QiaAmp Viral RNA kit 
(Qiagen) was used to extract viral RNA. Frozen samples that had been stored at -80°C were 
thawed on ice and 140 µl of sample was mixed with 560 µl AVL buffer, supplied by the kit, and 
incubated for 10 minutes at room temperature. This ensured lysis of vector particles and 
inhibition of RNases. Carrier RNA (1.1 µg/reaction; supplied by the kit) had been added to the 
AVL buffer to protect the relatively low amounts of viral RNA from degradation by residual 
RNase activity and to increase its binding to and recovery from the silica-based spin column 
membrane. A volume of 560 µl absolute ethanol (HAYMAN Speciality Products) was added to 
each sample and viral RNA purified using the Qiagen spin columns.  
An equal volume 10 µl of a total of 60 µl eluted viral RNA was used for gDNA elimination and 
RT reaction as described below. Negative control was cell supernatant from 293T cells that had 
not been transiently transfected with vector DNA.  
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2.4.4.3. Principle of Q-RT-PCR 
Quantitative reverse transcriptase polymerase chain reaction (Q-RT-PCR) was applied to 
quantify RNA copies in vector harvests or cell lysates. A two-step protocol was used: 1) reverse 
transcription of sample RNA into cDNA and 2) Q-PCR of cDNA.  The cDNA target sequence, 
here a 273 bp product, is amplified in a PCR in the presence of a DNA dye (SYBR® Green) 
binding double stranded DNA. During the PCR reaction SYBR® Green binds the amplified 
double-stranded DNA molecules, resulting in the emission of fluorescence. A passive reference 
dye, ROXTM, is present compensating for non-PCR–related variations in fluorescence detection 
caused by slight variations between wells due to reaction volume variations or the position of 
the well. The reference dye provides a stable baseline to which PCR-related fluorescent signals 
are normalised. It is necessary when using any light cyclers from Applied Biosystems, such as 
the 7500 Fast Real-Time PCR System that was used in these experiments. The intensity of the 
SYBR® Green fluorescent signal is directly related to the logarithmic amount of amplified cDNA 
target sequence and increases in a linear fashion compared to the number of PCR cycles. The 
number of the PCR cycle after which the fluorescent signal rises above the baseline fluorescent 
signal and starts to increase exponentially is the threshold cycle (Ct). The Ct of the sample Q-
PCR is then compared to the Ct of the standard reaction Q-PCR in which the amount of DNA 
the copy number at the beginning of the PCR is known. PCR standard was the pHV DNA 
plasmid diluted in nuclease free water to 106, 105, 104, 103 and 102 copies per µl. The 
calculation for pHV plasmid DNA standard is shown in Table 4. In knock-down experiments 
STAR-RDpro-pHV as well as 293T transient producer cells package LVs carrying the vector 
genome HV, hence for measuring the number of vector genome RNA the same primer pair can 
be used in the Q-RT-PCR reaction. The primer SFFV Fw and SFFV Rev (Table 3) bind to the 
region upstream of the SFFV promoter driving GFP expression and within the SFFV promoter, 
respectively. To quantify vector genome RNA copies in cell lysates results were normalised to 
human ß-actin mRNA copies (primer: HB actin Fw and HB actin Rev, designed by Sean Knight, 
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Table 3). The standard plasmid was made by Sean Knight who cloned the PCR product of HB 
actin Fw and Rev into pGEM T- easy (Clontech, Mountain View, CA, USA). 
 
2.4.4.4. Reverse Transcription and Q-PCR of Vector Harvests and Cell Lysates 
of GIPZ Producer Cells 
For reverse transcription of viral RNA into cDNA with a recombinant reverse transcriptase the 
QuantiTect Reverse Transcription Kit (Qiagen, Limburg, Netherlands) was used. Genomic DNA 
(gDNA) that co-purifies during RNA extraction was eliminated by adding gDNA Wipeout Buffer 
to each sample followed by incubation at 42°C for 2 min. For reverse transcription of RNA 
extracted from producer cells 800 ng of total RNA were mixed with the reverse transriptase, 
oligo-dT and random primer, Quantiscript RT Buffer containing dNTPs and an RNase inhibitor. 
The samples were then incubated at 42 °C for 15 minutes followed by enzyme inactivation at 
95°C for 3 min. For reverse transcription of viral RNA extracted from vector harvest 10 µl of 
viral RNA (equivalent to viral RNA extracted from 23.3 µl vector harvests) were used. The 
reverse transcriptase has RNA-dependent DNA polymerase activity synthesising cDNA as well 
as RNase H activity degrading RNA in RNA:DNA hybrids. To confirm complete gDNA wipe-out 
for each sample a ‘no RT’ control reaction was set up and analysed by Q-PCR. This control 
reaction did contain all components apart from the reverse transcriptase and was used to 
confirm the complete elimination of gDNA. Wipe-out of genomic DNA was necessary to avoid 
overestimation of RNA contents caused by amplification of gDNA in the PCR of vector samples. 
Q-PCR was performed using QuantiTect® SYBR® Green PCR kit (Qiagen, Limburg, Netherlands). 
For Q-PCR of cDNA 2 µl of template cDNA prepared from producer cells and vector harvests 
(equivalent to viral RNA extracted from 2.3 µl vector harvests) were mixed with relevant 
forward and reverse primer and the QuantiTect SYBR Green master mix (Qiagen, Limburg, 
Netherlands) (Table 5). The master mix contains a HotStarTaq DNA Polymerase, dNTP mix as 
well as the fluorescent dyes SYBR® Green I and ROXTM. The HotStarTaq DNA polymerase is 
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inactive at room temperature preventing the formation of misprimed products and primer–
dimers during reaction set up and in the first denaturation step. Reactions were performed in a 
96 well Q-PCR plate (Thermo Fisher Scientific) sealed with optically clear adhesion film. The 
set-up of PCR reactions is shown in Table 5. Outlined in Table 6 is the PCR method used. In 
negative control reactions addition of the polymerase was omitted and set up in duplicate 
wells (‘No RT’ controls). All samples were analysed in triplicate wells. An example standard 
curve of Q-PCR of β-actin in cell lysates after reverse transcription is shown in Figure 5. For 
data analysis of Q-PCR results in cell lysates the comparative CT method also referred to as the 
2-ΔΔCT method was used, with 2-ΔΔCT = [(CT gene of interest -CT internal control) sample A - (CT 
gene of interest -CT internal control) sample B], in which sample A is SFFV and sample B is beta-
albumin. Using this comparative analysis the comparison of CT values of reverse transcribed 
viral RNA to CT values of the DNA plasmid standard curve can be avoided. The comparative CT 
method assumes that amplification efficiencies of SFFV and beta-actin Q-PCRs are equal or at 
least differ by less than 10%; however the amplification efficiencies were not directly 
compared in these experiments.  
 
2.4.5. Lentiviral Vector Protein Detection using Silver Staining and Western 
Blotting 
Viral proteins were semi-quantified in several samples types. To analyse viral proteins in crude 
vector samples 2 µl were loaded per gel lane. For analysis of SEC fractions 40 µl of one 4 ml 
fraction were used. For Western blotting of pooled SEC fractions, fractions were concentrated 
by centrifugation filtration using Amicon Centrifugal Filter Unit (Millipore, Billerica, MA, USA) 
at 4000 xg until sample volume was reduced to 40 µl (100 fold concentration). To detect viral 
proteins in vector preparations for LC-MS/MS analysis 50 ng, 100 ng or 250 ng of the purified, 
desalted and concentrated samples were analysed. Western blotting was also used for knock-
down of host cell and viral protein detection. For establishment of knock-down efficiency by 
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shRNAs targeting selected cellular proteins 10 µg to 30 µg of total protein of LV producer cell 
lysates were loaded per gel. 45 µl of corresponding vector harvests were analysed to evaluate 
p24 protein levels. 
Samples were subjected to SDS polyacrylamide electrophoresis (SDS-PAGE) using 10% 
acrylamide gels (Table 7 and 8). Proteins were separated on 1mm thick gels (150 V, 1.5 hours) 
and visualised by silver staining using the Silver Stain PlusOne kit (GE Healthcare, Little 
Chalfont, UK) or SilverXpress kit (Invitrogen), according to the provided protocol. For detection 
by Western blotting proteins were separated on 1.5 mm thick gels (150 V, approximately 2 
hours). For Western blotting, proteins were transferred (200 mA, 2.5 hours) from the gel to a 
Hybond enhanced chemiluminescence (ECL) nitrocellulose membrane (GE Healthcare, Little 
Chalfont, UK). Membranes were blocked by incubation for 1 hour in PBS with 0.1% Tween-20 
(Sigma-Aldrich) and 5% milk powder (Marvel, Original Dried Skimmed Milk Powder) 
(PBS/0.1%T/5%milk) on a horizontal shaker, followed by binding of specific proteins to the 
primary antibody. Membranes were incubated overnight sealed in transparent film with the 
relevant detecting antibody diluted in PBS/0.1%T/0.5%milk. Antibodies used were: anti-p24 
(1:100, mouse monoclonal, ARP 365, CFAR, NIBSC, UK; binds sequence NPPIPVGEIY in p24 of 
HIV-1 Gag), anti-VSV-G (1:2000, mouse monoclonal, Sigma-Aldrich), anti-RDpro pg70 (1:2000, 
goat polyclonal, Quality Biotech Inc., Camden, NJ, USA), anti-AHANAK (1:500, mouse-
monoclonal, Abcam, Cambridge, UK), anti-TSG101 (1:500, rabbit-polyclonal, Sigma-Aldrich), 
anti-ALIX (1:1000, rabbit polyclonal), anti-EEF1A (1:500, mouse-monoclonal), anti-ENO1 (1:500, 
mouse-monoclonal), anti-MARCKSL1 (1:1000, rabbit-polyclonal) and anti-GAPDH (1:5000, 
mouse-monoclonal, all by Millipore, Billerica, MA, USA).  Proteins were transferred on to a 
nitrocellulose membrane (Hybond enhanced chemiluminescence (ECL) nitrocellulose 
membrane (GE Healthcare)) for 1 hour (or 2.5 hours for the transfer of AHNAK) at 200 mA. 
Membranes were washed for 3x 10 minutes in PBS/T. Either horseradish-Peroxidase (HRP) 
conjugated secondary anti-mouse or anti-rabbit antibodies were incubated with the 
membranes diluted 1:2000 in PBS/T/0.5%milk for 1 hour (Sigma-Aldrich). Followed by washing 
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the membrane for 3x 10 minutes in PBS/T, protein signals were developed using ECL Western 
Blotting Detection Reagents and exposed to ECL Hyperfilm (both by GE Healthcare, Little 
Chalfont, UK). For densitometry readings of Western blot signals the software Image J (version 
1.46r) was used. 
 
2.5. Knock-Down of Cellular Protein Expression 
2.5.1. GIPZ shRNA-Lentiviral Vector Preparation  
Lentiviral vector particles carrying the pGIPZ vector genome (LVs-GIPZ) were prepared by co-
transfection of packaging plasmid p8.91, VSV-G envelope expression plasmid pMDG and the 
SIN-lentiviral vector genome plasmid, pGIPZ, carrying a shRNA encoding a part of the antisense 
sequence for the mRNA targeted protein. PGIPZ plasmids were purchased from Thermo Fisher 
Scientific and provided as E.coli bacteria stab cultures. Target sequences of all shRNAs used are 
listed in Table 9. The plasmid contains the LV genome elements 5’ and 3’ LTR, central 
polypurine tract (cPPT), the packaging sequence Ψ and a WPRE. The shRNA is based on the 
endogenous miRNA 30 (mir-30). ShRNA expression is marked by the reporter gene turbo green 
fluorescent protein (tGFP) driven by the cytomegalovirus (CMV) promoter upstream of an 
internal ribosome entry site (IRES) driving the expression of puromycin. PGIPZ plasmid 
preparation is described in section 2.2.3. Each stab culture was streaked out on an LB agar 
plate containing 100 µg/ml ampicillin and incubated overnight at 37°C. The next day 5 ml of LB 
(with 100 µg/ml ampicillin) were inoculated with a single colony picked of the agar plate and 
incubated for approximately 8 hours at 37°C on a shaker at 300 rpm. Plasmid DNA was 
extracted from each culture using a DNA plasmid extraction kit (Qiagen, Limburg, 
Netherlands). 
293T cells were plated in 10 cm dishes at a density of 3x106 cells per dish in 10 ml complete 
DMEM., 24 hours after plating, medium was changed to 8ml complete DMEM and cells were 
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transiently transfected with 1μg of p8.91, 1 µg of pMDG and 1.5 µg of pGIPZ as well as 36 µl 
Fugene transfection reagent in 800 µl Opti-MEM® Reduced Serum Medium, GlutaMAX™ per 
10 cm dish. Twenty-four hours after transfection the medium was changed to 8 ml complete 
DMEM. The first time cell supernatant was collected at 48 hours post transfection and stored 
at 4°C overnight followed by the second collection at 72 hours. First and second collection of 
supernatants were pooled, filtered (0.2 µm cellulose acetate, Schleicher & Schwell Micro 
Science) and concentrated 40 fold by ultracentrifugation at 48 000 x g for 2 hours (Beckman 
Coulter, L-90K, SW28) at 4°C. Aliquots were stored at -80°C. Titration of GIPZ-LV preparations 
was carried out as described in section 2.3.2. 
 
2.5.2. Transduction of LV Producer Cells with GIPZ-LVs to Deliver shRNA 
STAR cells or 293T cells were plated in 6 well plates at a density of 6x105 cells per well and 
transduced 24 hours later with pGIPZ-LVs at MOI 10 in complete DMEM medium with 8 µg/ml 
polybrene. To identify the shRNA with highest knock-down efficiency 293T cells were 
transduced with one of the shRNAs in Table 9. At least two shRNAs were analysed per target 
protein.  Transduced cells were selected in puromycin containing medium (10 µg/ml) starting 
twenty-four hours after transduction and maintained from then onwards in puromycin 
conditioned medium.  
 
2.5.3. Production of LVs by STAR-GIPZ and 293T-GIPZ Cells 
After a minimum of one week in selection medium STAR-GIPZ and 293T-GIPZ cells were 
seeded at a density of 6x105 cells per well of a 6-well plate. For the transfection of 6 wells of 
293T-GIPZ cells 24 hours later 1 µg pMDG, 1 µg p8.91 and 1.5 µg of pHV were mixed with 36 µl 
Fugene (Roche, Burchess, Hill, UK) and 800 µl Opti-MEM® Reduced Serum Medium, 
GlutaMAX™ (Invitrogen) after medium change to 1.33 ml of fresh DMEM per well. The next 
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day the medium was changed to 2 ml fresh DMEM and 48 hours and 72 hours post 
transfection 2 ml of cell supernatant were collected. After filtration through 0.45 µm cellulose 
acetate syringe filters (Schleicher & Schwell Micro Science) vector harvests were frozen and 
stored at -80°C for later analysis. For vector harvests from STAR-GIPZ producers the medium 
was changed to 2 ml of fresh medium 48 hours after plating and 24 and 48 hours later (day 4 
and 5 after plating) supernatant collected, filtered and stored as described above. At the time 
of the second vector harvest (day 5 after plating), producer cells were lysed and target host 
protein expression was analysed by Western blotting.   
 
2.5.4. Preparation of Cell Lysates 
Cell lysates for knock-down analysis by Western blotting was prepared from STAR and 293T 
cells as well as STAR-GIPZ and 293T-GIPZ cells of knock-down analysis experiments (section 
2.5.3.; experiments of chapter 4). A confluent well of a 6-well plate of cells was washed with 
500 µl cold PBS. Cells were lysed by adding 150 µl of cold cell lysis buffer. On ice the plate was 
shaken for 10 minutes before lysates were collected and centrifuged at 13 000 xg at 4°C for 20 
min. Supernatants were transferred to pre-chilled 1.5ml tubes and lysates stored at -80°C. 
Alternatively protein concentration was determined immediately using the bicinchoninic acid 
(BCA) assay (Thermo Fisher Scientific).  
 
2.5.5. Protein Concentration Measurement using BCA assay  
Total protein concentration was measured using the bicinchoninic acid (BCA) assay (Thermo 
Fisher Scientific) in the microplate format. Following the manufacturer’s protocol standard 
dilutions of 2000 to 25 µg/ml of bovine serum albumin (BSA; Thermo Fisher Scientific) were 
made in protein lysis buffer and 20 µl of each standard as well as 20 µl of cell lysate sample 
(diluted 1:5 in protein lysis buffer) used in the assay. The absorbance was measured at 562 nm 
using a microplate reader (SpectraMax 340PC; Molecular Devices, Sunnyvale, CA, USA). 
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Samples were diluted in protein lysis buffer to a concentration of 1 µg/µl and SDS-PAGE 
sample buffer added before storage at -20°C for further analysis by Western blotting. 
 
2.5.6. Functional Category and Canonical Pathway Analysis of LC-MS/MS 
Data 
IPA (Ingenuity® Systems [www.ingenuity.com], Mountain View, CA, USA) was used to 
determine the most significant molecular and cellular functions and cellular pathways in the 
LC-MS/MS datasets. Datasets in the form of Excel spreadsheet lists of UniProt identifiers were 
uploaded into the application. For core analysis of a dataset default settings were applied and 
only direct relationships between proteins that have been experimentally confirmed 
considered. 
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2.6. Materials and Methods - Appendix  
 
Table 1: Vector Samples for LC-MS/MS Analysis 
Lentiviral Vector 
Sample 
Components  
VSV-G-GFP transiently produced, VSV-G Env, Gag/Pol, vector genome 
(pRRLSIN.cPPT.PGK-GFP.WPRE; transgene: GFP) and Rev 
VSV-G-Empty transiently produced,  VSV-G Env, Gag/Pol protein and Rev 
Gag/Pol-GFP transiently produced, Gag/Pol, vector genome (pRRLSIN.cPPT.PGK-
GFP.WPRE; transgene: GFP) and Rev 
VSV-G only transiently produced, VSV-G Env, vector genome (pRRLSIN.cPPT.PGK-
GFP.WPRE; transgene: GFP); control sample 
RDpro-GFP stably produced by STAR-RDpro-pHV expressing RDpro envelope 
protein, Gag/Pol, vector genome (pHV, transgene: GFP), Tat and Rev 
RDpro-Empty stably produced by STAR-RDpro, expressing RDpro envelope protein, 
Gag/Pol, Tat and Rev, no vector genome 
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Table 2: DNA plasmids used in Transient Transfections 
Plasmid Source comments
p8.91 (Zufferey et al., 1997) 
Plasmid Factory (Bielefeld, 
Germany)  
Expression plasmids for CMV 
driven Gag-Pol; used in 
transient transfection 
experiments chapter 5 to 
prepare GIPZ-LVs 
pMDG (Naldini et al., 1996) 
Plasmid Factory  
Expression plasmids for CMV 
driven VSV-G; used in 
transient transfection 
experiments chapter 5 to 
prepare GIPZ-LVs 
RD-pro Y. Ikeda (Ikeda et al., 2003, 
Cosset et al., 1995) 
Expression plasmids for MLV-
LTR driven RDpro 
ß-actin Sean Knight Expression plasmid for cDNA 
of exon 4 of human ß-actin 
driven by T7 promoter 
pHV (Ikeda et al., 2003, 
Kotsopoulou et al., 2000) 
LV genome; 5’LTR: CMV-R-
U5; 3’LTR: U3-R-U5; SFFV 
driving GFP 
pGIPZ Thermo Fisher Scientific SIN-LV genome,  shRNA gene 
pMD2.G Addgene (Cambridge, MA, 
USA) # 12259 (Trono lab) 
Expression plasmid for CMV 
driving VSV-G; used in 
transient transfection 
experiments chapter 3 
pRSV-Rev Addgene (Cambridge, MA, 
USA)  # 12253 
(Dull et al., 1998) 
Expression plasmid for RSV 
driving Rev 
pMDLg/pRRE Addgene (Cambridge, MA, 
USA)  #12251 
(Dull et al., 1998) 
Expression plasmids for CMV 
driven Gag-Pol; used in 
transient transfection 
experiments chapter 3 
pRRLSIN.cPPT.PGK-GFP.WPRE Addgene (Cambridge, MA, 
USA)  # 12252 
(Follenzi et al., 2000) 
SIN-LV genome; 5’LTR:  CMV-
R-U5, 3’LTR: ΔU3-R-U5; PGK 
driving GFP 
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Figure 5: Map of DNA plasmids after integration into producer cells for transient vector 
production showing LV relevant elements only: A) Plasmids of the Second Generation 
Packaging System, pGIPZ, p8.91 and pMDG were used for preparation of GIPZ-LVs (section 
2.5.1). Plasmids pHV, p8.91 and pMDG were used for transient transfection of 293T-GIPZ cells 
(section 2.5.3). B) Plasmids of the Third Generation Packaging System, pRRLSIN.cPPT.PGK-
GFP.WPRE, pMDLg/RRE, pRSV-Rev and pMDG.2 were used for transient transfection of 293T 
cells (section 2.3.1).  
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Figure 6: Example of standard curve for p24 ELISA (using Lenti-X™ p24 Rapid Titer Kit 
chapter 5). 
 
Table 3: Primer for Q-PCR of Vector RNA Genome.  
Target mRNA Primer Name Primer Sequence 
SFFV SFFV Fw CGATAAGCTTGATATCGAATTCCT 
SFFV Rev TGCGGTGACCATCTGTTC 
1. Human ß-actin HB actin Fw TGGACTTCGAGCAAGAGATG 
HB actin Rev GAAGGAAGGCTGGAAGAGTG 
Q-PCR primer (purchased from Invitrogen): SFFV primer bind to the region upstream of the 
SFFV promoter driving GFP expression and within the SFFV promoter. Vector genome RNA 
copy numbers were normalised to ß-actin copy numbers in cell lysates. 
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Table 4: Calculation of pHV Plasmid DNA Standard Molecular Weight Used in Q-PCR of 
Vector RNA Genome.  
Standard Plasmid Size 
(bp) 
Molecular 
Weight (Da) 
Mass (g) / copy Weight of 1010 
copies (ng) 
pHV 7918 5225880 8.67 x 10-18 86.78 
ß-actin 3146 2076360 3.45 x 10-18 34.48 
The size of the plasmid was used to calculate the molecular weight of one vector genome copy 
(with 1 bp = 660 Da and 1Da = 1.66x10-24 g) from which the mass of 1010 in nanograms (ng) was 
calculated and used to make a 1010 plasmid/µl aliquot in Buffer EB (Qiagen), this was serially 
diluted to give aliquots of 106, 105, 104, 103 and 102 plasmids/µl. 
 
Table 5: PCR Reaction Set-Up.  
Component Concentration Volume per reaction 
(μl) - Standards 
Volume per reaction 
(μl) - Samples 
Primer F 20 μM (final 0.4) 0.5 0.5 
Primer RC 20 μM (final 0.4) 0.5 0.5 
QuantiTect SYBR 
Green master mix 
na 12.5 12.5 
RNase-Free Water na 6.5 9.5 
Template cDNA 
(added in to each 
reaction individually) 
na 5 2 
Total Reaction 
Volume 
na 25 25 
Standard and sample reactions differ in volume of template added; 5 µl and 2 µl were added, 
respectively. 
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Table 6: Q-PCR Program  
Step Time Temperature (°C) 
PCR initial heat activation 15 min 95 
3-step cycling (40 cycles)   
Denaturation 15 sec 94 
Annealing 30 sec 55 
Extension 30 sec 72 
Melting curve 
 
 
Figure 7: Example standard curve of Q-PCR of β-actin after reverse transcription of cell lysate 
RNA, see section 2.4.4.4. Efficiency = 10(-1/slope)-1 = 10(-1/-3.325)-1 = 99.8%. 
 
Table 7: Composition of Acrylamide Gels used in Western Blotting.  
Component Separating Gel (10%) Stacking Gel (4%) 
dH2O 7.94 ml 6.8 ml 
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Tri-HCL 5 ml of 1.5M (pH 8.8) 1.25 ml of 0.5M (pH 6.8) 
30 % Acrilamide-Bisacrylamide 
(Bio-Rad, Hercules, CA, USA) 
6.6 ml 
 
1.7 ml 
20% SDS (media facility, NIBSC) 100 µl  50 µl  
APS 200 µl  100 µl  
TEMED 20 µl  10 µl  
All reagents were purchased from Sigma-Aldrich unless stated otherwise. 
 
Table 8: Composition of Buffers Used in Western Blotting.  
Buffer Composition 
Phosphate Buffered Saline 
(PBS) 
10 mM sodium phosphate dibasic, 156 mM sodium 
chloride, 2mM potassium phosphate monobasic, pH 7.2 to 
7.4 
Cell lysis buffer 1% Triton X-100 in PBS (Sigma-Aldrich) containing protease 
inhibitors: cOmplete(R)TM EDTA-free, broad spectrum 
inhibitors of serine and cysteine proteases (Roche, 
Burchess, Hill, UK) 
SDS-PAGE sample buffer 50 mM Tris-HCL, pH 6.8, , 10% glycerol, 2% SDS, 12.5 mM 
EDTA, 0.02% bromophenol blue, 1% ß-mercaptoethanol 
SDS-PAGE running buffer (10x) 250 mM Tris base, 1.92 M glycine, 1 % SDS, pH 8.3 
Transfer buffer (10x) 250 mM Tris base, 1.92 M glycine, pH 8.3 
All reagents were purchased from Sigma-Aldrich unless stated otherwise. 
 
 
Table 9: pGIPZ-shRNA Plasmids.  
Target protein shRNA # pGIPZ ID shRNA target  (antisense) 
ALIX 2 V2LHS_64522 TTTCGTTGCAGTAATTCAG 
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  3 V2LHS_64525 TGATCTGTTAACCAAATCG 
  11 V2LHS_64521 TTAGTCAATATAGACTGAG 
  18 V2LHS_64526 TAATCTGCAGCCTGATTAG 
AHNAK 1 V2LHS_233334 TAACTGCAGGTGTTTGTTG 
  6 V2LHS_92221 TAGATCAGGAGCTCCTACG 
  8 V2LHS_160999 TTATGTCAATTTCAGGGCC 
  10 V2LHS_98839 TCCAGTGCTGATGGCTGTG 
  13 V2LHS_98840 TTGCATTCCAGTGCTGATG 
  38 V3LHS_360956 GAGACAACAACATCAGCCT 
  39 V3LHS_360958 AGAAGAGGAGGACAGTCGG 
  41 V3LHS_360959 TAAATTGAAATCAACATCA 
EEF1A 4 V2LHS_113620 TTGTAGACATCCTGGAGAG 
  29 V3LHS_360005 TACAATACCGGTAACAACG 
MARCKSL1 27 V3LHS_412143 TGAACTTGAGTAAGACATT 
  20 V2LHS_259022 TCTTCTGAGGCTGCACTAG 
  26 V3LHS_412142 AAGGGACCATCTTCAACTG 
  42 V3LHS_412141 AAGACATTTATAAAAACCT 
ENO1 17 V2LHS_113737 TTGTCCCGGAGCTCTAGGG 
  37 V3LHS_408476 TTGAGCACAAAACCACCGG 
  40 V3LHS_408477 TTTGAGCACAAAACCACCG 
TSG101 45 V3LHS_305576 ACTTCTTGATCTAAACGGG 
  46 V2LHS_56429 TGCAATAACTTATTCTGGG 
Non-silencing 
control 
  ATCTCGCTTGGGCGAGAGTAAG 
Selected host proteins were targeted with at least two shRNAs to determine which shRNA 
achieves the highest protein knock-down. PGIPZs were purchased from Thermo Fisher 
Scientific using the pGIPZ ID. Highlighted in green are shRNA sequences that were used in 
experiments analysing host protein knock-down effects on vector production.
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3. Lentiviral Vector Production and Purification by 
Size Exclusion Chromatography 
3.1. Introduction 
In several clinical trials lentiviral vectors (LVs) have been shown to successfully treat several 
diseases, including rare inherited diseases for which there are currently no alternative long-
term therapies available other than allogeneic hematopoietic stem cell transplantation (HSCT). 
Clinical trials for the treatment of monogenic disorders such as beta-thalassaemia (Cavazzana-
Calvo et al., 2010), Wiscott-Aldrich syndrome (Biffi et al., 2013) and Metachromatic 
Leukodystrophy (MLD) (Biffi et al., 2013) successfully used ex vivo transduction of 
haematopoietic stem cells (HSCs) with LVs delivering the correct form of disease related genes. 
LVs also have the potential to be applied as vaccines as they can efficiently transduce dendritic 
cells (Lopes et al., 2011, Yang et al., 2011, Rodriguez et al., 2012). Consequently, LVs will not 
only be used increasingly in later stages of clinical trials with larger cohorts of patients, they 
are also being developed for applications targeting larger groups of individuals.  
With the increasing need for large amounts of LVs, their design and method of production are 
constantly under development. Vector production in current clinical trials and in most 
laboratory based applications has been based on transient transfection of 293T cells. High titer 
vectors can be produced; however this lasts only for a few days of production and can vary 
between batches. Manufacturing vectors by good manufacturing practice (GMP) with this 
method is expensive due to the requirement of high amount of plasmid DNA, transfection 
reagents and labour time and difficult to scale up (Merten et al., 2011).  
A packaging cell line stably expressing LVs would circumvent these problems. The 
development of such stable producer cells is based on the stable expression of all packaging 
components followed by introduction of the transfer vector by either transfection or 
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transduction. Several packaging cell lines have been developed but due to toxicity of vector 
components, resulting from overexpressed viral proteins such as Rev and VSV-G in producer 
cells, tetracycline-dependent inducible systems have been used. Vector production, specifically 
viral gene expression is regulated by either withdrawal or addition of tetracycline (Broussau et 
al., 2008, Stewart et al., 2009, Stewart et al., 2011). However addition or removal of induction 
reagents can complicate downstream purification processes. Furthermore difficulties in the 
stable expression of HIV-1 gag-pol impaired the development of a high titer packaging cell line.  
 
The producer cell line STAR stably expresses high levels of a codon optimised HIV-1 gag-pol 
introduced by transduction with murine leukaemia virus (MLV) derived vectors as well as rev 
and tat (Ikeda et al., 2003). The commonly used VSV-G Env has a wide cell tropism and good 
stability but is known to be cytotoxic when stably expressed in producer cells (Burns et al., 
1993). Alternatively the γ-retroviral envelope RDpro, derived from RD114 Env, was used in 
STAR cells as it can efficiently transduce HSC and is not cytotoxic (Relander et al., 2005, Bell et 
al., 2010). Further improvements of the STAR cell line need to be undertaken since produced 
LVs are less infectious compared to VSV-G pseudotyped particles with transduction titers 
about ten-fold below transiently produced (Ikeda et al., 2003, Strang et al., 2004, Bell et al., 
2010). 
In order to analyse the protein content of LVs they need to be separated from non-associated 
proteins. Several methods for viral vectors downstream processing have been described that 
involve vector concentration and purification from producer cell supernatant. Microfiltration is 
often used to clarify vector containing supernatant and serves as the initial step of vector 
purification immediately after vector harvest. Producer cells and cell debris can be removed 
from the cell culture supernatant by filtration through membranes with a pore size of 0.2 µm 
and 0.45 µm (Segura et al., 2005, Segura et al., 2006b). Ultrafiltration is a very gentle method 
to concentrate large amounts of vector containing supernatant and employs a membrane such 
as polyethersulfone with a high molecular weight cut-off (for example 300 kDa). This can be 
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followed by diafiltration to exchange the buffer for subsequent chromatography (Segura et al. 
2005). Parameters such as pressure, stirring rate and process times need be kept low in order 
to have satisfying recovery rates (Cruz et al., 2000). Tangential flow modes, using hollow fibres, 
are easier to scale up as build-up of solids on the membrane is low due to tangential flow of 
the retentate to the membrane, allowing a higher flow rate (Geraerts et al., 2005). 
Alternatively ultracentrifugation concentrates vectors from supernatant by separation of 
vectors using centrifugal force allowing the removal of cell culture media (Burns et al., 1993). 
However proteins with similar or greater density to viral particles co-concentrate during the 
process. Vectors purified by sucrose-density ultracentrifugation have been shown to be 
contaminated with microvesicles that have a similar density to vectors (Bess et al., 1997). 
Furthermore this method is also cumbersome, difficult to scale up and reduces functional 
particles yields significantly (Baekelandt et al., 2003). Using rate zonal ultracentrifugation, 
vectors are separated by size and density from contaminants including defective vectors and 
cell membrane vesicles, however this method achieved a relatively low recovery of infectious 
particles (37%) (Segura et al., 2006a). Furthermore, since the size of microvesicles is thought to 
range between 50 to 500 nm, vesicles of similar size to vectors would not be removed by this 
method. 
These initial steps in vector downstream processing are primarily focused on removal of cells, 
cell debris and the reduction of harvest volume. They are followed by the actual purification 
step removing most impurities in cell supernatants from vectors. For the elimination of 
plasmid DNA and genomic DNA from host cells current methods used for large scale LV clinical 
grade purification include benzonase (endonuclease) treatment followed by membrane based 
anion-exchange chromatography (AEXc) (Schweizer and Merten, 2010, Aiuti et al., 2013, Biffi 
et al., 2013). Anion-exchange chromatography is the absorption of the negatively charged 
vectors to the positively charged chromatographic supports such as diethylaminoethanol 
(DEAE) anion-exchangers (Merten et al., 2011, Aiuti et al., 2013, Biffi et al., 2013). 
Unconcentrated vector supernatant can be loaded directly onto the column. The volume of 
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applied supernatant is limited by the protein binding capacity of the anion-exchange support. 
Based on quantitative PCR data of the vector genome of eluted particles recovery rates were 
low, ranging from 22 % to 68% (Scherr et al. 2002). Instead of agarose or resin beads the 
column matrix can consist of a membrane. Mustang Q anion-exchange cartridges contain an 
anion-exchange support on a membrane with a large pore sizes (0.8 µm) and filtered 
supernatants can be loaded. For laboratory scale vector processing of up to 1500 ml vector 
harvests can be processed in Mustang Q ion exchange filter capsules with a capacity of 900 ml 
(Slepushkin et al., 2003). Capsules with a capacity of 5 litres are now available (GE Healthcare, 
Little Chalfont, UK). Rodrigues et al. (2008) showed that viral particles can be separated from 
envelope protein-free vectors and soluble envelope proteins due to their lower binding 
strengths at physiological pH. Vectors pseudotyped with envelopes other than VSV-G can also 
be purified such as gibbon ape leukaemia GALV-Env (Rodrigues et al., 2008) or RD114 and 
rabies virus Env glycoproteins (Kutner et al., 2009) making this techniques applicable for a wide 
range of viral vectors. Other chromatography methods have been used to purify clarified and 
concentrated vector preparations. Affinity chromatography using heparin affinity matrices 
allows vector particle elution at moderate salt concentrations compared to AExc (350 mM and 
900 mM NaCl, respectively). To prepare concentrated vectors for affinity chromatography an 
extra step of ultrafiltration into heparin absorption buffer is required. Heparin affinity 
chromatography purified vectors are only partly purified and polishing by size exclusion 
chromatography is required (Segura et al., 2005).  
Size exclusion chromatography (SEC) separates proteins according to the hydrodynamic 
volume of their molecules. Larger molecules migrate faster through the matrix, which consists 
of porous, non-absorbing material, such as sepharose. This method was used during 
processing of a HIV-1 based VSV-G pseudotyped lentiviral vector in a phase I clinical trial 
(Levine et al., 2006). SEC has a dilution effect that requires the feed and also the eluate to be 
concentrated after chromatography. Infectious particle recovery is high (80%) (Slepushkin et 
al. 2003), though this can be significantly reduced during subsequent concentration steps. 
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Other factors, such as low flow-rate, which require long processing times, make this method 
difficult to use in bulk production of LVs and is more suitable in small scale experiments or as a 
final polishing step (Segura et al. 2005). Vector sample production protocols currently used for 
clinical applications use SEC for polishing to remove salts and small sized-contaminants as well 
as a reformulation step, in order to change medium (Aiuti et al., 2013, Biffi et al., 2013). 
According to suppliers specification macromolecules in the range of 4x104 to 2x107 relative 
molecular mass (Mr) can be separated using Sephacryl 500-HR media. It is estimated that 
immature and mature HIV-1 virions have an average mass of 277 MDa (or 2.7x108 Mr) (Carlson 
et al., 2008), hence vector particles are above the exclusion limit of 2x107 Mr and expected to 
elute in the void peak.  
For downstream processing of LVs produced in this study a combination of microfiltration 
using 0.45 µm cellulose acetate filters to separate vectors from cells and cell debris, followed 
by concentration by ultracentrifugation and SEC purification was employed. Purified vectors 
were then desalted by dialysis and further concentrated by lyophilisation.  
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3.2. Aim 
The aim of this chapter was the production of LVs and their purification using size exclusion 
chromatography. Purified samples are characterised regarding their viral protein content. Two 
different vector production methods are directly compared: the transient transfection method 
using calcium phosphate precipitation (Ca2PO4) adopted for the production of LV in clinical 
trials and LV production from the stable producer cell line STAR (Ikeda et al., 2003). 
Preparation of purified vectors for subsequent protein content analysis by liquid-
chromatography mass spectrometry (LC-MS/MS) is also presented. 
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3.3. Results 
Six different vector samples were prepared (see chapter 2, section 2.3.1) to compare host cell 
proteins in transiently and stably produced vectors (Figure 6). Transiently produced vectors 
were 1) VSV-G-GFP:  by  transfecting plasmids coding for VSV-G Env, structural protein 
Gag/Pol, a vector genome with GFP marker gene and Rev; 2) VSV-G-Empty: by  transfecting 
plasmids coding for VSV-G Env, Gag-Pol and Rev, 3) Gag/Pol-GFP: by  transfecting plasmids 
coding for Gag/Pol, vector genome and Rev. 4) VSV-G only: a sample carrying only the VSV 
envelope was prepared by transient transfection of 293T cells with the VSV-G expression 
plasmid and the SIN-LV genome plasmid. Gag/Pol-GFP was used as an envelope free-control 
sample hypothetically lacking host proteins associated with VSV-G or RDpro envelope protein. 
The VSV-only control was used to potentially identify proteins that are associated with VSV-G 
envelope protein. Vectors were stably produced by STAR-RDpro cells continuously producing 
LVs, by expressing RDpro envelope protein, Gag/Pol, vector genome with marker protein GFP 
and Rev (=RDpro-GFP, sample 5) (Ikeda et al., 2003) or without a vector genome (RDpro-
Empty, sample 6).  
A transiently produced vector sample RDpro-GFP, produced by transfection of RDpro Env, 
structural protein Gag/Pol, a vector genome with GFP marker gene and Rev would have 
completed the set and potentially allowed to distinguish between host proteins that associate 
with VSV-G or RDpro Env, but was not included due to time constraints.  
 
Figure 8: Summary of five lentiviral vector samples for the study of associated cellular proteins. 
Transiently produced samples include two VSV-G-pseudotyped samples (with or without a 
vector genome) as well as samples of vector particles without an envelope protein (Gag/Pol-
GFP) or a sample of harvests from 293T cells transiently transfected only with VSV-G Env and 
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vector genome plasmid DNA, omitting Gag/Pol DNA encoding structural proteins (VSV-G only). 
Two stably produced samples were produced by the packaging cell line STAR and include 
RDpro-pseudotyped vectors with and without a vector genome.  
 
3.3.1 Production of LVs –Differences in Titer of Transiently and Stably 
Produced Vectors 
The transduction titer of five batches of transiently produced VSV-G-GFP and stably produced 
RDpro-GFP was assessed by transducing 293T cells with concentrated LV preparations followed 
by measuring GFP positive cells by FACS. The average transduction titer for VSV-G-GFP and 
RDpro-GFP batches were 34.3±9.0x106 TU/ml and 3.4±2.9x106 TU/ml, respectively, 
demonstrating an average about 10 fold higher infectious titer of transiently than stably 
produced vectors. Vector batches used for LC-MS/MS sample preparations are shown in Table 
10.  
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Table 10: Viral Vector Batches used in Sample Preparation for LC-MS/MS Analysis 
 
Transduction titer is stated in transducing units per ml (TU/ml). A batch consists of vector 
samples harvested from producer cells plated and processed in one experiment. 40 fold 
concentrated VSV-G pseudotyped transiently produced vector samples had a transduction titer 
about 10 fold higher compared to 40 fold concentrated vectors produced by stable production. 
 
ba
tc
h 
# producer cell line transfected plasmids 
TU/ml 
(concentration 
factor) 
VSV-G-GFP (1) 55 293T VSV-G/Gag-Pol/GFP 24.6x106 (40) 
 58 293T VSV-G/Gag-Pol/GFP 36.0x106  (40) 
 74 293T VSV-G/Gag-Pol/GFP 42.3x106 (40) 
VSV-G-Empty (2) 56 293T VSV-G/Gag-Pol na 
 62 293T VSV-G/Gag-Pol na 
 75 293T VSV-G/Gag-Pol na 
Gag/Pol-GFP (3) 57 293T Gag/Pol/GFP na 
 60 293T Gag/Pol/GFP na 
 63 293T Gag/Pol/GFP na 
 76 293T Gag/Pol/GFP na 
VSV-G-only (4) 103 293T VSV-G/GFP na 
RDpro-GFP (5) 64 STAR_RDpro_pHV none 0.9x106 (40) 
 67 STAR_RDpro_pHV none 2.5x106 (40) 
 87 STAR_RDpro_pHV none 2.8x106 (40) 
 91 STAR_RDpro_pHV none 13.3x106 (240) 
 93 STAR_RDpro_pHV none 2.8x106 (240) 
 95 STAR_RDpro_pHV none 4.9x106 (240)
RDpro-Empty (6) 65 STAR_RDpro none na 
 68 STAR_RDpro none na 
 88 STAR_RDpro none na 
 92 STAR_RDpro none na 
 94 STAR_RDpro none na 
 96 STAR_RDpro none na 
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Concentration factor of stably produced batches was increased to 240 fold to increase 
transduction titer (section 2.5.). 
 
3.3.2. Size Exclusion Chromatography of Vectors – Elution of LVs in Void  
During ultracentrifugation large cellular and subcellular debris are concentrated alongside 
vector particles and form part of the vector sample that was resuspended in Opti-MEM (hence 
referred to as crude sample). Size Exclusion Chromatography (SEC) was used to separate 
vector particles from small proteins.  Columns were packed with Sephacryl-500–HR medium 
with a bed volume of 140 ml and TEN buffer as mobile phase flowing at 0.8 ml/minutes (see 
section 2.3.2 of Materials and Methods chapter).  
For SEC 900 µl of crude vector sample were collected per column. The overlay of 
representative SEC protein elution profiles for each of the five vector samples is shown in 
Figure 7.  Figure 7 A shows a batch of three transiently produced samples VSV-G-GFP, VSV-G-
Empty and Gag/Pol-GFP with a void peak maximum between 0.8 and 1.0 mVolts (0.0008-0.001 
absorbance units [AU] at 280 nm), with Gag/Pol-GFP samples having the smallest void peak. 
Figure 7 B shows the equivalent for a batch of three stably produced samples, RDpro-GFP and 
RDpro-Empty showing void peak heights at 0.25 mVolts. Void peak heights of stably produced 
samples ranged from 0.1-0.25 mVolts (0.0001-0.00025 AU at 280 nm), hence they contain a 
lower amount of total proteins in the void fraction. Using the Sephacryl 500-HR column, the 
void peak in all samples was well separated from following peaks containing lower molecular 
weight proteins. Fractions containing the void peak were collected for further analysis and 
processed for LC-MS/MS. Control samples were 900 µl Opti-MEM that had not been in cell 
contact and Opti-MEM that was 24 hours incubated with 293T cells (900 µl). SEC 
chromatograms of these controls (Figure 7 C) showed a void peak of <0.1 mVolts, which is 2.5 
fold lower than the void peak height of stably produced samples (Figure 7 B) and up to 10 fold 
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lower than that of transiently produced samples (Figure 7 A), indicating that the void peak 
fractions of purified vector samples contain mainly proteins derived from vector production.  
Resuspension of vector samples in complete DMEM after ultracentrifugation resulted in high 
BSA levels in crude vector samples as shown in Figure 7 D. The protein that eluted at ~120 
minutes post-injection is believed to be derived from FCS in the complete DMEM as the peak 
height in samples resuspended in complete DMEM was about 10 fold higher than in vector 
samples resuspended in serum reduced Opti-MEM (Figure 7 A to C). Therefore reduced serum 
OptiMEM was used for vector preparation of all samples prepared for LC-MS/MS analysis. The 
size chromatography profile of 900 µl sample elution buffer TEN confirms all of the peaks 
represent protein and none of them are background noise (Figure 7 E). 
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Figure 9: SEC void peaks from cell supernatants collected from vector producing cells contain 
up to 2.5 to 10 fold more proteins compared to those collected from untransfected 293T cells. 
SEC chromatograms of vector samples, 900 µl of each concentrated vector sample were 
applied to the SEC column, representative elution profiles are shown. A)  transiently produced 
vector samples, VSV-G-GFP, VSV-G-Empty and Gag/Pol-GFP, B) stably produced vector 
samples, RDpro-GFP, RDpro-Empty, batch number (#) of vector preparation is indicated, 
C) Opti-MEM and Opti-MEM incubated 24hrs on 293T cells, D) RDpro-GFP vector preparations 
resuspended in complete DMEM (incl. 10 %FCS) after ultracentrifugation instead of serum 
reduced Opti-MEM, E) TEN buffer. 1 mVolts = 0.001 AU at 280 nm 
 
Analysis of p24 levels in SEC fractions of one RDpro-GFP sample by ELISA was used to 
determine which fractions contained the maximum vector particles. The detection range of the 
p24 ELISA used here is between 78 pg and 5 ng of p24 allowing the direct application of SEC 
fractions without an extra dilution or concentration step. The ELISA set up used here only 
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compares levels of p24 among fractions and cannot measure absolute levels of the protein in 
each of them. This was potentially due to two limitations in the early assay development. 1) 
The standard curve buffer contained 10% sheep serum and is normally used for crude samples 
that still contain FCS from DMEM used in vector production, whereas the SEC fractions are in 
TEN buffer without serum proteins, hence absolute OD405 readings of the samples were not 
comparable to absolute OD405 readings of the standard curve. 2) High concentration of 
Extravidin, an improved form of Streptavidin, resulted in a very fast enzymatic reaction after 
addition of the substrate p-nitrophenyl phosphate. The fast development did not allow reading 
high concentrated samples before the OD405 was out of detection range (>2.0 OD405). Since this 
assay was only intended to identify the fractions that contained highest amount of p24, OD405 
readings of SEC fractions relatively to each other were compared and no further experiments 
were conducted. P24 ELISA of RDpro-GFP shows that the highest amount of p24 protein is in 
the void peak (maximum in fraction 13, Figure 8).  
 
Figure 10: Maximum of p24 protein elutes in void peak fraction. Overlay of the SEC 
chromatogram of the analysed RDpro-GFP vector sample (900 µl, 40 fold concentrated, 1 
mVolts = 0.001 AU at 280 nm, y-axis in red) and p24 ELISA OD405nm readings (y-axis in blue) of 
each of the RDpro-GFP sample SEC fractions (RD-SEC, x-axis). Fraction 13, part of the void 
peak, shows highest OD405 reading of all analysed fractions. 0.8 ml/minutes in TEN buffer. 
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Elution of vector particles in the void peak was confirmed by Western blotting of the viral 
proteins. SEC fractions containing peak A to F were collected (Figure 9 A, peak A = void peak). 
Western blotting of viral proteins of these fractions showed detectable amounts of p24, VSV-G 
or RDpro only in the void peak of VSV-G-GFP and RD-GFP vector samples (peak A Figure 9B). In 
later eluting peaks (peaks B1 to F) no viral proteins were detected.  
 
Figure 11: Viral proteins elute in void peak fraction. A) Representative SEC chromatogram of 
vector sample RDpro-GFP with labelled peaks A-F and fractions, B) Western blotting of viral 
proteins p24 and envelope proteins RDpro or VSV-G in different peak fractions; 1 mVolts = 
0.001 AU at 280 nm. Signals for viral proteins were only detected in the void peak (peak A) 
fraction and not in later eluting protein peaks. 
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3.3.3. SDS-PAGE Silver Staining of Purified Vector Samples 
For evaluation of LV purification by SEC, crude and purified vector samples were directly 
compared by silver staining of proteins after separation by SDS-PAGE. 2 µl of 900 µl crude 
samples were loaded per lane, equivalent to 0.22 % of total crude vector sample purified by 
one SEC run. In comparison 1 % of the 4 ml void peak fraction (40 µl) was applied. The silver 
stain in Figure 10 shows that dominant protein bands in SEC void peak fractions correlate with 
viral proteins sizes (57 kDa= VSV-G Env, 55 kDa = Gag precursor pr55Gag, 24 kDa = capsid/p24)  
and overall SEC fractions contain less protein. Many protein bands that can be seen in crude 
samples are not detectable in void peak fractions. With a detection limit of 0.8 ng of protein 
this method shows that these proteins have been significantly reduced. 
 
Figure 12: Vector purification by SEC. Silver Staining of SDS-PAGE of crude compared to SEC 
purified vector sample (0.22% of 900 µl crude sample loaded on SEC column, 1% of 4 ml void 
peak fraction). SEC fractions contain less protein, dominant bands are at the position of viral 
proteins pr55Gag (55 kDa), capsid p24 (24 kDa) and VSV-G Env (57 kDa). 
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3.3.4. Recovery of Infectious Particles in Void Peak  
The transduction titer of void peak fractions was measured to assess if purified vector samples 
contain infectious vector particles. 293T cells were transduced with 0.45 µm filtered SEC void 
peak fractions of one VSV-G-GFP and one RDpro-GFP vector sample. The number of infected 
cells (GFP-positive cells) was counted by FACS. A total of 12% infectious vector particles could 
be recovered from crude samples after SEC purification in the analysed void peak (fractions 3 
and 4) of the VSV-G-GFP vector sample (Figure 11 A & B, batch #78). Fractions 3 and 4 in the 
vector sample RDpro-GFP contained only 3% of the number of infectious particles in the crude 
sample loaded on the column (Figure 11 C, batch #95).  
 
Figure 13: Recovery of infectious vector particles after SEC purification. A) SEC chromatogram 
of void peak of VSV-G-GFP vector sample, indicating analysed fractions for transfection titer, 1 
mVolts = 0.001 AU at 280 nm, B) Percentage of total infectious vector particles recovered from 
SEC fractions 3 and 4 of samples VSV-G-GFP batch #78 and C) RDpro-GFP batch #95. 
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3.3.5. 240 fold Concentration of Stably Produced Samples Results in 
Comparable Amount of Viral Proteins to 40 fold Concentrated 
Transiently Produced Samples 
 
Sample preparation of vector preparations for LC-MS/MS analysis involved the concentration 
of harvested cell supernatant by ultracentrifugation. Transiently and stably produced vector 
harvests were initially concentrated 40 fold. Compared to the void peak height of stably 
produced samples, void peaks of transiently produced samples were up to 10 fold higher when 
pseudotyped with VSV-G Env and up to 5 fold higher without an envelope protein (Figure 
12 A). Semi-quantitative analysis by densitometry (see section 2.4.5) of p24 in void peak 
fractions of concentrated vectors showed that the viral protein is about six fold lower in stably 
produced vector samples compared to transiently produced samples (Figure 12 B). LC-MS/MS 
of 40 fold concentrated stably produced samples resulted in the detection of very few protein 
species (chapter 3, section 4.3.1.1). Even though stably produced samples were confirmed to 
contain viral proteins, the results of this first LC-MS/MS batch raised the concern that 
produced RDpro-pseudotyped samples did not contain sufficient numbers of viral particles to 
detect cellular proteins in low abundance and might not be comparable to transiently 
produced samples. 
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Figure 14: 40 fold concentrated stably produced vector samples contain 6 to7 fold lower 
amount of p24 than 40 fold concentrated transiently produced samples. A) Representative 
void peak height of SEC of 900 µl transiently and stably produced samples; SEC chromatograms 
of transiently produced samples result in 6 to 10 fold higher void peaks than of stably 
produced vectors, B) Western blotting of Gag (anti-p24) show semi-quantitative analysis by 
densitometry of viral protein signal strengths; levels of p24 in transiently produced samples 
are 6 to 7 fold higher (6x or 7x) and levels of GagPr55 14 to 37 fold higher compared to stably 
produced samples (1x) ; for protein detection void peak fractions were desalted and 
concentrated. 
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To gain comparable amounts of core protein p24 in transiently and stably produced samples 
vectors, hence comparable numbers of viral particles, vectors produced by STAR-RDpro-pHV 
and STAR-RDpro cells were concentrated 240 fold instead of 40 fold by ultracentrifugation 
(from now on referred to as 240 fold and 40 fold concentration). Purification of vectors using 
SEC showed an average of a 3 fold higher void peak (0.33-0.8 mVolts) compared to 40 fold 
concentrated stably produced samples (0.1-0.25 mVolts) (Figure 13 A). Western blotting of 
equivalent amounts of total protein per sample showed that 240 fold concentrated stably and 
40 fold concentrated transiently produced samples contain comparable amounts of viral 
protein p24 (Figure 13 B). On average the transduction titer is 3 to 4 fold higher in 240 fold 
compared to 40 fold concentrated stably produced samples, hence infectivity of 240 fold 
concentrated RDpro-GFP vectors was still at least 3 fold lower compared to 40 fold VSV-G-GFP 
vectors (Figure 13 A). Void peak heights of VSV-G only 240 fold concentrated samples are 
about 6 fold higher than void peaks of 40 fold concentrated VSV-G pseudotyped vector 
samples (Figure 13 C). Purified vector samples were prepared for LC-MS/MS analysis. 
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Figure 15: 240 fold concentrated stably produced vector samples contain similar viral protein 
amounts compared to 40 fold transiently produced vector samples. A) Representative void 
peak height of SEC of 900 µl 40x transiently and 40x/240x stably produced vector samples and 
transduction titer (TU/ml); void peak height average of 0.33-0.8 mVolts in 240 x compared to 
~0.25 mVolts in 40 x concentrated stably produced sample; TU/ml increased 3 to 4 fold. B) 
Western blotting of Gag (anti-p24) and envelope protein RDpro and VSV-G show comparable 
amount of viral proteins when 250 ng total protein of 240 fold stably produced and 40 fold 
transiently produced samples are loaded. C) Void peak height of VSV-G only batch #103; 240 
fold concentrated. 
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For comparison of viral and total protein content of purified transiently and stably produced 
vector samples for LC-MS/MS analysis, equivalent amounts of total protein of all vector 
samples were loaded on one acrylamide gel and visualised by Western blotting and silver 
staining. Western blotting of viral protein p24 shows that the processed Gag capsid protein 
p24 is the dominant form over the precursor protein pr55Gag in stably and transiently 
produced samples (Figure 13 A). Pr55Gag is not detectable in RDpro-Empty and transiently 
produced samples. A longer exposure time of the blot might reveal weak signals around the 
size of 55 kDa as was seen in previous Western blots of these samples (Figure 13 B). The 
control ‘VSV-G only’ does not contain p24 as expected which was confirmed later by LC-
MS/MS (chapter 4). Presented in Figure 13 B is the Western blot of viral envelope proteins RD-
pro and VSV-G. As expected the Gag/Pol-GFP control sample does not contain VSV-G protein.  
Silver staining of these purified vector samples revealed only a few different bands in these 
samples which corresponded to the size of viral proteins identified by Western blot and 
confirm that dominant proteins in these samples are vector derived (Figure 14 C). Bands at the 
positions corresponding to the size of viral Env proteins RDpro (76 kDa) or VSV-G (57 kDa) 
respectively were detected only in samples that were expected to contain an Env protein, 
including RDpro-GFP as well as VSV-G-GFP, VSV-G-Empty and VSV-G only. In accordance with 
these results no signal at the position of 76 or 57 kDa was detected at that position in Gag/Pol-
GFP vector sample confirming it does not contain an Env protein. RDpro Env in RDpro-Empty 
samples was below detection limit using silver staining, which is 0.8 ng total protein per lane. 
Silver staining of stably produced samples shows a weak signal at position equivalent to 76 kDa 
(Figure 13 C), suggesting RDpro envelope protein is of lower concentration compared to VSV-
G-envelope protein in transiently produced samples. Signals at position of 57 kDa are the most 
dominant band in VSV-G pseudotyped samples and are likely to be the VSV-G envelope 
protein. However pr55Gag might contribute to that signal as it is also visible in silver stained 
stably produced samples (Figure 13 C and Figure 15). The capsid protein p24 was detected at 
the position of 24kDa in stably and transiently produced samples and was absent in VSV-G only 
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samples as expected. Silver staining of lower amounts of samples (Figure 15; 50 ng instead of 
100ng total protein/lane) confirm that dominant proteins correspond to the size of viral 
proteins with p24 being the most abundant protein in stably produced purified vector samples. 
 
 
 
Figure 16: Purification by SEC of all five vector samples and VSV-G control. A) Western Blotting 
of SEC-purified vector sample (250ng/lane) shows p24 in all LV samples and not in ‘VSV-G only’ 
control as expected. Less pr55Gag is detected in RDpro-Empty samples compared to RDpro-
GFP and transiently produced samples, B) RDpro and VSV-G protein Western blotting of SEC-
purified vector sample (250ng/lane). A) and B) Western blotting confirms that vector samples 
eluted in SEC void peak containing mainly viral proteins, shown by silver stain. C) Silver Stain of 
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SEC-purified vector sample (100ng/lane), dominant bands correlate with viral protein sizes. 
RD+=RDpro-GFP, RD-=RDpro-Empty, V+=VSV-G-GFP, V-=VSV-G-Empty, Vonly=VSV-G-only, 
G/P=Gag-Pol-GFP. 
 
 
 
Figure 17: Comparable amounts of p24 in vector samples for LC-MS/MS. Silver staining of SDS-
Page of vector samples after SEC purification and preparation for LC-MS/MS analysis. 
Transiently and stably produced samples show dominant bands at the position of pr55Gag (55 
kDa) and capsid p24 (24 kDa), the latter being of comparable signal strength. Signals at position 
equivalent of 57 kDa is stronger in transiently produced samples, correlating to the size of VSV-
G Env, whereas RDpro Env (76 kDa) is below detection limit. (V+ = VSV-G-GFP, V- = VSV-G-
Empty, RD+ = RDpro-GFP, RD- = RDpro-Empty); 100 or 50 ng total protein/lane loaded as 
indicated.  
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3.3.6. Desalting and Lyophilisation of SEC Void Fractions in Preparation for 
MS study 
Purified vector samples in SEC void peak fractions could not be analysed directly by LC-MS/MS. 
This is because proteins in vector samples needed to be digested by trypsin under the 
condition of pH 8.0. SEC fractions were eluted in TEN buffer (150 mM NaCl, 1 mM EDTA, 10 
mM Tris-HCl) that had a pH of 7.4, thus was too low for adequate protein digestion by trypsin. 
For each vector sample between eight and sixteen void peak fractions were pooled and 
dialysed to exchange TEN buffer (pH 7.4) with 10 mM ammonium bicarbonate (ABC, pH 8.5). 
ABC is volatile and sublimes into ammonium, water and carbon dioxide making it attractive for 
buffer exchange when the protein sample needs to be salt free and without any additional 
components added by dialysis which would stay behind after lyophilisation (Overcashier et al. 
1997). Assuming complete equilibration after dialysis over night the salt concentration of 
sample was reduced 375 times in ABC at that stage resulting in a salt molarity of 0.4 mM NaCl, 
0.0026 mM EDTA and 0.026 mM Tris-HCL. The buffer was changed twice the following day and 
samples dialysed for at least 2 hours after each buffer change. This resulted in a total salt 
dilution factor of 52.7x106. A minimum of 10 µg of total protein in a small volume of up to 500 
µl was needed for each vector samples for a LC-MS/MS run. To reduce sample volume dialysed 
fractions were freeze dried and resuspended in water. To quantify the total proteins in 
samples for LC-MS/MS analysis, an assay needed to be developed that allowed measuring low 
concentrations of total protein in a small sample volume. The standard Bradford assay was 
modified by increasing the sample to dye ratio. An aliquot of 5 µl of sample was diluted 1:160 
in water before addition of 200 µl concentrated Bradford dye. Furthermore the sample was 
acidified by adding 10 µl of 0.1 N HCl helping protein binding to Coomassie® Brilliant Blue G-
250 (Ramagli and Rodriguez, 1985). Assay details for the measurement of vector samples MS 
set 2 are shown in Table 11. After protein quantification samples were processed in the 
proteomics facility for LC-MS/MS analysis. 
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Table 11: Bradford Assay of Purified Vector Sample Set 2 for LC-MS/MS.  
Standard curve     OD595 reading 1 
OD595 
reading 2 
OD595 
reading 3 
OD595 
AVERAGE 
Protein 
(µg/ml) Total protein (µg) 
BSA concentration 
(µg/ml) 
volume of BSA 
(50 µg/ml, µl) 
10 mM ABC
(µl) 
0.1N HCl 
(µl) H2O (µl)     
diluted 
1:160 (5 µl 
in 800 µl) 
in 
200 µl 
0 0 5 10 785 0.0106 0.0119  0.0113   
0.125 2 5 10 783 0.0117 0.0238  0.0178   
0.3125 5 5 10 780 0.0346 0.0419  0.0383   
1.25 20 5 10 765 0.0836 0.0909  0.0836   
1.875 30 5 10 755 0.1378 0.1410  0.1394   
samples  sample (µl)         
RDpro-GFP  5 10 785 0.0171 0.0219 0.0172 0.0187 0.11 3.52 
RDpro-Empty  5 10 785 0.0107 0.0149 0.0197 0.0151 0.06 1.92 
VSV-G-GFP  5 10 785 0.0369 0.0454 0.0324 0.0382 0.41 13.12 
VSV-G-Empty  5 10 785 0.0252 0.0338 0.0347 0.0312 0.30 9.60 
 
 
 
Modified Bradford assay can detect low amounts of protein (0.125-1.875 µg/ml total protein). 
Total protein in 200 µl of dialysed and freeze dried SEC purified from 7.2 ml crude vector samples. 
The here developed modified Bradford assay allowed to use only 5 µl of prepared vector sample. 
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3.3.7. Summary of Vector Sample Preparation for LC-MS/MS 
In total three sets of transiently and stably produced vector samples were prepared for LC-
MS/MS analysis. A summary of the sample preparation process is outlined in Figure 16. Initially 
MS sets 1 and 2 of the five vector samples (VSV-G-only was only analysed in MS set 3) were 
produced by 40 fold concentration using ultracentrifugation. The amount of total protein was 
below 5 µg for RDpro-GFP of set 1 and 2 as well as for RDpro-Empty set 2 samples. As 
described in the following chapter (chapter 4) only very few different protein species were 
detected in stably produced samples. In order to analyse equivalent amounts of vector 
particles by LC-MS/MS, the amounts of viral protein p24 in stably and transiently produced 
samples was normalised by concentrating stably produced samples 240 fold, resulting in MS 
set 3 of stably produced samples (Table 12). Only the results from a comparable number of 
viral particles in stably and transiently produced samples allowed a meaningful comparison of 
the number of different cellular protein species in samples produced by different production 
methods and pseudotyped with different envelope proteins. Furthermore including another 
vector sample, transiently produced RDpro pseudotyped vectors, would could have allowed 
distinguishing between vector core or viral envelope associated proteins.  
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Figure 18: Vector Sample Processing for LC-MS/MS Analysis: Vectors were harvested in cell 
culture medium and processed in several steps before viral and host protein detection by LC-
MS/MS.  
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Table 12: Overview of Vector Samples Prepared for Mass Spectrometry (MS) analysis 
vector 
sample 
MS  
set 
40 x  
crude  
sample 
(ml) 
240 x 
crude 
sample 
(ml) 
total input of  
transducing  
units  
(x106 TU/ml) 
pooled  
void  
fractions 
(4ml x) 
total  
protein 
(µg) 
total  
protein 
used for 
MS (µg) 
VSV-G-GFP set 1 7.2 - 238.7 8 8.6 8.6 
VSV-G-Empty 7.2 - - 8 16.6 8.6 
Gag/Pol-GFP 7.2 - - 8 11.7 8.6 
VSV-G-GFP set 2  7.2 - 302.4 8 12.4 12.4 
VSV-G-Empty 7.2 - - 8 9.1 9.1 
VSV-G-GFP set 3 13.5 - 1314.9 15 76.5 10 
VSV-G-Empty 13.5 - - 15 67.1 10 
Gag/Pol-GFP 12.6 - ND 16 34.7 10 
VSV-G-only set 1 - 7.0 - 8 138.2 10.0 
RDpro-GFP set 1 7.2 - 6.5 8 2.5 2.5 
RDpro-Empty 7.2 - - 8 10.4 10.4 
RDpro-GFP set 2 7.2 - 15.1 8 3.4 3.4 
RDpro-Empty 7.2 - - 8 1.7 1.7 
RDpro-GFP set 3 - 10.8 50.9 12 20.8 10.0 
RDpro-Empty - 10.8 - 12 58.2 10.0 
 
Three sets of each transiently and stably produced samples were analysed by LC-MS/MS. MS 
sets for stably produced samples include 40 (MS set 1 and 2) and 240 fold (MS set 3) 
concentrated preparations; whereas transiently produced vector samples included only 40 fold 
concentrated vector samples (MS set 1, 2 and 3; VSV-G control 240 fold concentrated) The 
total amount of protein used for LC-MS/MS analysis is shown. One void peak fraction (4ml) 
was derived from 900 μl crude vector harvest, which is derived from 18 ml of crude 
unconcentrated vector harvest from one 15 cm dish (see section 2.3.1).  
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3.4. Discussion 
Growing numbers of clinical trials for larger patient cohorts require large scale vector 
production which is difficult to achieve with the transient transfection methods currently used 
in clinical protocols. The packaging cell line STAR (Ikeda et al., 2003) uses RDpro as an 
alternative envelope to VSV-G. In comparison to VSV-G, RDpro is not as toxic to producer cells, 
it is more resistant to inactivation by human serum (Strang et al., 2004) and its receptor is 
abundant on HSCs. The aim of this part of the study was to assess production and purification 
of LVs using the two different vector production methods for subsequent analysis by mass 
spectrometry (LC-MS/MS) followed by comparison of identified vector associated cellular 
proteins (chapter 4). Transiently produced samples included two VSV-G-pseudotyped samples 
(with or without a vector genome; VSV-G-GFP and VSV-G-Empty) as well as particles without 
RDpro or VSV-G envelope protein (Gag/Pol-GFP). Furthermore a sample without HIV-1 proteins 
was prepared (VSV-G-only). Stably produced samples were RDpro-pseudotyped vectors with 
and without a vector genome produced by the packaging cell line STAR (Ikeda et al., 2003).  
Analysis of vector samples showed that the transduction titer of crude samples was 10 fold 
higher in 40 fold concentrated transiently compared to 40 fold concentrated stably prepared 
samples. Western blotting showed that purified vector samples produced by STAR cells 
contained about 6 fold lower amounts of viral protein p24 compared to VSV-G pseudotyped 
transiently produced samples packaged by a comparable number of producer cells. Increasing 
the concentration factor of crude samples to 240 fold resulted in comparable p24 levels in 
vector samples. However these vectors were still at least 3 fold less infectious than VSV-G-
pseudotyped particles. Higher infectivity of VSV-G LVs in comparison to RDpro-pseudotyped 
LVs has also been reported in other studies (Ikeda et al., 2003, Strang et al., 2004, Bell et al., 
2010).  
After concentration of stably produced samples was increased 6 fold to a total concentration 
factor of 240, p24 levels in purified vectors increased 6 fold, comparable to p24 levels in 
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transiently produced samples. However the transduction titer of 240 fold concentrated RD was 
only increased by 3 fold, indicating that the 240 fold concentration resulted in higher level of 
non-infectious vectors. This may potentially be due to shedding of RDpro Env during 
concentration, thus a high concentration factor is possibly not suitable for vector particles 
pseudotyped with RDpro Env. Up-scaling of vector production by increasing the concentration 
factor is relatively easy due to the progress made in vector production process development of 
stable producer cell lines, such as their adaption to grow in suspension culture in large 
bioreactors (Ghani et al., 2006, Broussau et al., 2008). Concentration factors of 200 (Merten et 
al., 2011) and up to 2000 (Schweizer and Merten, 2010) have been used in vector production. 
High concentration factors might affect some envelope proteins more than others. It needs to 
be ensured that vectors are not damaged during preparation for clinical application resulting in 
low or non-infectious particles to avoid administration of high doses of viral proteins.  
Various methods have been employed to perform vector purification during vector processing 
for their clinical application. In up-scaled manufacturing protocols of clinical trials anion-
exchange chromatography (AExc) has been used to purify HIV-1 derived (Schweizer and 
Merten, 2010, Merten et al., 2011) and EIAV derived LVs (Stewart et al., 2010). Publications of 
recent clinical trials describe similar vector production processes (Aiuti et al., 2013, Biffi et al., 
2013). Vectors are clarified by filtration and purified by diethylaminoethyl (DEAE) AExc which is 
based on the purification of negatively charged proteins including vector particles by a 
positively charged chromatographic support and subsequent elution with high salt buffer at 
increasing ionic strength. Also referred to as gel filtration, SEC can follow and is used for final 
removal of trace contaminants such as smaller proteins with a similar negative charge than 
vector particles and for reformulation in storage buffer including adjustments of pH (Aiuti et 
al., 2013, Biffi et al., 2013). In comparison to AExc SEC has been shown to be less scalable due 
to its dilution effect; therefore it is less suitable as the first step in downstream vector 
processing however it can be used for vector purification in small scale experiments with low 
samples volumes (Slepushkin et al., 2003, Levine et al. 2006).  
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Purification of LVs by SEC has been used in our laboratory (Keating et al., 2008). Others have 
used process sequences of clarification and concentration by ultrafiltration of harvested 
vectors followed by SEC purification without an additional purification step (Slepushkin et al., 
2003, Levine et al., 2006). Sephacryl S-500 medium has been applied for purification of VSV-G 
pseudotyped LV products, VRX496, used in a small scale clinical trial for the treatment of HIV 
positive individuals. Transfiguracion et al. (2003) have assessed purification results of SEC by 
analytical AExc showing that the main non-viral protein contaminants in crude samples were 
BSA and low molecular proteins were not detectable in purified samples. Our results showed 
that void peak fractions contained vector particles as demonstrated by ELISA, Western blotting 
and detection of infectious particles. Levels of p24 protein were the highest in void peak 
fractions relative to all other fractions collected over the entire length of the chromatography 
run. By Western blotting viral proteins p24 and envelope RDpro as well as VSV-G were only 
detected in fractions corresponding to the void peak and not in fractions of later eluting peaks. 
This suggests that vector particles are of comparable mass to wild type HIV-1 virions of 277 
MDa (Carlson et al., 2008) by eluting at the expected time in the void peak. Furthermore 
results show that Sephacryl 500-HR SEC media is suitable for separation of vectors from 
molecular weight contaminants with a size of <2x107 Mr.  
Identification of potential true differences in vector associated host proteins among vector 
samples can only be ensured when possible co-purification of comparable sized proteins or 
protein aggregates with vectors is prevented as they could be identified as false-positive vector 
associated proteins. Tubulovesicular structures, similar to microvesicles, have been found in 
concentrated LVs pseudotyped with VSV-G (Pichlmair et al., 2007). The vector sample, 
Gag/Pol-GFP, did not carry VSV-G Env and was prepared to distinguish cellular proteins 
associated with vectors from VSV-G vesicle bound proteins in MS samples. Gag/Pol-GFP vector 
samples were produced by transiently transfection of the Gag-Pol packaging plasmid and GFP 
transfer vector (pRRLSIN.cPPT.PGK-GFP.WPRE) into 293T cells without any envelope encoding 
plasmid. Pr55Gag can assemble into virus like particles (VLPs) in the absence of envelope 
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proteins in cells and secrete extracellular (Gheysen, 1989). In our experiments the Gag/Pol 
encoding plasmid was transfected into cells, hence HIV-1 protease was expected to be 
expressed cleaving Pr55Gag allowing the detection of capsid p24 protein in vector samples. 
Detection of similar levels of p24 in purified Gag/Pol-GFP samples as well as a similar void peak 
height compared to other transiently produced samples indicated that LV sample Gag/Pol-GFP 
contained comparable numbers of viral particles without an envelope protein. Furthermore a 
sample, ‘VSV-G only’, was prepared by transfection of the VSV-G Env plasmid and GFP transfer 
vector plasmid and did not express HIV-1 structural proteins in order to investigate which 
proteins could be associated with VSV-G Env itself. Void peak fractions of this sample were 
anticipated to contain less protein than samples containing vector particles; hence the VSV-G 
only sample was concentrated 240 fold. Western blotting of the VSV-G-only sample showed 
similar levels of VSV-G Env to VSV-G-GFP and VSV-G-Empty samples, indicating transiently 
produced VSV-G pseudotyped samples contained similar levels of VSV-G complexes, such as 
aggregates and vesicles. 
Future investigations can be undertaken regarding the removal of impurities closely related to 
the size and shape of functional LVs, such as non-viral membrane vesicles. Another purification 
step could be included that can separate viral particles from vesicles. Rate zonal 
ultracentrifugation using iodixanol, a density gradient medium, has been used to eliminate cell 
membrane vesicles during purification of MoMLV-derived retroviral particles (Segura et al., 
2006a). In order to assess if any contaminating vesicles are present electron microscopy of 
crude and purified vector particles can be performed (Transfiguracion et al., 2003, Pichlmair et 
al., 2007). Further control samples can be included, such as harvests from mock-transfected 
293T cells, transfected with DNA plasmids not carrying HIV-1 or VSV-G sequences. In addition 
vectors could be produced in serum free medium, using for example, Opti-MEM, already from 
24 hours post-transfection (see section 2.3.1). 
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Vector purity was analysed using silver staining. During silver staining of polyacrylamide gels 
separated vector samples, silver ions are reduced to free metallic silver after forming 
complexes with a biochemical group of amino acids or nucleic acids (Merril and Pratt, 1986, 
Switzer C Robert, 1979). Silver stains showed that dominant bands of concentrated and 
purified vector samples correlated with the size of viral proteins detected by Western blotting. 
Purified samples contained fewer different protein species as many protein bands detected in 
crude samples could not be detected in purified vector samples.  
Fully functional vector particles, up to 12% of crude VSV-G pseudotyped vectors, could be 
recovered in SEC void peak fractions. Recovery of infectious particles of RDpro-GFP samples 
was lower and may be due to low numbers of infectious vector particles in crude samples and 
lower stability of the RDpro Env protein compared to VSV-G Env. Detection of infectious 
particles in void peak fractions confirms results from p24 ELISA and Western blotting, showing 
elution of vector particles in the void peak with some of them being mature and infectious. A 
recovery of up to 80% of infectious particles of purified transiently produced VSV-G 
pseudotyped LVs by SEC with Sephacryl S-500 medium has been reported previously 
(Slepushkin et al., 2003). Transfiguracion et al. (2003) separated VSV-G pseudotyped 
transiently produced LVs from smaller contaminants with a Sepharose CL-4B gel matrix using 
the same buffer as or study, TEN buffer (chapter 2), but a lower flow rate of 0.4 ml/minutes. 
Several fractions were titered including void peak fractions as well as fractions before and after 
the void peak showing that all are containing infectious particles with the majority of infectious 
particles recovered in the void peak fraction. Infectious particles in all measured fractions 
added up to an overall recovery of 70% of infectious viral particles loaded on the SEC column. 
Here only two fractions were titered, the void peak and the next fraction eluting after the void 
peak. Later eluting fractions could contain infectious particles hence the percentage of overall 
recovered infectious vectors may be higher than 12% in transiently produced samples. 
However the aim was to collect vector containing fractions without compromising purity of 
vector particles. Quantification of overall recovery was not relevant for protein analysis of 
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vector particles, hence only the void peak fraction containing highest levels of particles was 
collected. On the other hand it needs to be taken into consideration that a reduced number of 
infectious particles could be due to vector particle damage or dissociation of vector-associated 
host cell proteins that mediate infectivity. This could also apply to host proteins that are vector 
associated due to a function in vector assembly and budding which could consequently be lost 
for subsequent LC-MS/MS analysis. An alternative SEC buffer could be used such as PBS or 
serum free cell culture medium used in gel filtration steps in vector preparation for clinical 
trials (Aiuti et al., 2013). Prior to SEC AExc is applied in these trials. AEx is either based on 
chromatography medium such as diethylaminoethyl (DEAE) or membranes (Mustang Q). AEx 
using Mustang Q membranes showed a slightly lower recovery of infectious titers (65%) in 
comparison to SEC (80%) (Slepushkin et al., 2003). Alternatively a gradually increasing salt 
concentration in the elution buffer allows dissociation and elution of vector particles. It was 
shown that vectors eluting at a high salt concentration have a lower transduction efficiency 
compared to vectors eluting at a lower salt concentration during the same chromatography 
run (Yamada et al., 2003). The high amount of salt in the elution buffer potentially damages 
vector particles by stripping off surface proteins. Generally though, for large scale purification 
purposes AEXc is more suitable than SEC as it does not require initial concentration of vector 
harvests due to high flow rates.   
Dialysis and lyophilisation were used to desalt and further concentrate vectors since the 
identification of host and viral proteins in purified vector samples by LC-MS/MS analysis did 
not require functional particles. In an attempt to retain all associated proteins in the purified 
vector samples a dialysis cassette with a low molecular weight cut- off of 10 kDa was used. In 
large scale vector production concentration of purified vector samples is normally carried out 
before re-formulation by SEC (Aiuti et al. 2013; Biffi et al. 2013). Merten et al. (2011) applied 
hollow fibre tangenital flow requiring a relatively complex set up compared to dialysis and 
lyophilisation when using for small scale vector purification.  
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The here presented results outline LVs preparation by two different production systems 
followed by a suitable method of vector purification for comparative analysis of vector 
associated host-protein. LC-MS/MS analysis results are described in the following chapter.   
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4. Protein Composition of Purified Vector Samples 
Analysed by Tandem Mass Spectrometry 
4.1. Introduction 
Lentiviral vectors (LVs) analysed in this study are based on HIV-1 group M subtype B isolate 
HXB2. The vectors contain structural proteins encoded by gag and pol as well as a vector 
genome, and are pseudotyped with either VSV-G Env or RDpro. Like most viruses, the 
replication of HIV-1 and packaging of HIV-1 derived vectors relies heavily on host cell proteins 
that interact with viral proteins during its replication or production in packaging cells, 
respectively. Several cellular proteins have been identified to interact with viral proteins during 
wild-type HIV-1 assembly. Studying the role of cellular proteins associated with purified wild 
type HIV-1, such as clathrin, has elucidated the involvement of host proteins in virus assembly 
and budding (Ott, 2008, Chertova et al., 2006). Clathrin-associated heterotetrameric adaptor 
protein (AP) complexes are involved in cellular cargo sorting and transport (Ohno 2006). In 
HIV-1 budding AP-1 and AP-2 bind to the C-terminus of HIV-1 Env subunit gp41 regulating its 
location to the virus budding site (Berlioz-Torrent et al., 1999). RNA interference (RNAi) 
induced AP-1u silencing showed a reduced Gag release from HIV-1 infected cells (Camus et al., 
2007).  
Previous studies have shown that purified lentiviral vectors incorporate or bind to cellular 
proteins, such as actin, heat shock 70kDa protein  1A/1B (HSPA1A) and programmed cell death 
6-interacting protein (ALIX) (Denard et al., 2009, Wheeler et al., 2007). Several groups 
(Wheeler et al., 2007, Segura et al., 2008, Denard et al., 2009) have used mass spectrometry 
(MS) to identify vector associated host cell proteins. Mass Spectrometry permits the 
comprehensive analysis of the protein composition of complex biological samples and is a well-
established technique. Proteins of a sample can be analysed by mapping of the detected 
peptides and peptide sequencing using tandem MS (MS/MS). MS/MS involves the 
132 
 
measurement of peptide mass by a mass spectrometer followed by fragmentation of the 
peptides using electrospray and a second mass spectrometer to identify the amino acid 
sequence. Peptide preparation can be achieved by two different approaches. Single protein 
analysis is based on separation of proteins of a sample in a two dimensional SDS-PAGE (2D-
PAGE) with subsequent excision of protein spots and digestion using a protease, commonly 
trypsin. In 2D-PAGE proteins are separated in one dimension by size and in the second 
dimension by isoelectric point (pI). This method was used to analyse the Haemophilus 
influenzae proteome identifying 502 different proteins (Langen et al., 2000). Also referred to as 
shotgun analysis, LC-MS/MS allows identification of a complex protein mixture. For analysis of 
complex samples two-dimensional LC-MS/MS (LC/LC-MS/MS) can be used, also called 
multidimensional protein identification technology (MudPIT) which is based on peptide 
separation by columns packed with a strong cation exchanger (SCX) and a reverse-phase (RP) 
liquid chromatography (Link et al., 1999). This method was used for the analysis of the 
Saccharomyces cerevisiae proteome detecting 1485 proteins (Washburn et al., 2001). 
For analysis of size exclusion chromatography (SEC) purified lentiviral vectors we use LC-
MS/MS, for which purified vector samples are trypsinised and resulting peptides desalted 
using reverse-phase chromatography columns (see chapter 2). LC-MS/MS has been used in 
previous studies of proteome analysis of purified virions such as HIV-1 (Chertova et al., 2006), 
Kaposi’s Sarcoma-Associated Herpesvirus (KSHV) (Zhu et al., 2005) and Epstein-Barr virus 
(Johannsen et al., 2004). 
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4.2. Aim 
The aim of this chapter is to analyse five different types of SEC-purified lentiviral vectors, as 
well as the VSV-G-only control sample, by LC-MS/MS to identify their associated cellular 
proteins and determine any similarities or differences. Vector samples include VSV-G 
pseudotyped transiently produced vector samples as well as RDpro-pseudotyped stably 
produced vectors. Vectors with and without a vector genome were analysed as well as a 
sample prepared by transient transfection of only VSV-G Env with the vector genome DNA 
plasmid used as carrier DNA. Differences and similarities in host cell protein composition 
among vector samples are described that are the basis for further analysis regarding their 
function in vector assembly and budding from the producer cell. 
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4.3. Results 
4.3.1. Optimisation of Vector Sample Preparation for MS analysis 
4.3.1.1. Sample Optimisation to increase Protein Quantity 
Initially two vector samples were analysed by LC-MS/MS including stably produced RDpro-GFP 
and transiently produced VSV-G-GFP. Void peak fractions from 7 SEC runs of 40-fold 
concentrated RDpro-GFP were pooled. Void peak fractions from 5 SEC runs of VSV-G-GFP were 
pooled and processed for mass spectrometry analysis. In stably produced samples only Gag 
protein was identified. In VSV-G-GFP vectors an additional six human and seven bovine 
proteins as well as VSV-G Env were detected.  
For MS analysis of the next set of vector samples (referred to as ‘MS set 1’ below) the total 
amount of proteins was increased to a level that could be detected by modified Bradford 
protein assay by pooling void peak fractions from 8 SEC runs, instead of 5 SEC runs, of each 
sample and processing as previously described (see chapter 3, Table 3). MS set 1 included five 
LV vector samples analysed by LC-MS/MS, namely VSV-G-GFP, VSV-G-Empty, Gag/Pol-GFP, 
RDpro-GFP and RDpro-Empty. RDpro-GFP and RDpro-Empty samples, produced by STAR cells, 
contained 2.5 µg and 10.4 µg total protein, respectively. Transiently produced samples 
contained between 8.6 and 16.6 µg total protein. A total protein amount of 8.6 µg of each 
transiently produced sample was analysed. The number of different human cellular protein 
species in transiently produced samples identified by MS ranged from 14 to 49 proteins 
whereas stably produced samples contained only 1 to 5 proteins.  
Results of the subsequently analysed MS set 2 were similar, with stably produced samples 
containing significantly lower levels of total protein after pooling of SEC void peak fraction and 
significantly less MS identified protein species. Transiently and stably produced vector samples 
of MS set 1 and 2 were prepared by harvesting from a comparable number of producer cells 
and processing vector harvests for MS analysis in the same way including 40 fold concentration 
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by ultracentrifugation. As previously described, semi-quantitative comparison of viral proteins 
in each vector sample showed that p24 protein levels in stably produced samples were 6 fold 
lower compared to transiently produced samples.  
Preparation of stably produced vector samples of MS set 3 included a six fold increase of 
concentration of vector harvests during ultracentrifugation to a final concentration factor of 
240. This ensured that a comparable level of p24, thus a comparable number of vector 
particles in stably and transiently produced samples was subjected to LC-MS-MS and 10 µg of 
total protein per vector sample were analysed (MS set 3) (see chapter 3).  
 
4.3.1.2. Sample Optimisation to reduce Salt Contents  
Initially, exploratory work was carried out, in which SEC eluted void peak fractions were 
concentrated by diafiltration. Diafiltration is similar to dialysis applying a semi-permeable 
membrane to separate macromolecules from low molecular-weight compounds. Amicon Filter 
Units with a cut-off value of 3 kDa (Millipore) were used and vector samples concentrated by 
centrifugation. Unlike dialysis, Amicon Filter diafiltration does not rely on passive diffusion but 
on centrifugation, forcing water and molecules that are below 3 kDa through the membrane, 
resulting in concentration of large size molecules such as vector particles. This was followed by 
buffer exchange using dialysis with 50 mM Tris buffer of pH 8.5. Subsequent lyophilisation of 
dialysed samples reduced samples to the required volume of less than 200 µl. However salt 
levels were too high in these samples to allow sufficient trypsin digestion of sample proteins. 
Increasing the number of pooled void peak fractions to eight fractions per vector samples 
resulted in larger sample volumes and even higher amounts of salt per sample. Sample 
preparation using diafiltration was not further pursued.  An alternative method of reducing the 
amount of salt in vector samples, dialysis, was carried out using ammonium bicarbonate (ABC) 
resulting in complete removal of salts and a pH of 8.0. Using larger dialysis cassettes made the 
concentration step by diafiltration between SEC and dialysis redundant. 
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4.3.2. LC-MS/MS Settings for Data Acquisition and Analysis 
Mass spectrometry data analysis was carried out using Thermo Proteome Discoverer 1.2. with 
built-in Sequest (Thermo Fisher Scientific, Waltham, MA, USA). This program correlates 
tandem mass spectra of fragment ions with the predicted mass from amino acid sequences of 
peptides obtained from a database (Eng et al., 1994). For data analysis a database was 
composed including all known human proteins (taxon identifier 9606), bovine proteins (9913), 
proteins from HIV-1 group M subtype B (isolate HXB2) (11706), VS-Indiana virus (strain San 
Juan) (VSIV) (11285) and RD114 virus (11834), RDpro envelope protein (Ikeda et al., 2003) and 
Green fluorescent protein (GFP) (P42212) downloaded from Uniprot (Uniprot Consortium, 
2012). Analysis and acquisition settings are described in chapter 2 (section 2.3.3.2.). A 
manufacture default filter setting of a minimum of 2 peptides per protein was applied for data 
acquisition requiring the detection of two different peptides per protein for confident protein 
identification. LC-MS/MS analysis of stably produced vector samples of MS set 1 resulted in 
identification of only 1 to 5 different cellular protein species. In comparison 14 to 49 different 
cellular protein species were detected in transiently produced samples. RDpro Env was not 
identified in stably produced vector samples when using the default MS settings. Hence for 
data analysis the initially used setting was relaxed so that a minimum of one peptide per 
protein was required to confidently identify a protein. However RDpro Env peptides were still 
not detected with the relaxed settings.  
Another MS method of data acquisition was used in order to increase the likelihood to select 
less abundant proteins in a sample. As described in chapter 2 (section 2.3.3.2.), during the MS 
survey scan the five most abundant ions are chosen dynamically for fragmentation. A tandem 
MS spectrum of fragmented ions is created and its peptide sequence identified, hence only 
peptides whose ions were selected in the MS survey scan are identified. Ions that are not 
selected during a survey scan, for example ions of low abundance, will not be processed and 
corresponding peptides not be identified. The alternative MS method of data acquisition that 
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was used rejects ions that had been selected in one survey MS scan from re-selection in the 
next MS survey scan in favour of selecting ions of other peptides, increasing the likelihood of 
identifying proteins that are of lower abundance in the sample. This method (from now on 
referred to as ‘rejection method’) was only used in analysing RDpro purified vector samples in 
MS set 3 and allowed the identification of 4% and 7% of RDpro Env protein sequence in RDpro-
GFP and RDpro-Empty vector samples, respectively (Table 13, column ‘MS set 3 rejection’).  
4.3.3. LC-MS/MS Data Analysis 
4.3.3.1. Identification of Viral Proteins in Purified LVs by LC-MS/MS 
Peptides of viral proteins were detected in purified vector samples by LC-MSM/MS, including 
peptides of HIV-1 Gag protein domains matrix (MA), capsid (CA) and p2 as well as peptides of 
protease (PR), reverse transriptase (RT) and integrase (IN). Peptides of viral envelope proteins 
VSV-G Env and RDpro Env were also detected. In all samples, but VSV-G-only, peptides of HIV-1 
Gag could be identified and was the most dominant protein apart from VSV-G-pseudotyped 
samples in which the VSV-G envelope protein was the most abundant protein detected. The 
percentage of covered protein sequence is shown in Table 13  for the samples of MS set 3 of 
transiently produced vectors (40 fold concentrated) and stably produced vectors (240 fold 
concentrated). The percentage of protein sequence that was identified using the rejection 
method for MS analysis of stably produced samples is also displayed (Table 13). Using the 
rejection method, more peptide sequences were identified covering a wider sequence range of 
a protein. For example, instead of 57% of peptide coverage, the peptide coverage of CA 
protein was increased to up to 79% using the rejection method. RDpro Env was only identified 
using the rejection method and peptides could be detected covering 4% to 7% of the RDpro 
amino acid (AA) sequence. Gag-p2 and PR were also only detected using the rejection method 
in stably produced samples. Coverage of CA protein sequence was the highest ranging 
between 57% and 79%, equivalent to 122 to 169 AA out of capsid’s 215 AA. Peptides of Gag-p6 
were never detected in stably produced samples but in transiently produced samples VSV-G-
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GFP and VSV-G-Empty. As expected no peptides of VSV-G Env were detected in Gag/Pol-GFP 
samples but in all other transiently produced samples produced by co-transfection including 
VSV-G Env and no peptides originating from Gag or Gag-Pol protein were detected in the VSV-
G-only sample. 
Table 13: Coverage of Viral Protein Sequences by LC-MS/MS in Purified Vectors  
viral 
protein 
protein 
length 
(amino 
acids) 
MS set 3 
 
MS set 3 
rejection 
MS set 3 
 
  
RDpro-
GFP 
(240x) 
RDpro-
Empty 
(240x) 
RDpro-
GFP 
(240x) 
RDpro-
Empty 
(240x) 
VSV-
G-
GFP 
(40x) 
VSV-
G-
Empty 
(40x) 
Gag/Pol-
GFP 
(40x) 
VSV-
G- 
only 
(240x)
Gag 
 
MA 130 AA 45% 46% 63% 66% 73% 96% 67% ND 
CA 215 AA 57% 57% 79% 61% 49% 50% 52% ND 
p2 13 AA ND ND 100% 100% ND ND ND ND 
p6 56 AA ND ND ND ND 27% 18% ND ND 
Pol 
PR 98 AA ND ND 21% ND 17% ND 18% ND 
RT 559 AA 3% 5% 33% 21% 17% 17% 17% ND 
IN 287 AA ND ND 15% 9% 15% 9% 1% ND 
VSV-G-Env 411 AA ND ND ND ND 20% 22% ND 41% 
RDpro Env 565 AA ND ND 4% 7% ND ND ND ND 
Coverage of percentage of protein sequence is shown for vector samples of MS set 3; RDpro-
pseudotypes are concentrated 240x and transiently produced vectors 40x by 
ultracentrifugation. The default MS analysis settings were used or the rejection method, as 
indicated. Detected viral proteins include (UniProt identifier): HIV-1 Gag-Pol polyprotein 
(P04585; NCBI Ref # NP_057849.4); VSV-G glycoprotein (P03522, NP_041715.1); RDpro protein 
sequence based on RD114 glycoprotein (A7LKA7) (Ikeda et al., 2003, Bell et al., 2010). ND= not 
detected. 
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4.3.3.2. Identified Host Cell Proteins 
The results of MS detected cellular proteins are presented in Table 14. Mass spectrometry 
analysis did not allow quantitation of proteins within one sample, hence proteins were listed in 
the order of their detection in MS set 1 of vector samples and then grouped for example heat 
shock proteins listed together. For MS analysis each vector samples was subjected to one to 
three MS runs. Colour coding shows if a protein was detected in one (grey), two (yellow) or 
three runs (green) out of a total three MS runs of one sample. Of each transiently and stably 
produced vector sample three sets were made and analysed by MS (MS set 1 to 3). The VSV-G-
only sample was analysed once. In total 93 different cellular proteins were identified for all 
samples and all sets regardless the number of runs they appeared in. 
 
4.3.3.3. Variation in Host cell Protein Identification due to Sample Difference  
Variation of results could be seen when analysing one vector sample. 1) Variations between 
MS runs of one set of a vector sample, for example Gag/Pol-GFP set 1 was analysed three 
times by MS. Ten cellular proteins were detected in all three MS runs (Table 14, green fields) 
and six cellular proteins in two out of three runs (Table 14, yellow fields). 2) Variations in the 
presence of a specific protein in different sets of one vector sample, for example VSVG-Empty. 
Many proteins were detected in set 1, 2 and 3 of VSV-G-Empty but some only in one set. For 
instance, 36 proteins were detected in one out of three sets and 26 proteins in more than one 
set. In VSV-G-GFP sets 35 proteins were detected only in one set and 18 proteins in more than 
one out of three sets. 3) Variations of the number of different host protein species between 
sets of a vector sample. The number of different detected host proteins varied in VSV-G-GFP 
sets between 21 and 38 different proteins and in VSV-G-Empty sets between 24 and 49 
proteins. 
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Between different vector samples a certain level of similarity could be identified. VSV-G-GFP 
and VSV-G-Empty shared 39 cellular proteins.  In Gag/Pol-GFP samples, that did not carry any 
envelope proteins, 10 or 14 cellular proteins were detected in MS set 1 and 3, respectively. 
Five cellular proteins were shared between these two sets. Since the viral protein VSV-G Env 
was detected in MS set 2 of Gag/Pol-GFP, albeit at relatively low abundance, the results of this 
sample are excluded from further analysis. Only myosin-9 was unique to Gag/Pol-GFP vector 
sets. However all of the other 19 different cellular protein species detected in Gag/Pol-GFP set 
1 and 2 were also detected in VSV-G-GFP and/or VSV-G-Empty. One set of VSV-G-only sample 
was prepared, concentrated 240 fold and analysed by MS. VSV-G Env was the most frequently 
detected protein. In total 61 different cellular protein species were identified in this sample. 
VSV-G-GFP, VSV-G-Empty and VSV-G-only shared 38 proteins. Nineteen of these proteins were 
not detected in the samples Gag/Pol-GFP and RDpro-pseudotypes, thus only detected in all 
three VSV-G pseudotypes. These included proteins such as Actin-alpha, Cofilin 2, Calmodulin 1, 
Neutral amino acid transporter, Solute carrier family 3, Glyceraldehyde-3-phosphate 
dehydrogenase and Triosephosphate isomerase. Interestingly, Neutral amino acid transporter, 
also known as RD114/simian type D retrovirus receptor and the heavy chain of Solute carrier 
family 3 have been only detected in VSV-G pseudotyped samples. Thirteen proteins were 
unique to the 240 fold VSV-G-only sample. 
All proteins that were identified in stably produced samples were also identified in transiently 
produced samples with the exception of AHNAK (or Desmoyokin; Neuroblast differentiation-
associated protein) a protein only identified in RDpro-GFP and RDpro-Empty samples of set 3 
(240 fold concentrated). Peptides of RDpro Env were only detected when using the rejection 
method and after relaxing the applied filters by lowering the minimum number of identified 
peptides per protein for its unambiguous identification from two to one. Consequently one 
peptide of the RDpro protein could be detected at high confidence or one or more peptides at 
low confidence in MS set 3 of RDpro-GFP and RDpro-Empty. 
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Finally some identified cellular proteins were common to all five stably and transiently 
produced vector samples containing HIV-1 structural proteins (VSV-G-GFP, VSV-G-Empty, 
Gag/Pol-GFP and RDpro-GFP and Empty), regardless of the concentration factor or MS 
detection method. These include Beta-Actin, Heat shock cognate 71, Heat shock protein 70, 
Histone cluster 1- H2ah, Clathrin heavy chain 1, Alpha-enolase (ENO1), ALIX, Elongation factor 
1-alpha (EEF1A) and Cyclophilin A (Cyp A). MARCKSL1 was common to VSV-G-GFP, VSV-G-
Empty as well as RDpro-GFP and RDpro-Empty LV samples. Several bovine proteins have been 
detected in vector samples for example Serum albumin, Hemoglobin fetal subunit alpha and 
beta, potentially carried over from fetal calf serum used in cell culture during vector 
production and are excluded from Table 14. Similar numbers of different protein species were 
detected in VSV-G and RDpro- pseudotypes when using the rejection method for RD-pro 
sample analysis (see section 4.3.2.) Overall, the same bovine protein species have been 
detected in VSV-G-pseudotypes and RDpro-pseudotypes. No cellular proteins were identified 
that are unique to vector samples that carry a vector genome (GFP transfer vector), suggesting 
that none of the detected cellular proteins is solely associated with viral RNA. 
 
4.3.3.4. Difference in Host cell Protein Identification due to Technical Variation 
The second type of variation in MS results of vector samples can be classed as technical 
variation. This includes 1) preparation of vector sample with a concentration factor of 40 fold 
or 240 fold and 2) use of default settings or rejection method for MS analysis. MS analysis of 
40 fold concentrated stably produced samples detected a low number of cellular protein 
species varying from 1 to 5. On average 4.5 µg total protein were analysed in MS set 1 and 2. In 
order to exclude the possibility that this was due to insufficient amounts of viral particles in 
the prepared sample, RDpro-pseudotyped vector concentration was increased from 40 to 240 
fold during production. Concentration of RDpro-pseudotyped vectors was increased by 6 fold 
to a final concentration factor of 240 by ultracentrifugation as previously described (see 
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chapter 3) and therefore 10 µg of total protein were subjected to MS (MS set 3). Compared to 
results of 40 fold concentrated RDpro pseudotyped samples, set 1 and set 2, a six fold 
increased concentration factor resulted in a small increase in the number of protein species 
detectable by LC-MS/MS. In 240 fold concentrated RDpro-GFP and RDpro-Empty samples 5 
and 8 cellular proteins species were identified, respectively, however compared to transiently 
produced samples this number is still substantially lower. This could indicate that RDpro-
pseudotyped vectors associate with less cellular proteins than VSV-G pseudotypes, however 
this hypothesis could only be confirmed if an additional sample, RDpro-GFP produced by 
transient transfection, was included in this study. To investigate if RDpro-pseudotypes contain 
many protein species that are less frequently detected, hence potentially of low abundance, 
MS set 3 of 240 fold stably produced samples was analysed using the above described 
rejection method of data collection. This increased the number of detected viral and cellular 
peptides to 15 different cellular protein species detected in RDpro-GFP and 19 cellular proteins 
in RDpro-Empty, comparable to Gag/Pol-GFP vectors.  
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Table 14: LC-MS/MS Identified Proteins in all Vector Samples (listed in the order of their detection in MS set 1 of vector samples, then grouped) 
total number of cellular/host proteins  21 23 38 49 24 27 61 14 10 1 4 5 15 5 2 8 19 
    VSV-G-GFP VSV-G-Empty 
V
S
V
-
G
 
-
o
n
l
y
 Gag-Pol-
GFP RDpro-GFP RDpro-Empty 
Full Protein Name UniProt  ID 
set 
1 
set 
2 
set 
3 
set 
1  
set 
2 
set 
3 
set 
3 
set 
1 
set 
3 
set 
1 
set 
2 
set 
3 
s
e
t
 
3
 
r
e
j
e
c
t
i
o
n
 
set 
1 
set 
2 
set 
3 
s
e
t
 
3
 
r
e
j
e
c
t
i
o
n
 
Glycoprotein G (VSV-G) P03522                                   
Gag-Pol polyprotein (HIV-1) P04585                                   
RDpro envelope (RD114) A7LKA7                                   
Actin, beta (ACTB) Q53G76                                   
Actin, alpha skeletal muscle (ACTA1) Q5T8M8                                   
Cofilin 1 , non-muscle (CFL1) G3V1A4                                    
Cofilin 2, muscle (CFL2) G3V5P4                                   
Calmodulin 1 (CALM1) E7ETZ0                                   
ATPase, Na+/K+ transporting, alpha 1 polypeptide 
(ATP1A1) 
B7Z3U6                                   
ATPase, Na+/K+ transporting, beta 3 polypeptide 
(ATP1B3) 
C9JA36                                   
Heat shock cognate 71kDa protein (HSC71) P11142                                   
Heat shock 70 kDa protein 1A/1B(HSPA1A) P08107                                   
Heat shock protein HSP 90-beta (HSP90AB1) P08238                                   
Tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, zeta 
polypeptide (YWHAZ) 
E7EX29                                   
Triosephosphate isomerase (TPI1) 
 
B7Z5D8                                   
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 Table 14 continued (2/5):   V+ V- V G/P R+ R- 
Full name UniProt  ID 
set 
1 
set 
2 
set 
3 
set 
1  
set 
2 
set 
3 
set 
3 
set 
1 
set 
3 
set 
1 
set 
2 
set 
3 
set 
3 R 
set 
1 
set 
2 
set 
3 
set 
3 R 
Histone cluster 1, H1c (HIST1H1C) 
 
P16403                                   
H2A histone family, member X (H2AFX) P16104                                   
Histone cluster 1, H2ah (HIST1H2AH) 
 
Q96KK5                                   
Histone H2B (HIST2H2BE) A8K9J7                                   
Histone cluster 1, H2bj (HIST1H2BJ) P06899                                   
Histone cluster 1, H4h (HIST1H4H) Q0VAS5                                   
Neutral amino acid transporter Q15758                                   
Solute carrier family 3 (AA transporter heavy 
chain), member 2 (SLC1A5) 
F5GZS6                                   
60S acidic ribosomal protein P2 (RPL2) P05387                                   
60S ribosomal protein L7a (RPL7A) P62424                                   
60S ribosomal protein L3 (PRL3) P39023                                   
Ribosomal protein L4 (RPL4) P36578                                   
Ribosomal protein L18 (PRL18) F8VYV2                                   
Ribosomal protein S8/S3 (RPS8/S3) Q5JR95                                   
Ribosomal protein L14 (RPL14) Q6IPH7                                   
Nucleophosmin (NPM1) P06748                                   
Elongation factor 1-alpha (EEF1A) Q504Z0                                   
Transferrin receptor protein 1 (TFRC) P02786                                   
Polyubiquitin-C (UBC) P0CG48                                   
Glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) 
E7EUT5                                   
Tubulin, alpha 1b (TUBA1B) Q8WU19                                   
Tubulin, alpha 1a (TUBA1A) Q71U36                                   
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 Table 14 continued (3/5):   V+ V- V G/P R+ R- 
Full name UniProt  ID 
set 
1 
set 
2 
set 
3 
set 
1  
set 
2 
set 
3 
set 
3 
set 
1 
set 
3 
set 
1 
set 
2 
set 
3 
set 
3 R 
set 
1 
set 
2 
set 
3 
set 
3 R 
Tubulin, beta class I (TUBB) Q5JP53                                   
Syntenin-1 (SDCBP) B4DHN5                                   
Chloride intracellular channel protein 1 (CLIC1) O00299                                   
Alpha-enolase (ENO1) P06733                                   
Guanine nucleotide-binding protein G(k) subunit 
alpha (GNAI3) 
P08754                                   
Clathrin heavy chain 1 (CLTC)  Q00610                                   
Programmed cell death 6-interactingprotein (ALIX) Q8WUM4                                   
Neuroblast differentiation-associated protein 
(AHNAK)  
Q09666                                   
Radixin (RDX) P35241                                   
MARCKS P29966                                   
MARCKS-related protein (MARCKSL1) P49006                                   
Annexin A2 (ANXA2) P07355                                   
Annexin A5 (ANXA5) E9PHT9                                   
Cyclophilin A (CYPA) A8K486                                   
Moesin (MSN) P26038                                   
Basigin (BSG) P35613                                   
Ezrin (EZR) E7EQR4                                   
Ras-related protein Rab-1A (RAB1A) B7Z8M7                                   
Ras-related protein Ral-A (RALA) P11233                                   
Ras-related protein R-Ras2 (RRAS2) B7Z6C4                                   
Ras-related protein Rab-7a (RAB7A) P51149                                   
Cortactin  (CTTN) Q96H99                                   
Y box binding protein 1 (YBX1) 
 
P67809                                   
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 Table 14 continued (4/5):   V+ V- V G/P R+ R- 
Full name UniProt  ID 
set 
1 
set 
2 
set 
3 
set 
1  
set 
2 
set 
3 
set 
3 
set 
1 
set 
3 
set 
1 
set 
2 
set 
3 
set 
3 R 
set 
1 
set 
2 
set 
3 
set 
3 R 
Brain abundant, membrane attached signal 
protein 1 (BASP1) 
P80723                                   
unconventional Myosin IC (MYO1C)  F5H6E2                                   
Myosin-9 (MYH9) P35579                                   
Desmoglein-2 (DSG2) Q14126                                   
Poly [ADP-ribose] polymerase 1 (PARP1) P09874                                   
Protein kinase C and casein kinase substrate in 
neurons 3 (PACSIN3) 
 
Q9UKS6                                   
Vesicle-associated membrane protein 3 (VAMP3) Q15836                                   
Plastin 3 (PFS3) B7Z6M1                                   
Profilin-1 (PFN1) P07737                                   
Prostaglandin F2 receptor inhibitor (PTGFRN) Q4QQP8                                   
Creatine kinase B-type (CKB) P12277                                   
Filamin A (FLNA) Q5HY54                                   
Lactadherin (MFGE8) Q08431                                   
Charged multivesicular body protein 4b (CHMP4B) Q9H444                                   
EH domain-containing protein  4 (EDH4) Q9H223                                   
Zinc finger CCCH-type antiviral protein 1 
(ZC3HAV1) 
Q7Z2W4                                    
Mov10, Moloney leukaemia virus 10, homolog 
(mouse) (MOV10) 
Q9HCE1                                   
Talin 1 (TLN1) Q5TCU6                                   
Polyadenylate-binding protein 4 (PABPC1) P11940                                    
Ubiquitin-like modifier activating enzyme 1 Q5JRR6                                   
Tubulin, beta 3 class III (TUBB3) Q9BV28                                   
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 Table 14 continued (5/5):   V+ V- V G/P R+ R- 
Full name UniProt  ID 
set 
1 
set 
2 
set 
3 
set 
1  
set 
2 
set 
3 
set 
3 
set 
1 
set 
3 
set 
1 
set 
2 
set 
3 
set 
3 R 
set 
1 
set 
2 
set 
3 
set 
3 R 
Plasma membrane calcium-transporting ATPase 1 
(ATP2B1) 
P20020                                   
Golgi-associated, gamma adaptin ear containing, 
ARF binding protein 2 (GGA2) 
O14564                                   
Secretory carrier-associated membrane protein 3 
(SCAMP3) 
O14828                                   
Ras-related C3 botulinum toxin substrate 1 (RAC1) A4D2P2                                   
Ras-related protein Rap-1b (RAP1B) B4DW94                                   
Alpha-actinin-4 (ACTN4) A4K467                                   
Lipolysis stimulated lipoprotein receptor (LSR) Q86X29                                    
Destrin (actin depolymerizing factor) (DSTN) F6RFD5                                   
Erythrocyte band 7 integral membrane protein P27105                                   
Fructose-bisphosphate aldolase A (ALDOA) P04075                                   
Importin subunit alpha-1 (KPNA2) Q53YE3                                   
Solute carrier family 9, subfamily A (SLC9A3R1) O14745                                   
Sorting nexin-9 (SNX9) Q9Y5X1                                   
Transgelin-2 (TAGLN2) P37802                                   
WD repeat-containing protein 1 (WDR1) O75083                                   
 
LC-MS/MS identified proteins listed in the order of their detection in MS set 1 of vector samples, then grouped into for example heat shock proteins, ribosomal 
proteins. UniProt accession number for each protein is given (http://www.uniprot.org/). Between 1 and 3 preparations per vector sample were analysed (MS sets). 
Identified proteins in RDpro-GFP and RDpro-Empty samples MS set 3 using the rejection method are indicated (‘set 3R’). Colour coding: a protein was detected in 
one (grey), two (yellow) or three runs (green) out of a total three runs of one set. Striped shading of RDpro Env in MS set 3R indicates only one peptide of this 
protein was detected at high confidence or 2 or more at low confidence. 
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In total, five cellular proteins, AHNAK, ALIX, MARCKSL1, ENO1 and EEF1A, were selected for 
further analysis that were common to most of the analysed samples and have not been 
associated with the HIV-1 life-cycle, in particular with assembly or budding of HIV-1 before. 
However they have been previously identified in HIV-1 virions, thus were interesting for 
further analysis. AHNAK, unique to RDpro-pseudotyped samples, was also further analysed. 
The coverage of their protein sequence by identified peptides is shown in Table 15. 
Peptides covering 1.8 % to 3.4 % of the 5890 AA long AHNAK sequence were detected in 
RDpro-pseudotypes and none in samples with VSV-G Env or Gag-Pol/GFP without an 
envelope protein; hence this protein may be associated with RDpro Env. Using the default 
MS acquisition method ALIX, MARCKSL1, ENO1 and EEF1A were identified in at least 4 out 
of the six different analysed vector samples. Applying the rejection methods for MS 
detection ALIX, ENO1 and EEF1A could be also detected in stably produced samples. 
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Table 15: Coverage of Selected Host Protein Sequences (in %) detected by LC-MS/MS in Purified Vectors 
protein 
protein 
length 
MS set 1*, 2** or 3 
 
MS set 3 
 
MS set 3 
rejection 
  
VSV-G –
GFP 
40x 
VSV-G – 
Empty 
40x 
Gag/Pol-
GFP 
40x 
VSV-G –
only 
240x 
RDpro-
GFP 
240x 
RDpro-
Empty 
240x 
RDpro –
GFP 
240x 
RDpro - 
Empty 
240x 
AHNAK 5890 AA ND ND ND ND 1.8% 3.4% 1.8% 1.2% 
ALIX 873 AA 5.2% 6.7% 6.0% 3.7% ND ND 4.7% 6.5% 
MARCKSL1 195 AA 39% 11%* ND 47% 37% 45% 36% 44% 
ENO1 434 AA 6.9% 7.3% 8.8% 13% ND ND 12% 14% 
EEF1A 308 AA 7.6%** 11% 7.6%* 11% ND ND 11% 11% 
 
Proteins detected in LC-MS/MS of each MS set vector sample: in 3 of 3 MS runs of each sample (green); 2 of 3 runs (orange); 1 of 3 runs (grey); protein length is 
given in amino acids (AA). Protein detected in set 1 (*) or set 2 (**).  
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4.3.5.3. Confirmation of the Presence of Selected Host Proteins  
Western blotting of p24 and envelope proteins VSV-G as well as RDpro in vector samples 
was used to verify the presence of viral proteins (see chapter 3). The presence of selected 
MS-identified host-proteins, AHNAK and ALIX, was also confirmed by Western blotting 
(Figure 17). 
 
Figure 19: Confirmation of LC-MSM/MS detected Host Proteins by Western Blotting in 
vector samples. ALIX was detected in purified vector samples by Western blotting in stably 
and transiently produced samples. The presence of AHNAK was confirmed in stably 
produced purified vector samples. RDpro-GFP (RD+), RDpro-Empty (RD-), Gag-Pol-GFP 
(G/P), VSV-G-GFP (V+), VSV-G-Empty (V-), VSV-G-only (V-only). 
 
4.3.5.4. Functions of Identified Host Proteins 
For functional characterisation and analysis of LC-MS/MS identified proteins, IPA 
(‘Interactive Pathway analysis’ of complex ‘omics data by Ingenuity® Systems; 
www.ingenuity.com; Mountain View, CA, USA) was used. Protein function analysis is based 
on functional annotations in the web-based Ingenuity® Knowledge Database. All identified 
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cellular proteins were collated in a list using the UniProt identifier and uploaded into IPA. 
The 93 identified cellular proteins were mapped by IPA, of which 52 are located in the 
cytoplasm, 15 in the nucleus, 24 at the plasma membrane and two proteins were classified 
as being located in the extracellular space (Lactadherin and WD repeat-containing protein 
1). Identification data was further categorised into functional families. Out of 93 proteins, 
23 were classified as enzymes, 12 as transporters, 5 as transcription regulators and the 
remaining 53 proteins were not classified.  
Cellular functions were identified and categorised. Categories with the most proteins of our 
dataset are shown in Table 16. About 51% LC-MS/MS identified proteins take part in the 
mechanisms of cellular assembly and organisation, cell function and maintenance as well as 
cell death. Some of the proteins fall into several functional categories as shown in Figure 
18, hence identified host proteins have more than one specific role. These identified 
proteins are annotated to function in processes such as the organisation of the cytoplasm 
and cytoskeleton, in microtubule dynamics, formation of cellular protrusions and in 
necrosis and apoptosis. 
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Table 16 : Top Molecular and Cellular Functions of LC-MS/MS Identified Proteins 
Functional 
Category 
Functions Annotation 
No. of 
Proteins 
Cellular Assembly 
and Organisation 
Organisation of 
Cytoplasm, Organisation 
of Cytoskeleton, 
Microtubule Dynamics, 
Formation of Cellular 
Protrusions 
Organisation of Organelle 45 
Cellular Function 
and Maintenance 
Engulfment of Cell, 
Phagocytosis, Endocytosis, 
Organisation of Filaments 
51 
Cell Death Necrosis, Apoptosis 50 
Top functional categories with at least 10 proteins per function annotation identified by LC-
MS/MS are shown using Ingenuity® Knowledge Database of IPA by Ingenuity® Systems. 
 
 
Figure 20: Venn diagram of top molecular and cellular functions of LC-MS/MS identified 
proteins classified by functional annotation of the Ingenuity® Knowledge Database of IPA by 
Ingenuity® Systems. Functional overlap of proteins is shown. 
 The IPA software maps the proteins in the dataset to the information in the Ingenuity®  
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Knowledge Base and then places the identified cellular proteins into well-established 
signalling or metabolic pathways, termed "canonical pathways". Canonical pathways have 
been defined as “idealised or generalised pathways that represent common properties of a 
particular signalling module or pathway” (Science magazine 
(http://stke.sciencemag.org/about/help/cm.dtl) as opposed to specific pathways in which 
components are known to act together in a particular organism, tissue or cell type. 
The top five pathways each with at least 10 associated proteins of the dataset are displayed 
along with the number of proteins from the dataset that map to each pathway over the 
total number of proteins that map to the canonical pathway in the Ingenuity® Pathways 
Knowledge Base is displayed in Figure 19A. These pathways include actin cytoskeleton 
signalling, epithelial adherence junction signalling and remodelling (Figure 19B), integrin 
signalling and clathrin mediated endocytosis (Figure 19C). Proteins associated with 
mechanisms of viral host cell exit and their association with the top five pathways is 
illustrated. Several proteins act in more than one pathway as depicted in the Venn 
diagrams. In this study proteins have been identified that have previously been shown to be 
involved in viral exit from host. Among them are two known factors involved in the ESCRT 
machinery, ALIX, identified in all vector samples as well as the VSV-G-only control and 
CHMP4, member of ESCRT-III, only identified in VSV-G-GFP and VSV-G-Empty samples. 
Members of the actin protein family, actin alpha and actin beta, have been detected in all 
vector samples. 
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Canonical Pathway 
Identified Proteins/ Total Number 
of Proteins of Canonical Pathway in 
Ingenuity® Pathways Knowledge 
Base 
Actin Cytoskeleton Signalling 15/242 
Epithelial Adherent Junction  Signalling  12/154 
Epithelial Adherent Junction Remodelling 10/70 
Clathrin Mediated Endocytosis 11/198 
Integrin Signalling 11/208 
Mechanism of Viral Exit from Host Cell 4/45 
 
 
 
Figure 21: LC-MS/MS Identified Proteins of the Top Five Canonical Pathways. A) Top five 
canonical pathways, at least 10 of the identified host proteins are associated to the listed 
pathways. Furthermore four proteins were identified out of 45 proteins that are associated 
with mechanisms of viral exit from host cells stored in the Ingenuity® Pathways Knowledge 
Base. B) Venn diagrams of proteins that are associated with at least one of the top five 
canonical pathways.  
 
A 
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4.3.5.5. Functions of Proteins Exclusive to Samples Containing VSV-G 
             (VSV-G-GFP, VSV-G-Empty and VSV-G-only)  
Functional category and pathway analysis of 19 proteins, that were exclusively identified in all 
three VSV-G Env-containing samples, including VSV-G-GFP, VSV-G-Empty and VSV-G-only, was 
performed using the Ingenuity® Pathway Knowledge Base. Ten out of 19 of these proteins are 
located at the plasma membrane, eight proteins in the cytoplasm and one protein in the 
nucleus. Functional categorisation using IPA software assigns these 19 proteins to be involved 
in cellular assembly and organisation, such as organisation of the cytoskeleton, microtubules 
dynamics and formation of cellular protrusions but also molecular transport (Table 17). Actin-
alpha, Cofilin 2, Radixin, Ezrin, Tubulin-beta class I, Protein kinase C and casein kinase substrate 
and Talin 1 are members of the cytoskeleton or take part in its organisation. Four of the 
proteins found in VSV-G containing samples work as transporters, including transmembrane 
transporters (SLC1A5, SLC3A2 and Basigin) as well as proteins helping vesicular transport, such 
as Vamp3. 
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Table 17: LC-MS/MS Identified Proteins Unique to Samples Containing VSV-G 
Full Name UniProt Identifier Family 
Cellular 
Location Function (NCBI Gene Annotation) 
Actin, alpha 
skeletal muscle 
(ACTA1) 
Q5T8M8 Other Cytoplasm structural constituent of cytoskeleton 
Cofilin 2, muscle 
(CFL2) G3V5P4 Other 
Cytoplasm/ 
Nucleus 
involved in the regulation of 
actin-filament dynamics, controls 
actin polymerization and 
depolymerisation in a pH-
dependent manner 
Calmodulin 1 
(CALM1) E7ETZ0 Other Cytoplasm 
member of the EF-hand calcium-
binding protein family 
Triosephosphate 
isomerase (TPI1) B7Z5D8 Enzyme Cytoplasm 
catalyses the isomerization of 
glyceraldehydes 3-phosphate 
(G3P) and dihydroxy-acetone 
phosphate (DHAP) in glycolysis 
and gluconeogenesis 
Neutral amino 
acid transporter 
(SLC1A5) 
Q15758 Trans-porter 
Plasma 
Membrane 
neutral amino acid transporter, 
can act as a receptor for 
RD114/type D retrovirus (Larriba 
et al., 2001) 
Solute carrier 
family 3 (amino 
acid transporter 
heavy chain), 
member 2 
(SLC3A2) 
F5GZS6 Trans-porter 
Plasma 
Membrane 
regulation of intracellular calcium 
levels and transports L-type 
amino acids 
Ras-related 
protein Rab-1A 
(RAB1A) 
B7Z8M7 Enzyme Cytoplasm 
member of the Ras superfamily of 
GTPases, cycles between inactive 
GDP-bound and active GTP-
bound forms, vesicle traffic from 
endoplasmic reticulum to Golgi 
apparatus 
Glyceraldehyde-3-
phosphate 
dehydrogenase 
(GAPDH) 
E7EUT5 Enzyme Cytoplasm 
catalyses energy-yielding step in 
carbohydrate metabolism, 
reversible oxidative 
phosphorylation of 
glyceraldehyde-3-phosphate in 
the presence of phosphate and 
nicotinamide adenine 
dinucleotide (NAD) 
Tubulin, beta class 
1 (TUBB) Q5JP53 Other 
Plasma 
Membrane 
major components of 
microtubules 
Radixin (RDX) P35241 Other Cytoplasm 
may be important in linking actin 
to plasma membrane, highly 
similar in sequence to both ezrin 
and moesin 
    
 
 
157 
 
Table 17 continued (2/2):     
Full Name UniProt Identifier Family 
Cellular 
Location Function (NCBI Gene Annotation) 
MARCKS P29966 Other Plasma Membrane 
substrate for protein kinase C, 
actin filament crosslinking protein 
Basigin (BSG) P35613 Trans-porter 
Plasma 
Membrane 
important in spermatogenesis, 
embryo implantation, neural 
network formation, tumour 
progression 
Ezrin (EZR) E7EQR4 Other Plasma Membrane 
cross-linkers between plasma 
membranes and actin-based 
cytoskeletons, key role in cell 
surface structure adhesion, 
migration and organisation 
Desmoglein-2 
(DSG2) Q14126 Other 
Plasma 
Membrane 
part of desmosomes, cell-cell 
junctions between epithelial cells  
Poly [ADP-ribose] 
polymerase 1 
(PARP1) 
P09874 Enzyme Nucleus 
important for differentiation, 
proliferation and tumour 
transformation, part of DNA 
strand break repair pathway 
Protein kinase C 
and casein kinase 
substrate in 
neurons 3 
(PACSIN3) 
Q9UKS6 Other Cytoplasm 
involved in linking actin 
cytoskeleton with vesicle 
formation 
Vesicle-associated 
membrane protein 
3 (VAMP3) 
Q15836 Other Plasma Membrane 
member of SNARE (Soluble NSF 
Attachment Protein Receptor), 
involved in vesicular transport 
from late endosomes to trans-
Golgi network 
EH domain-
containing protein  
4 (EHD4) 
Q9H223 Enzyme Plasma Membrane role in early endosomal transport 
Talin 1 (TLN1) Q5TCU6 Other Plasma Membrane 
cytoskeletal protein, 
concentrated in areas of cell-
substratum and cell-cell contacts, 
plays a significant role in actin 
filament assembly and in 
spreading and migration of 
various cell types 
Proteins identified in all three samples containing VSV-G with UniProt identifier and cellular 
location are shown; proteins were detected in at least one MS sample, functional annotation 
taken from NCBI Entrez Gene (http://www.ncbi.nlm.nih.gov/gene/) or other sources as 
indicated. 
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4.3.3.5. Functions of Host Proteins Common to Transiently and Stably Produced 
LV Samples 
Eight cellular proteins are common to all transiently and stably produced vector samples as 
well as VSV-G-only control including  Beta actin, HSC71, HSPA1A, HIST1H2AH, Alpha-enolase, 
ALIX and Cyclophilin A. Clathrin heavy chain 1 was detected in all vector samples but VSV-G-
only control. Elongation factor 1 alpha and MARCKSL1 were common to VSV-G-GFP, VSV-G-
Empty as well as RDpro-GFP and RDpro-Empty LV samples and their individual functions are 
shown in Table 18. Categorising these proteins using IPA software shows that six of them are 
functioning in cellular proliferation. HSPA1A and HIST2AHA are not categorised by IPA but with 
chaperone activity and DNA structure organisational functions, respectively, they are also 
essential for cell maintenance. Three chaperones proteins HSC71, HSPA1A and CypA are 
common to all LC-MS/MS analysed LV samples. Beta actin and ALIX are involved in viral exit 
from cells. ALIX is a factor of the Endosomal Sorting Complexes Required for Transport (ESCRT) 
and functions in multivesicular body (MVB) biogenesis.  
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Table 18: Functions of Proteins Common to Transiently and Stably Produced LV Samples 
Full Name UniProt Identifier Family 
Cellular 
Location Function (NCBI Gene Annotation) 
Actin, beta 
(ACTB) Q53G76 Other Cytoplasm 
member of actin protein family, plays a 
role in cell motility, structure and 
integrity 
Heat shock 
cognate 71 
kDa protein 
(HSC71) 
P11142 Enzyme Cytoplasm 
chaperone, ATPase in the disassembly of 
clathrin-coated vesicles during transport 
of membrane components through the 
cell 
Heat shock 70 
kDa protein 
1A/1B 
(HSPA1A) 
P08107 Enzyme  Cytoplasm  
stabilizes existing proteins against 
aggregation, mediates  folding of newly 
translated proteins in the cytoplasm and 
in organelles, involved in the ubiquitin-
proteasome pathway 
Elongation 
factor 1-alpha 
(EEF1A) 
Q504Z0 
Trans-
lation 
regulator 
Cytoplasm 
isoform of the alpha subunit of the 
elongation factor-1 complex, which is 
responsible for the enzymatic delivery of 
aminoacyl tRNAs to the ribosome 
Histone H2ah 
(HIST2AHA) Q96KK5 Other Nucleus 
basic nuclear proteins that are 
responsible for the nucleosome structure 
of the chromosomal fiber in eukaryotes 
Clathrin heavy 
chain 1 (CLTC) Q00610 Other 
Plasma 
Membrane 
major protein component of cytoplasmic 
face of intracellular organelles (coated 
vesicles and coated pits), intracellular 
trafficking of receptors and endocytosis 
of macromolecules 
Alpha-enolase 
(ENO1) P06733 Enzyme Cytoplasm 
homodimer composed of two alpha, two 
gamma or two beta subunits, functions as 
a glycolytic enzyme 
Programmed 
cell death 6-
interacting 
protein (ALIX) 
Q8WU
M4 Other Cytoplasm 
functions within ESCRT pathway, in 
intraluminal endosomal vesicle formation 
and in enveloped virus budding 
MARCKS-
related 
protein 
(MARCKSL1) 
P49006 Other Cytoplasm 
member of myristoylated alanine-rich C-
kinase substrate (MARCKS) family, 
cytoskeletal regulation, protein kinase C 
signalling and calmodulin signalling, 
formation of adherent junction 
Cyclophilin A 
(CypA) A8K486 Enzyme Cytoplasm 
member of the peptidyl-prolyl cis-trans 
isomerase (PPIase) family, catalyse the 
cis-trans isomerization of proline imidic 
peptide bonds in oligopeptides, 
accelerate protein folding 
Proteins identified in all five VSVG-G as well as RDpro-pseudotyped vector samples with 
UniProt identifier and cellular location; proteins were detected in at least one replicate of each 
vector sample, functional annotation taken from NCBI Entrez Gene 
(http://www.ncbi.nlm.nih.gov/gene/). 
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4.3.3.6. AHNAK - Cellular Protein Unique to RDpro-VSV-G and RDpro-Empty 
AHNAK or Neuroblast differentiation-associated protein has been identified only in stably 
produced LV samples pseudotypes with RDpro Env. Analysis of the IPA database shows that it 
has been found in several subcellular locations such as the nucleus, cytoplasmic vesicles and 
intercellular junctions. 
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4.4. Discussion 
The aim of this chapter was to analyse the LC-MS/MS results comprising the cellular protein 
composition of six different lentiviral vectors purified by size exclusion chromatography (SEC). 
Any differences or similarities in host cell protein composition were investigated in an attempt 
to use this data as a basis for further analysis of their function in vector assembly and budding 
from the producer cell.  
Quality of Results. Initially this study aimed at determining differences between vector 
production systems, between transiently and stably produced vectors, and pseudotypes. Many 
cellular proteins were repeatedly identified in the same vector sample among different MS 
sets or production batches of one vector sample and were also shared between different 
vector samples indicating their stable association with these vector samples. VSV-G-GFP, VSV-
G-Empty and VSV-G-only had 38 cellular proteins in common. Variations among different 
vector samples could be due to differences in the production system or vector components 
(VSV-G or RDpro Env) but also due to different expression levels of some of the cellular 
proteins in the STAR and 293T producer cells.  STAR cells have been modified to contain 
several additional expression cassettes that may affect cell characteristics resulting in the 
differential expression of some proteins compared to 293T cells. However, the observed 
variations in the identified proteins between different MS sets of one sample indicate that 
analysis of three batches of a vector may not be sufficient to determine which proteins are 
truly unique for each vector.  
The type of MS analysis used here does not allow an absolute quantification of proteins in 
each sample, however viral proteins were the most frequently detected proteins in all vector 
samples confirming that viral vectors are major components of MS analysed samples. Gag and 
VSV-G Env were identified in the corresponding samples as expected, that is peptides of Gag-
Pol polyprotein were detected in all samples apart from VSV-G-only. VSV-G Env was detected 
in the samples VSV-G-GFP, VSV-G-Empty and VSV-G-only but not in Gag/Pol-GFP.  
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Most dominant functional categories of identified proteins. This comparative analysis shows 
that the identified host cell proteins function predominantly in organisation of cytoskeleton 
and are involved in actin cytoskeleton signalling, including members of the actin and tubulin 
family as well as actin interacting proteins. Tubulins are a major component of the 
microtubules, part of the cytoskeleton. Proteins, vesicles or cell organelles are transported 
along microtubules and actin filaments towards the plasma membrane (Welte, 2004). 
Interaction with tubulin and viral proteins during transport to the assembly site (Jolly et al., 
2007) could cause incorporation of tubulins into vectors. Also many of the identified proteins, 
such as ALIX, Rab1A, Rab7A, unconventional myosin IC, Vamp3 and GGA2, Clathrin heavy chain 
1are found in the plasma membrane or function in vesicle trafficking. 
MS analysis identified certain proteins that are particularly interesting for further analysis of 
their function or potential role in LV assembly. Proteins that were detected in most HIV-1 Gag 
containing LV samples and have been less well studied regarding HIV-1 assembly include 
Alpha-enolase, ALIX and Elongation factor 1-alpha. MARCKSL1 was common to all enveloped 
samples, regardless if pseudotyped with VSV-G or RDpro envelopes.  
Literature analysis of the MS identified proteins in HIV-1 assembly. The involvement of some 
of the here identified proteins in HIV-1 assembly has been documented. Incorporation of actin 
into HIV-1 particles and binding of actin by Gag was documented (Wilk et al., 1999). Functional 
significance of the host cell cytoskeleton in HIV-1 assembly was then confirmed by fixed cell 
immunofluorescence labelling and confocal microscopy (Jolly et al., 2007). After inhibition of 
actin and tubulin in HIV-1 infected T cells assembly of Gag and Env at lipid raft-like domains at 
the plasma membrane was disrupted. Depolymerisation of actin decreased Gag release and 
virion infectivity. Actin and tubulin inhibitors reduced Env incorporation, suggesting that HIV-1 
follows microtubule-directed routes within the cytoplasm towards the plasma membrane 
(Jolly et al., 2007). Chaperones HSP70 and HSC71, along other heat shock proteins, have been 
shown by western blotting to be incorporated into virion membranes and might bind HIV-1 
163 
 
Gag, holding it in assembly-competent conformation during transport to plasma membrane 
(Gurer et al., 2002). Western blotting has also confirmed the binding of Cyclophilin A to HIV-1 
Gag of sucrose purified HIV-1 virions produced by HeLa cells (Franke et al., 1994). In contrast, 
other cytoplasmic abundant prolyl isomerases were not incorporated suggesting a specific 
interaction with HIV-1 Gag. CypA incorporates into virions by binding to the MA/CA domain of 
Pr55Gag (Luban et al., 1993), however the role of MA/CA-bound CypA during assembly has not 
be determined. In early steps of the HIV-1 life cycle CypA binds CA of HIV-1 Gag post-infection 
directing the nuclear import of the HIV-1 preintegration complex (PIC) (Schaller et al., 2011a) 
but this interaction is believed to involve CypA from the infected cell rather than the virion 
producer cell. EEF1A was shown to bind MA and NC of HIV-1 Gag (Cimarelli and Luban, 1999) 
and analysis of effects on replication of HIV-1 Gag mutants that cannot bind EEF1A showed 
reduced levels of viral proteins in cell supernatants. The exact role of this interaction in viral 
replication could not be determined yet. ALIX, a factor of the Endosomal Sorting Complexes 
Required for Transport (ESCRT) is known to assist in the viral budding process of HIV-1 and 
EIAV by binding to HIV-1-p6 or EIAV-p9 of Gag (Strack et al., 2003). Clathrin forms the coat of 
vesicles transporting cellular cargo. Its cellular partners include adaptor proteins AP-1, -2, -3 
and -4 linking clathrin to membrane lipids (Edeling et al., 2006). AP-1 and AP-2 have been 
shown to bind HIV-1 Env gp41 C-terminus regulating the subcellular location of Env (Berlioz-
Torrent et al., 1999). AP-1µ, a subunit of AP-1, also binds Gag and silencing of AP-1µ by RNA 
interference showed a reduced Gag release from transfected cells (Camus et al., 2007). Since 
these proteins were also found in VSV-G-only samples it is not possible to confidently exclude 
the possibility that these proteins may also associate with budding VSV-G for example in the 
form of vesicles and co-purify with vectors.  However, results of the publications described 
above, show that these proteins may play an active role in viral particle formation.  
Comparison to other proteomics studies of viral vectors or enveloped virions. Of the proteins 
identified in all five HIV-1 Gag containing LV samples Beta-Actin, HSPA1A, HSC71, CypA, EEF1A, 
ENO1, and ALIX have been reported in one or more studies to be associated with wild type 
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HIV-1 virions by MS analysis (Chertova et al., 2006, Saphire et al., 2006, Ott, 2008) or lentiviral 
vectors (Wheeler et al., 2007, Denard et al., 2009). Our data is put into context of published 
studies on the cellular proteins previously identified by MS analysis in viral vector samples and 
enveloped viruses other than HIV-1. Some of the proteins that were identified in our vector 
samples by LC-MS/MS have also been shown to be associated with budding virions by MS/MS 
as listed in Table 19, supporting the possibility that some of these detected proteins play a role 
in vector assembly.  
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Table 19: LC-MS/MS Identified Proteins Common to Enveloped Viruses and Vectors 
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Actin, beta Q53G76 ACTB                   
Actin, alpha skeletal 
muscle  
Q5T8M8 ACTA1               A1   
Tubulin, alpha 1b Q8WU19 TUBA1B  1   1C     A3       
Tubulin, alpha 1a  Q71U36 TUBA1A                   
Tubulin, beta class I Q5JP53 TUBB                   
Clathrin heavy chain 1  Q00610 CLTC                   
Programmed cell death 6-
interacting protein (ALIX) 
Q8WUM
4 PDCD6IP                   
Elongation factor 1-alpha Q504Z0 EEF1A1    1,2   2           
Alpha-enolase  P06733 ENO1                   
Cyclophilin A A8K486 PPIA                   
Glyceraldehyde-3-
phosphate 
dehydrogenase  
E7EUT5 GAPDH                   
Heat shock cognate 71 
kDa protein  
P11142 HSPA8                   
Heat shock 70 kDa 
protein 1A/1B  
P08107 HSPA1A                   
Heat shock protein HSP 
90-beta  
P08238 HSP90AB1                   
Neuroblast 
differentiation-associated 
protein (AHNAK)  
Q09666 AHNAK                   
Annexin A2 P07355 ANXA2 A1/2   
A1/
2 
A2/
6     
A1/
2     
Annexin A5  E9PHT9 ANXA5 P62937         6       
Cofilin 1 , non-muscle G3V1A4  CFL1                   
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Radixin  P35241 RDX                   
Moesin  P26038 MSN                   
Ezrin  E7EQR4 EZR                   
Ras-related protein Rab-
1A 
B7Z8M7 RAB1A                    
Ras-related protein R-
Ras2 
B7Z6C4 RRAS2                   
Ras-related protein Rab-
7a  
P51149 RAB7A                   
Polyubiquitin-C  P0CG48 UBC Ubi Ubi Ubi         Ubi4 Ubi 
Syntenin-1  B4DHN5 SDCBP                    
Chloride intracellular 
channel protein 1 
O00299 CLIC1                   
Guanine nucleotide-
binding protein G(k) 
subunit alpha  
P08754 GNAI3   Go       2       
Triosephosphate 
isomerase 
B7Z5D8 TPI1                   
Histone cluster 1, H1c  P16403 HIST1H1C                   
H2A histone family, 
member X 
P16104 H2AFX                   
Histone H2B  A8K9J7 HIST2H2BE                   
Histone cluster 1, H2bj P06899 HIST1H2BJ                   
Histone cluster 1, H4h Q0VAS5 HIST1H4H                    
Y box binding protein 1  P67809 YBX1                   
F-actin-capping protein 
subunit alpha-1  
P52907 CAPZA1                   
Plastin 3  B7Z6M1 PLS3                    
Profilin-1  P07737 PFN1                   
Filamin A Q5HY54 FLNA                    
Talin 1 Q5TCU6 TLN1                    
Transferrin receptor 
protein 1  
P02786 TFRC                   
Myosin-9  P35579 MYH9                   
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Prostaglandin F2 receptor 
inhibitor 
Q4QQP8 PTGFRN                   
EH domain-containing 
protein  4  
Q9H223 EHD4   1       1       
ATPase, Na+/K+ 
transporting, alpha 1 
polypeptide 
B7Z3U6 ATP1A1                   
Tyrosine 3-
monooxygenase/tryptop
han 5-monooxygenase 
activation protein, zeta 
polypeptide 
E7EX29 YWHAZ                    
Solute carrier family 3 
(amino acid transporter 
heavy chain), member 2 
F5GZS6 SLC3A2                   
60S acidic ribosomal 
protein P2  
P05387 RPLP2                   
60S ribosomal protein 
L7a  
P62424 RPL7A                   
60S ribosomal protein L3  P39023 RPL3                   
Ribosomal protein L4 P36578 RPL4                   
Ribosomal protein S8/S3 Q5JR95 RPS8/S3                   
Nucleophosmin P06748 NPM1                   
MARCKS-related protein P49006 MARCKSL1                   
Poly [ADP-ribose] 
polymerase 1  
P09874 PARP1                   
Basigin  P35613 BSG                   
Creatine kinase B-type P12277 CKB                   
Lactadherin  Q08431 MFGE8                   
Tubulin, beta 3 class III Q9BV28 TUBB3                    
Alpha-actinin-4 A4K467 ACTN4         1         
Fructose-bisphosphate 
aldolase A  
P04075 ALDOA                   
 
Comparison of LC-MS/MS identified host cell proteins in our vectors with published studies 
using MS analysis of enveloped secreted virions of: Human Immunodeficiency Virus-1  (HIV-1) 
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(Chertova et al., 2006); Kaposi’s Sarcoma-Associated Herpesvirus (KSHV) (Zhu et al., 2005); 
Human Cytomegalovirus (HCMV) (Varnum et al., 2004); Epstein-Barr-virus (EBV) (Johannsen et 
al., 2004); Influenza Virus (Shaw et al., 2008); VSV-New Jersey strain (Moerdyk-Schauwecker et 
al., 2009); except vaccinia virus, which are intracellular mature virions (Chung et al., 2006); 
comparison with viral vectors derived from MMLV (Segura et al., 2008) or HIV-1 (Wheeler et 
al., 2007, Denard et al., 2009). Annotations in the green boxes indicate if another family 
member of an identified protein in our study was found in the referenced study.  
 
In addition to the proteins described in the text above some of the other host proteins 
detected here have been identified by another group using reverse phase LC-MS/MS in 
sucrose-gradient in purified, CD45 depleted monocyte derived macrophages (MDM)-produced 
HIV-1 virions from full-length infectious molecular clone NLAD8 (Chertova et al., 2006). These 
host proteins include actin binding proteins Ezrin, Radixin, Filamin and Talin 1 and other 
transmembrane proteins (Annexin A2 and A5, RRAS2). Other proteins detected in our samples 
such as GAPDH and Ubiquitin were also found in wild type HIV-1 virions, purified by sucrose 
gradient ultracentrifugation after harvest from 293T cells or Jurkat T cells (Saphire et al., 
2006a).  
Interestingly only one of all LC-MS/MS detected proteins, AHNAK (or neuroblast 
differentiation-associated protein or desmoyokin) was unique to RD pseudotyped vectors 
RDpro-GFP and RDpro-Empty produced by STAR cells. AHNAK has been previously detected in 
MDM-produced HIV-1 virions (Chertova et al., 2006). Virions produced in Chertova’s study 
were prepared by transfecting a HIV-1 provirus-encoding DNA plasmid into MDMs. Envelope 
proteins are not the same in Chertova’s and our study (HIV gp160 and VSV-G Env, 
respectively), suggesting that AHNAK is not necessarily associated with the RDpro envelope in 
our samples. To date a function for AHNAK in the context of virus formation has not been 
described. It will be further analysed and its potential role in vector formation discussed in the 
following chapter (chapter 5).  
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Proteins only detected in VSV-G pseudotypes included GAPDH, RAB1A, Tubulin beta class 1, EH 
domain containing protein 4. These proteins have also been detected in a study of Vesicular 
Stomatitis virus (VSV) propagated in A549 human lung carcinoma cells and purified by sucrose-
gradient (Moerdyk-Schauwecker et al., 2009) indicating that these cellular proteins might 
associate with VSV-G Env specifically.  
In the study by Chung et al. (2006) vaccinia virus was propagated in HeLa cells, intracellular 
mature virions (IMV) were extracted from homogenised cells by sucrose- gradient 
ultracentrifugation and twenty-three host proteins were detected using MS, of which 12 are 
also detected in our study. Sixteen out of 21 proteins identified by LC-MS/MS in virions of 
Kaposi’s Sarcoma-Associated Herpesvirus (KSHV), also known as human herpes virus 8 (Zhu, et 
al 2005), are shared with our study. KSHV virions were grown in the cell line BCBL-1, a primary 
effusion lymphoma cell line latently infected with KSHV, and purified by double gradient 
ultracentrifugation. In virions of Human Cytomegalovirus (HCMV) a total of 71 host proteins 
were identified by MS/MS of which 24 were also found in our samples (Varnum, 2004). Virions 
were grown in human dermal fibroblasts, followed by purification using sorbitol cushion 
ultracentrifugation and nycodenz gradient, a nonionic iodinated gradient medium. Forty-eight 
host proteins were identified by LC-MS/MS in virions of the gammaherpesvirus Epstein-Barr-
virus (EBV) after purification by dextran-ultracentrifugation and deglycosylation. Twenty-one 
out of 48 identified proteins were also detected in our samples, including the most frequently 
detected proteins tubulin, actin-binding proteins and cofilin (Johannsen, 2004). MS analysed 
Influenza virions, propagated in MDCK cells canine kidney cells, purified by sucrose gradient 
ultracentrifugation and deglycosylated, shared 9 proteins out of 16 detected cellular proteins 
with our vectors, such as Beta-Actin, Tubulin alpha and beta, Cofilin, Profilin-1 (Shaw, 2008).  
To date there is no published study of RD114 virion protein composition.  
Mass spectrometry has also been used for host protein identification in retroviral vector 
samples. Moloney murine leukaemia virus (MMLV) vector particles pseudotyped with VSV-G 
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were harvested from the 293-GPG packaging cell line, concentrated by diafiltration and 
purified by rate zonal ultracentrifugation followed by an extra step, purification by SEC (Segura 
et al., 2008). Out of 25 identified host proteins 15 proteins were identified that were also 
found in our samples. Most of them have been identified in at least one other virus shown in 
Table 19.  
The overlap in identified cellular proteins between our and some of the studies on enveloped 
viruses or vectors is up to 50% and covers mainly proteins of the cytoskeleton or cytoskeleton 
regulators but also proteins associated with vesicular trafficking and transmembrane proteins. 
Functional categories of cellular proteins found in SEC purified vector samples are similar to 
the ones identified in virions purified by sucrose gradient. This could be due to similarities in 
assembly and budding processes in different enveloped viruses that lead to association with 
similar cellular proteins, for example secretory pathway trafficking of envelope proteins.  
Alternative methods have been described to find links of host cell proteins to HIV-1 replication. 
Screens using siRNA to knock down cellular expression of human genes in HIV-1 infected HeLa 
or 283T cells were used to analyse differences in infectious particle production and particle 
infectivity (Brass et al., 2008, König et al., 2008, Zhou et al., 2008).  Out of 842 identified genes 
in all three screens, 34 were identified in at least two screens. There is no overlap of these 34 
proteins with proteins detected by MS in our study.  Variations in the experimental set up of 
the three screens are thought to cause the small overlap of candidate genes common to all 
three siRNA screens. Similarly the difference in procedures to our project does not allow 
simple comparison of data.   
Less cellular proteins in RDpro compared to VSV-G pseudotypes. Mass spectrometry of vector 
samples showed less cellular protein species in RDpro-pseudotyped vectors compared to 
transiently produced vectors when analysing a comparable number of viral particles. A third 
set of stably produced samples was analysed (MS set 3) containing similar levels of p24 viral 
protein, 10 µg of total protein, to make RDpro-pseudotyped samples comparable to transiently 
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produced MS samples regarding their particle numbers. Results showed that samples 
produced by STAR cells contain less cellular proteins than transiently produced samples even 
when a comparable number of viral particles were analysed. To confirm that RDpro-
pseudotyped vectors truly contain less host proteins, a transiently produced sample of RDpro-
pseudotyped vectors would have had to be included in this study. Similar to RDpro-
pseudotypes, Gag/Pol-GFP vector samples, without a viral envelope, contained substantially 
fewer host cell proteins than VSV-G pseudotypes. This could be due to the possibility that 
more cell derived vesicles are present in VSV-G pseudotyped vectors and were co-purified with 
vector particles in transiently produced samples.  
VSV-G vesicles. VSV-G vesicles have been shown to co-purify with vector preparations by 
continuous sucrose gradient ultracentrifugation produced by 293T cells (Pichlmair et al., 2007). 
Cell membrane derived vesicles have been identified in wild type HIV-1 virion preparations 
from T cells that co-purified along HIV-1 virions by sucrose- gradient ultracentrifugation. These 
vesicles were found to be of similar density to HIV-1 virions and between 50 to 500 nm in size 
compared to 100 nm HIV-1 virions (Gluschankof et al., 1997, Bess et al., 1997). It has been 
shown that treatment with the serine protease subtilisin digests proteins on the surface but 
not inside the virions (Ott et al., 1995) and in combination with subsequent sucrose-gradient 
centrifugation reduced the presence of proteins in the vector particle sample that are 
potentially derived from vesicles (Ott et al., 1996). Discrimination between host cell proteins 
incorporated in virions and externally bound or co-purified proteins can also be achieved by 
using another serine protease, proteinase K, treating vectors before MS analysis (Denard et al., 
2009, Moerdyk-Schauwecker et al., 2009). Denard et al. (2009) identified the following 
proteins after protease K treatment, hence they are thought to be inside virions, which are 
shared with proteins found in our study: Beta-Actin, Clathrin, HSPA1A, HSC71, Synthenin, 
GAPDH, CypA, EEF1A, ENO1, Annexin A2 and A5, Ezrin as well as ALIX. However, complete 
elimination of co-purified vesicles was not achieved when using subtilisin digests (Ott et al., 
1995) hence this method may not be used for confident location of proteins in vector samples. 
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Thus, at least some of the 38 proteins only detected in VSV-G pseudotyped sample, described 
in the results of this study, could originate from host proteins associated with VSV-G or 
potentially with co-purified VSV-G vesicles. Protease digestion in combination with a method 
that visualises candidate surface proteins such as immunogold labelling could verify if a protein 
is associated with the vector surface or inside the vectors (Segura et al., 2008). 
Specificity of Protein Association. Based on our results and those of other vector and virus 
studies, different viral particles seem to have commonly associated cellular proteins regardless 
of the production system or the vector pseudotypes. Gurer et al. (2005) showed that co-
transfection of producer cells with DNA plasmids expressing HIV-1 provirus and a mutant form 
of HSP70 completely abolished HIV-1 virion formation. Hence the association of some of the 
here identified host cell proteins that were also identified in above described studies of MS 
analysed wild type viruses might be due to an essential role in assembly and budding of 
vectors or viruses. On the other hand of all the here identified proteins in particular those 
highly abundant in the cell, especially at the plasma membrane, the vector assembly site (for 
example actin and tubulin), could be incorporated into viral particles purely or partly due to 
their presence. A study analysed HIV-1 cores, HIV-1 virions without envelope proteins, by LC-
MS/MS. These HIV-1 cores were purified from different cell types, including an infected T cell 
line and THP1 cells (a model of monocytes) as well as activated THP1 cells (a model of MDMs) 
by sucrose-gradient ultracentrifugation and a 1% Triton X-100 layer (Santos et al., 2012). 
Classification of the 202 identified cellular proteins showed that the majority are RNA-binding 
proteins, components of the cytoskeleton and cytoskeleton regulators, chaperones, DNA-
binding proteins, proteins involved in vesicular transport and components of the ubiquitin-
proteasome system, similar to the major categories of the proteins identified in our study. The 
authors show that proteins of the cytoskeleton are incorporated in the different HIV-cores and 
hypothesise that this is due to their high abundance in the cell and their location relative to the 
assembly site increasing the likelihood of their acquisition by virions during assembly and 
budding (Santos et al., 2012). However, high abundance at viral assembly site and an actual 
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role in assembly is not mutually exclusive as above discussed publications show where roles of 
actin and tubulin in HIV-1 assembly (Jolly et al. 2007) and specific binding of HIV-1 Gag to actin 
(Wilk et al., 1999) have been documented. Also, overlap of results of our study with a study on 
HIV-1 virions produced in a different cell type, MDMs, compared to 293T cells used here, 
suggests that at least a subset of these host cell proteins is not randomly incorporated 
(Chertova et al., 2006). 
Technical aspects. Surprisingly, in any of the RDpro-pseudotypes, RDpro Env was only detected 
when using the rejection method in LC-MS/MS, the method that selects also less abundant 
peptides for MS/MS analysis. This resulted in detection of one peptide of RDpro Env protein 
confidently and up to three peptides at low confidence covering 4 to 7 % of the whole RDpro 
Env protein sequence. It has been suggested that the wild type envelope of RD114 does not 
incorporate efficiently into lentiviral vectors and it was shown that a modified form of the 
envelope can incorporate more stably on to vector particles (Sandrin et al., 2002). Strang et al. 
(2003) documented that the infectious titer of RDpro-pseudotyped vectors after concentration 
by ultracentrifugation could be increased by reducing centrifugation speed whereas lower spin 
speeds did not increase VSV-G pseudotyped vector titer, indicating that RDpro Env is more 
fragile than VSV-G Env. Due to lower infectious titer of LVs pseudotyped with wild type RD114 
Env, modified versions of the protein have been designed before. RDpro, used in this study, 
was created by replacing the R peptide cleavage site with the HIV-1 matrix/capsid (MA/CA) 
protease cleavage sequence (Ikeda et al., 2003). This increased the infectious titer of LVs 
pseudotyped with RDpro compared with RD114 but it is not known if it also increased the 
stability, hence the here used RDpro might not be efficiently incorporated on to vector 
particles resulting in reduced presence of RDpro peptides in MS vector samples. 
Alternatively, the lack of detected RDpro Env peptides could be due to the glycosylation of 
RDpro envelope protein. MS analysis used here did not allow the detection of peptide 
glycosylation as MS study of protein or peptide glycosylation requires specialised instrument 
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settings. Hence this modification was not included in the protein database. Generally, 
potential reasons for not detecting glycosylated peptides are the lower efficiency of ionisation 
of glycosylated compared to non-glycosylated peptides (Ruiz-May et al., 2012). Alternatively, 
glycosylated peptides exceed the mass scan region. High-molecular weight modifications, 
caused by glycosylation, can shift the molecular weights of the glycosylated peptides out of the 
mass scan region in which they can be sequenced (Parker et al., 2010), hence glycosylated 
peptides can be difficult to detect by MS/MS. VSV-G Env and RDpro potentially have many N-
and O-glycosylation sites, as predicted by Expasy-GlcoMod 
(http://web.expasy.org/glycomod/), hence many RDpro Env peptides could be heavily 
glycosylated. The calculated molecular weight, using Expasy-ProtParam 
(http://web.expasy.org/protparam), based on the amino acid sequence of RD114 SU (amino 
acid position 18 to 509) (Sandrin et al., 2002) is 53920.7 Da. However, the migration pattern of 
the RD114 SU in polyacrylamide gels indicates an actual size of 7000 Da (Strang et al., 2004), 
hence the additional mass of 16079.3 Da is likely to be derived from glycans attached to RD114 
SU. A way to potentially improve RDpro Env detection is to treat purified vector samples with 
N- and O-glycanases, so that more deglycosylated peptides from RDpro Env are available for 
sequencing using our experimental conditions. Johannsen et al. (2004) reported detection of 
Epstein-Barr virus (EBV) glycoprotein only after EBV samples were deglycosylated using N- and 
O-glycanases. However, deglycosylation does not always result in the detection of increased 
protein species. A comparison of MS identified host protein of glycosylated and deglycosylated 
influenza virus showed that the same number of protein species were detected with and 
without sample deglycosylation (Shaw et al. 2008). None of the 17 different VSV-G peptides 
we detected in VSV-G pseudotyped vector samples have an N-glycosylation motif, as predicted 
by Expasy-GlcoMod (http://web.expasy.org/glycomod/).  However they are all located 
between positions 175 to 488 of the amino acid sequence, part of the VSV-G ectodomain and 
contain serine or threonine residues, potential sites for O-glycosylation, hence the presence of 
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potential glycosylation sites does not necessarily mean these sites are heavily glycosylated and 
prevent peptides from being detected by MS. 
MS analysis of our samples did not detect the myristoylated N-terminal amino acid glycine of 
MA of HIV-1 Gag (Veronese et al., 1988), supporting the assumption that in our samples post-
translational modifications hinder MS detection of peptides. The peptide mass that contains 
this myristoylated amino acid might be out of the predicted mass region as myristate adds a 
molecular mass of 228 Da (NCBI, pubchem, http://pubchem.ncbi.nlm.nih.gov/). 
 
Aspects to consider in future work. For complete MS sample analysis all vector samples should 
be analysed using the same conditions, specifically using a comparable number of vector 
particles (as was used in all viral vector samples of MS set 3), the same data acquisition 
method, such as the rejection method and the same data analysis method (minimum amount 
of peptides required per protein). This would potentially detect low abundance peptides in 
VSV-G pseudotypes that were not detected using the normal acquisition method, allowing a 
more accurate estimation of how many more proteins can be detected in VSV-G-pseudotypes 
compared to RDpro-pseudotypes. 
Data of identified host proteins must be treated with caution and association of host proteins 
with vectors should be confirmed by other methods such as knock-down of protein expression 
in producer cell followed by titration of produced vectors, however most of the proteins 
described above are essential to the function of the producer cell, for example proteins of the 
cytoskeleton or other proteins encoded by housekeeping genes. Effects of a complete knock-
down of these host proteins on vector production may not exclusively be accounted to the 
missing interaction of host and viral proteins but could be also caused by the reduced 
housekeeping function of the cellular protein. An interaction of host and viral protein may also 
be determined using a co-immunoprecipitation assay in cell lysates to isolate a specific host 
protein and analyse if it is bound to a viral protein. Furthermore an additional sample could be 
analysed such as the supernatant of untransfected 293T cells that is concentrated in the same 
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way as vector samples in order to potentially identify which of the MS detected proteins in our 
vector samples are unrelated to vector production.  
Future work will focus on proteins that are common to all vector samples and are less well 
characterised and for those reasons may be considered relevant in vector particle assembly 
and budding from the producer cell. 
5. Effects of Cellular Protein Expression on Producer 
Cells in Lentiviral Vector Production 
 
5.1. Introduction 
The retroviral genome encodes only a limited number of proteins making an extensive 
interaction of replicating viruses with the host-cell machinery essential. Host proteins interact 
with viral proteins throughout the HIV-1 replication cycle. Especially interesting for this study 
are interactions of cellular and viral proteins during the late stages of HIV-1 virus replication 
that are related to vector production including viral protein expression, transport to the 
assembly site and budding. Among the reported host-virus interactions is the recruitment of 
the endosomal sorting complex (or ‘endosomal sorting complex required for transport’, ESCRT) 
by p6 of HIV-1 Gag to support budding of immature viral particle from the infected cell 
(Balasubramaniam and Freed, 2011). It also has been shown that matrix (MA), part of Gag 
binds to the cell membrane as an important step in virus assembly (Saad et al., 2006). HIV-1 
envelope protein precursor gp160 is synthesized and glycosylated in the rough endoplasmic 
reticulum (RER) before cleavage to the mature glycoprotein gp120 by cellular proteases such 
as furin (Checkley et al., 2011, Hallenberger et al., 1992). Lentiviral vectors (LVs) used in this 
study are derived from HIV-1 virus hence may depend on host cell protein interaction in a 
similar way to wild type HIV-1. The mass spectrometry (MS) detection of host cell proteins 
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associated with purified virus particles and viral vectors is one approach to identify host factors 
that interact with the virus or vector and play a role in their generation within the cell. Proteins 
that were found in purified vector samples in this project have also been reported in one or 
more studies to be associated with wild type HIV-1 virions, such as the transcription factor 1-
alpha (EEF1A1), programmed cell death 6-interacting protein (ALIX or AIP1), annexin A2 or 5 
and alpha-enolase (Chertova et al., 2006, Saphire et al., 2006, Ott, 2008) and in studies on 
crude or purified LVs (Wheeler et al., 2007, Denard et al., 2009).  
 
The main aim of the project presented here was to improve the understanding of fundamental 
virus-host interaction in viral vector assembly, in particular, the protein-protein and protein-
RNA interactions during viral particle assembly and formation. Mass spectrometry of purified 
vector samples identified certain proteins that are particularly interesting for further analysis 
of their function or potential role in LV assembly. This chapter focuses on proteins that are less 
well characterised regarding a role in HIV-1 replication and were detected in most of the 
analysed vector samples or unique to a specific vector sample, hence may be relevant in vector 
particle assembly and budding from the producer cell. The focus of this project will include the 
following proteins. AHNAK (alternatively neuroblast differentiation-associated protein or 
desmoyokin) is unique to STAR cell produced vectors in this study. AHNAK has been described 
the first time in desmosomes of bovine muzzle epidermis (Shtivelman et al., 1992, Hieda and 
Tsukita, 1989). It was found to be distributed in the cytoplasm and nuclei in keratinocytes 
(Hashimoto et al., 1995). It locates to the plasma membrane when bound to protein kinase C 
(PKC) (Hashimoto et al., 1995, Lee et al., 2008) and is thought to activate protein kinase C-
alpha (Lee et al., 2008) suggesting its implication in cell signalling. Other studies identified it as 
an activator of phospholipase C-γ (Sekiya et al., 1999). In cardiomyocytes AHNAK was shown to 
connect actin in the cytoskeleton to the ß2a-subunit of cardiac L-type Ca2+ channels (Hohaus et 
al., 2002). It has also been found in cytoplasmic vesicles which undergo exocytotic fusion after 
calcium increase (Borgonovo et al., 2002). To date AHNAK has not been associated with a role 
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in viral replication but it has been detected as a host cell protein in monocyte derived 
macrophage- (MDM) produced HIV-1 virions (Ott et al., 1996, Chertova et al., 2006) and was 
recently highlighted in a study screening for HIV-1 responsive phosphoproteins that impact on 
HIV-1 replication in MAGI cells (Wojcechowskyj et al., 2013). MAGI cells are also called HIV 
indicator cells and derived from HeLa cells expressing CD4, CCR5 and ß-galactosidase under the 
control of a truncated HIV-1 LTR. HIV-1 can be only expressed in the presence of Tat, thus 
expression levels can be directly related to HIV-1 expression levels (Kimpton and Emerman, 
1992). AHNAK knock-down mediated by small interfering RNAs (siRNA) resulted in reduced 
HIV-1 entry in MAGI cells between three to 25 fold compared to the ‘non-targeting siRNA’ 
control (Wojcechowskyj et al., 2013). One of the proteins identified by mass spectrometry 
(MS) in all purified vector samples is elongation factor 1-alpha (EEF1A1). It is known for binding 
and transport of aminoacyl-tRNA to the ribosome as part of translation of RNA into amino acid 
sequence. It also associates with HIV-1 reverse transcriptase and integrase in reverse 
transcription (Warren et al., 2012) and has been detected in HIV-1 virions (Saphire et al., 
2006a) and HIV-1 derived LVs (Wheeler et al., 2007, Denard et al., 2009). Another protein 
detected in all vector samples was alpha-enolase (ENO1). It is of interest for further analysis as 
it has been shown to interact with the Marek’s Disease Virus (MDV), a herpesvirus causing a 
lymphoproliferative disease of chickens (Niikura et al., 2004) and was also detected in MDM-
produced HIV-1 virions (Chertova et al., 2006) as well as LVs (Denard et al., 2009). 
Myristoylated alanine-rich C-kinase substrate-related protein 1 (MARCKSL1) is one of the two 
members of the MARCKS protein family and is involved in membrane-cytoskeletal signalling, 
such as cell migration, adhesion and secretion and phagocytosis. It was identified in all vector 
samples apart from non-enveloped Gag/Pol-GFP vectors. The second family member, MARCKS, 
was identified in VSV-G pseudotyped samples only and has been reported to be 30 fold 
upregulated in Eppstein-Barr virus infected cells of Burkitt’s lymphoma (BL) (Birkenbach et al., 
1993). It has not yet been associated with HIV-1 however it is still an interesting candidate for 
further studies. One of the proteins detected in MS analysis and common to all purified vector 
179 
 
samples was ALIX (ALG-2-interacting protein X or programmed cell death 6-interacting protein 
PDCDI6P). It has been connected to endosome trafficking and plays a role in multivesicular 
bodies biogenesis, binding to charged multivesicular body protein 4 (CHMP4) (Katoh et al., 
2003). ALIX has also been detected in proteome studies of HIV-1 virions, LVs and gamma-
retroviruses (RVs) (Chertova et al., 2006, Wheeler et al., 2007, Denard et al., 2009, Segura et 
al., 2008). Instead Tumour susceptibility gene (TSG101) is thought to be important for in HIV-1 
budding. It is not one of the proteins that was identified in MS analysis of LVs in this project 
but it is another component that is involved in viral budding through the ESCRT machinery and 
is a known factor of the ESCRT-I complex (Babst et al., 2000).  
 
To interrogate the function of a protein one approach is to reduce or abolish its expression and 
study subsequent effects on a specific phenotype. The use of RNA interference (RNAi) leads to 
sequence specific knock-down of protein expression by reducing RNA levels in the target cell 
which in turn results in reduced protein expression. To study host-virus interactions this 
technique can be used on an individual protein basis as presented here or in cell based high-
throughput screening methods and has been applied to identify host-factors for HIV-1 
infection in 293T (Brass et al., 2008, König et al., 2008) and HeLa cells (Zhou et al., 2008, Brass 
et al., 2008) as well as in the T-cell line, Jurkat (Kok et al., 2009).  None of the candidate 
proteins AHNAK, EEF1A, ENO1, MARCKSL1 or ALIX had been identified as host cell factors in 
these studies, however the authors do not provide full lists of all transcripts that were 
screened. Neither are genes listed whose transcript expression did not influence HIV-1 
infectivity. Zhou et al. (2008) used TSG101 as a positive control. They depleted by siRNA 
TSG101 expression in 293T cells, infected with proviral HIV-1 and transduced indicator cells 
with the produced virus which showed significantly reduced the infectivity. In this chapter it 
was attempted to knock-down protein expression of MS identified proteins AHNAK, EEF1A1, 
ENO1, MARCKSL1 and ALIX as well as TSG101 in producer cells of both transient and stable 
systems by delivering small hairpin RNA (shRNA) using LVs to the packaging cells to study 
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effects on LV production and infectivity. The principle of shRNA is based on the RNAi or RNA 
silencing, whereby double-stranded RNA (dsRNA) induces the homology-dependent 
degradation of cognate mRNA. This principle was first discovered in nematodes (Fire et al., 
1998) followed by the discovery in plants (Hamilton and Baulcombe, 1999) and is well 
preserved across different species.  
There are at least three classes of endogenous RNAs: micro RNAs (miRNAs), endogenous small 
interfering RNAs (endo-siRNAs) and PIWI interacting RNAs (piRNAs). PiRNAs or repeated-
associated small interfering RNAs (rasiRNAs) were found first in D. melanogaster expressed in 
germ-line cells regulating the silencing of transposons (Aravin et al., 2003). Micro RNA and 
endo-siRNA are mainly post-transcriptional regulators by base-pairing with their specific target 
mRNA leading to translational repression and exonucleolytic mRNA decay. The first miRNA, lin-
4, has been identified in C.elegans (Lee et al., 1993). A miRNA primary precursor RNA (pri-RNA) 
is transcribed in the nucleus forming a stem loop which is recognised by Drosha and cropped 
to form precursor RNA (pre-RNA) (Lee et al., 2002, Lee et al., 2003). The hairpin is then 
exported to the cytoplasm by exportin 5 (EXP5) (Yi et al., 2003). A dsRNA-specific 
endonuclease (DICER) digests pre-RNA into 22 nucleotide long dsRNA molecules (Bernstein et 
al., 2001) that are loaded onto a nuclease complex to form an RNA-induced silencing complex 
(RISC) (Hammond et al., 2000). The guide strand for the dsRNA remains in the complex 
whereas the passenger strand gets degraded. The RISC then targets the complementary 
endogenous gene transcript by base-pairing and cleaves the mRNA, leading to reduced protein 
translation and in return decreased protein expression.  
 
For in vitro knock-down of protein expression a shRNA can be engineered. ShRNAs are based 
on endogenous miRNAs. A single strand RNA folds into a hairpin shape and is then cut into a 
shorter dsRNA (Paddison et al., 2002). To deliver them to the target cell they are cloned into a 
lentiviral vector genome plasmid that is then packaged into LV particles (shRNA-LVs). Upon 
transduction of the target cells with shRNA-LVs the shRNA sequence is integrated into the cell 
181 
 
genome and stably expressed. Vector genome plasmids used in these experiments are GIPZ 
lentiviral shRNAs purchased from Thermo Scientific. The plasmid contains the LV genome 
elements 5’ and 3’ LTR, central polypurine tract (cPPT) to increase transcription, the packaging 
sequence psi (Ψ) and the Woodchuck hepatitis virus posttranscriptional regulatory element 
(WPRE or WRE) to enhance expression of the transgene, in this case of the shRNA.  The shRNA 
is based on the endogenous miRNA 30 (mir-30) providing efficient processing in the target cell. 
To mark shRNA expression the reporter gene turbo green fluorescent protein (tGFP) driven by 
the cytomegalovirus (CMV) promoter is included and placed upstream of an internal ribosome 
entry site (IRES) that drives the expression of an antibiotic selection marker, puromycin (Figure 
20) and the shRNA.  
 
 
Figure 22: Human pGIPZ shRNAmir lentiviral genome plasmid (Thermo Scientific).Vector 
elements: long terminal repeats 5’ and 3’ LTR, central polypurine tract (cPPT), packaging 
sequence (psi,Ψ), Woodchuck hepatitis virus posttranscriptional regulatory element (WPRE or 
WRE), short hairpin RNA based on miRNA-30 (shRNAmir), turbo green fluorescent protein 
(tGFP) driven by cytomegalovirus (CMV), internal ribosome entry site (IRES), puromycin (puro). 
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5.2. Aim 
 
The aim of this chapter was the analysis of selected host proteins that were identified in 
purified lentiviral vector samples by MS, for their potential effect on vector production from 
producer cells. SiRNA was applied to knock-down expression of one selected protein at a time 
in packaging cells. Knock-down levels of several candidate proteins were screened and 
proteins with considerable reduction of expression levels selected for further study. Vectors 
produced by knock-down-producer cells were characterised by quantification of numbers of 
infectious particles as well as physical particle numbers before and after protein knock-down. 
 
5.3. Results  
 
Lentiviral vectors (GIPZ-LVs) carrying  a shRNA sequence were prepared by co-transfection of 
293T cells with DNA plasmids expressing HIV-1 gag-pol (p8.91) and VSV-G envelope (pMDG) as 
well as a pGIPZ plasmid carrying a shRNA targeting AHNAK, EEF1A1, ENO1, MARCKSL1, ALIX or 
TSG101 (Thermo Scientific). The negative shRNA control GIPZ scramble was used consisting of 
a shRNA sequence of random nucleotides that does not code for any known mammalian 
genes. Repeat-experiments are referred to as ‘sets’ of samples. For analysis of infectious titers 
vectors of each knock-down producer and control vectors were harvested from triplicate wells. 
Physical titers and protein expression were analysed from single or duplicate wells. Statistical 
analysis was carried out for assays in which samples were analysed in duplicate or triplicate 
per set.  
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5.3.1.  Screen for Efficient Knock-Down of shRNAs Targeting MS 
Identified Host Proteins 
Several shRNAs were tested targeting different sequence parts of a host cell protein. 293T cells 
were transduced with a GIPZ-LV and selected in puromycin. Antibiotic selection kills the cells 
that do not express shRNA as GIPZ encodes a puromycin resistance gene, expressed along with 
the shRNA from the internal ribosome entry site (Figure 20). After at least ten days in 
puromycin selection medium cell lysates were analysed by western blotting for expression of 
the specific host protein. Knock-down of EEF1A and MARCKSL1 expression was weak even with 
the most effective shRNA #4 and #20, respectively (Figure 21A and B). ENO1 expression was 
still relatively high compared to the control after transduction with any of the GIPZ-ENO1-LVs 
#40, #17 or #37 (Figure 21C). Alternative methods of knock-down for these proteins should be 
explored. The highest reduction in AHNAK expression (Figure 21D) was seen using shRNA #6, 
#38 and #39. ALIX expression (Figure 21E) was mostly diminished by shRNA #18 and TSG101 
protein levels were reduced best by shRNA #46 (Figure 21F). The negative knock-down control 
were lysates of 293T cells that were not transduced with any LV-GIPZ (‘no shRNA’) or LV-GIPZ-
scramble. The shRNA with the highest level of knock-down, that is lowest western blot signal 
compared to the control for each host protein, including shRNA #6 for AHNAK, #18 for ALIX 
and #46 for TSG101, was selected and used in subsequent experiments. As knock-down of 
ALIX, AHNAK and TSG101 showed the good knock-down results compared to EEF1A, 
MARCKSL1 and ENO1, only three proteins were selected for further analysis.  
Examination of AHNAK, ALIX and TSG101 knock-down effects on vector production is 
presented in this chapter. AHNAK is unique to stably produced vector pseudotyped with the 
RDpro envelope from the stable packaging cell line STAR, hence it was of interest to investigate 
if reduced AHNAK expression influences vector production in STAR cells differently to the 
production of VSV-G pseudotyped vectors produced in 293T cells. ALIX as one of the proteins 
detected by MS in all vector samples and with its known function regarding HIV-1 budding was 
another interesting candidate. Knock-down of TSG101 in HIV-1 infected cells had been shown 
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to have reduced the infectivity of produced HIV-1 virions before (Martin-Serrano et al., 2003, 
Zhou et al., 2008) and was expected to serve as positive control for vector production. 
 
 
Figure 23: Knock-down efficiency of shRNA in 293T-GIPZ cell lysates. Knock-down levels of host 
proteins EEF1A (A), MARCKSL1 (B), ENO1 (C), AHNAK (D), ALIX (E) and TSG101 (F) were 
analysed. For each host protein different shRNA targets were tested to identify the one with 
highest knock-down efficiency (weakest signal strength compared to the control). Negative 
control were 293T cells without transduced GIPZ-LV (‘no shRNA’). ShRNA targets AHNAK #6, 
ALIX #18 and TSG101 #46 were selected for subsequent knock-down experiments. 
 
5.3.2.  Analysis of GIPZ-LV producer cells  
To deliver each host cell protein specific shRNA to the producer cells, STAR-RDpro-pHV (STAR) 
and 293T cells were transduced with GIPZ-LVs at MOI 10. Twenty-four hours after 
transduction, puromycin selection was started and cells remained in puromycin conditioned 
medium throughout the study to maintain the expression of shRNA over time. Cultures were 
kept at least ten days in selection medium before the start of vector production.  
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5.3.2.1. STAR-GIPZ LV producer cell analysis  
In order to confirm knock-down of protein expression in STAR-GIPZ producer cells, the first set 
of STAR cell lysates was analysed at day 16 and 22 after transduction with GIPZ-LVs, 
representing set I.   The second set of knock-down STAR cells was analysed on day 10 and 17 
(representing set II). At each time point western blotting of AHNAK and TSG101 (Figure 22) or 
AHNAK and ALIX (Figure 23) was carried out showing significant reduction in protein 
expression. Negative controls were STAR-GIPZ-scramble cells and STAR cells that expressed a 
shRNA targeting another host protein as well as STAR cells that had not been transduced with 
GIPZ-LVs (‘no shRNA’). 
 
Figure 24: shRNA mediated knock-down of AHNAK and TSG101 protein expression in STAR 
cells. Assessment of knock-down efficiency of AHNAK and TSG101 in STAR-GIPZ cell lysates in 
set I and II. STAR cells were transduced with GIPZ-LVs and selected in puromycin for at least 10 
days before cell lysates were analysed by western blotting of host cell proteins AHNAK, 
TSG101. Equal loading of total protein was verified by western blotting of GAPDH, 10 µg of 
total protein of cell lysates per lane were loaded. Negative control were STAR cells without 
transduced GIPZ-LV (‘no shRNA’). Protein molecular sizes are indicated.  
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Figure 25: shRNA mediated knock-down of ALIX and AHNAK protein expression in STAR cells. 
Assessment of knock-down efficiency of AHNAK and ALIX in STAR-GIPZ cell lysates in set I. 
STAR were transduced with GIPZ-LVs and selected in puromycin for at least 10 days before cell 
lysates were analysed by western blotting of host cell proteins AHNAK and ALIX; equal loading 
of total protein was verified by western blotting of GAPDH, 10 µg of total protein of cell lysates 
per lane loaded. Negative control were STAR cells without transduced GIPZ-LV (‘no shRNA’). 
Protein molecular sizes are indicated.  
 
Following the knock-down of selected host proteins, effects on stable vector production by 
STAR-GIPZ cells were analysed. Effects on expression of vector RNA and proteins within the 
producer cells are described in this section. To determine if knock-down of candidate host cell 
proteins influenced vector RNA levels of the stably expressed transfer vector HV inside the cell, 
HV vector RNA copy fold changes in producer cell lysates from STAR-GIPZ-AHNAK and STAR-
GIPZ-TSG101 compared to RNA genome levels STAR-GIPZ-scramble were measured by Q-RT-
PCR, normalised to human beta-actin copies per cell (see section 2.4.4.4). To ensure specific 
amplification of vector genome HV, primers targeting the cPPT-SFFV promoter boundary 
upstream of GFP, were used. Across four repeat-experiments viral RNA copies in producer cells 
STAR-GIPZ-AHNAK and STAR-GIPZ-TSG101 ranged from 0.62 to 2.5 fold change compared to 
STAR-GIPZ-scramble in two experiments. Per experiment one well of cell per knock-down and 
set I   day 12                              set I  day 20
pGIPZ shRNA   ALIX    AHNAK    scramble no shRNA    ALIX   AHNAK  scramble  no shRNA
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control sample were analysed, hence no statistical analysis was possible. RNA copy fold change 
in STAR-GIPZ-AHNAK and STAR-GIPZ-TSG101 producer cells compared to STAR-GIPZ-scramble 
was almost unchanged in set I day 16 and set II day 10. Overall no consistent difference in RNA 
levels of any of the samples compared to the scramble control was observed ( 3Figure 25).  
  
 
Figure 26: No consistent effect of shRNA mediated knock-down of AHNAK and TSG101 on the 
vector RNA genomes shown as fold change compared to scramble control (=1) in four repeat-
experiments of Q-RT-PCR in STAR-GIPZ. The viral RNA genome copy fold change in STAR-GIPZ-
AHNAK, -ALIX and –TSG101 was normalised to STAR-GIPZ-ß-actin. N=3 for Q-PCR, n = 1 for 
sample replicates. 
SFFV fold change in 
host cell KD samples 
compared to scramble
set day GIPZ
sample 
ID
Ct beta 
actin Ct SFFV 2^-deltadeltaCt
I 16 AHNAK 179 26.0 26.0 0.94
I 16 TSG101 180 24.9 24.9 0.96
I 16 scramble 181 28.3 28.2 1.00
I 16 no shRNA 182 31.9 31.9 0.96
I 22 AHNAK 183 17.4 22.4 2.48
I 22 TSG101 184 17.8 23.6 1.48
I 22 scramble 185 17.3 23.7 1.00
I 22 no shRNA 186 17.8 24.8 0.62
II 17 AHNAK 187 27.2 27.4 0.78
II 17 TSG101 188 25.9 25.9 0.95
II 17 scramble 189 28.2 28.0 1.00
II 17 no shRNA 190 29.3 29.6 0.79
II 13 AHNAK 196 17.4 23.1 2.15
II 13 TSG101 197 17.6 23.3 2.20
II 13 scramble 198 19.7 26.5 1.00
II 13 no shRNA 199 20.8 27.7 1.00
188 
 
 
Western blots of viral protein p24 in producer cell lysates were analysed to assess if host cell 
RNA knock-down had an effect on vector production at the stage of viral RNA transcription and 
expression. This method allowed the semi-quantitative comparison of p24 levels of STAR-GIPZ 
cells to each other. Results for western blotting of one well of producer cell lysate of each day 
are shown in Figure 25. P24 levels in producer cells of set I showed that these are slightly 
increased in STAR-GIPZ-TSG101 and STAR-GIPZ-AHNAK compared to STAR-GIPZ-scramble p24 
levels. This was confirmed only for STAR-GIPZ-TSG101 producers of set II. The overall 
differences in p24 levels could be due to minor variability between experiments. This semi-
quantitative method can also detect p55 Gag protein. Levels of p55 are less varied suggesting 
AHNAK, ALIX and TSG101 knock-down did not affect Pr55 Gag-precursor expression. Increased 
levels of p24 in STAR-GIPZ-TSG101 could be due to modifications in Pr55 Gag processing after 
TSG101 knock-down. Taken together with the results of vector RNA copy analysis in producer 
cells knock-down of AHNAK and TSG101 expression has no major impact on viral protein 
expression. 
 
Figure 27: No considerable effect of shRNA mediated knock-down of AHNAK and TSG101 on 
Gag precursor and p24 levels in STAR-GIPZ cells; western blot of STAR-GIPZ-cell lysates in four 
sets of samples showed comparable levels of p24 in three out of four set; equivalent loading of 
total protein was verified by western blotting of GAPDH, 10 µg of total protein of cell lysates 
per lane. 
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5.3.2.2. 293T-GIPZ LV producer cell analysis 
Following LV-GIPZ transduction of 293T cells and selection in puromycin they were transiently 
transfected to produce LVs followed by analysis of producer cells and vectors on (day 13 and 
20 post-GIPZ transduction; set I). The GIPZ transduction and transient transfection procedures 
were repeated in 293T cells followed by analysis of cells and vectors 17 days after GIPZ 
transduction, representing set II. At each time point western blotting of AHNAK, ALIX, TSG101 
and GAPDH was carried out to confirm that target host protein expression levels stayed 
reduced and were comparable before each vector production shows 293T-GIPZ-LV producer 
cell lysates of all three sets Figure 26. 
 
 
Figure 28: shRNA mediated knock-down of AHNAK, ALIX and TSG101 protein expression in 
293T cells is stable over time. Assessment of knock-down efficiency of AHNAK, ALIX and 
TSG101 in 293T-GIPZ cell lysates in set I and II. 293T cells were transduced with GIPZ-LVs and 
selected in puromycin for at least 10 days and cell lysates analysed by western blotting of host 
cell proteins AHNAK, ALIX and TSG101; equivalent loading of total protein was verified by 
western blotting of GAPDH, 10 µg of total protein of cell lysates per lane loaded. Negative 
control were 293T cells without transduced GIPZ-LV (‘no shRNA’). Protein molecular sizes are 
indicated.  
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To assess ALIX and AHNAK protein expression levels with or without transduction of STAR and 
293T cells with GIPZ-LV, they were directly compared in western blots of cell lysates (Figure 
27). This allowed comparison of the baseline protein expression before shRNA treatment as 
well as the comparison of shRNA knock-down efficiency in the two cell lines. Comparison of 
protein levels in STAR-GIPZ-ALIX and STAR-GIPZ-scramble shows that STAR and 293T cells 
express similar levels of AHNAK protein as well as similar levels of ALIX protein compared to 
protein levels in STAR-GIPZ-AHNAK and STAR-GIPZ-scramble, indicating that integration of 
vector components in STAR cells did not alter the expression of ALIX or AHNAK. A high level of 
knock-down efficiency seven days post-GIPZ transduction was achieved in both, STAR and 
293T cells, in comparison to GIPZ-LV producers that expressed a shRNA targeting another host 
protein.  
 
Figure 29: Knock-down efficiency of ALIX and AHNAK by shRNA is similar in STAR and 293T cells 
and baseline expression levels in both cell lines are comparable; western blotting allows direct 
comparison of protein knock-down efficiency in STAR-GIPZ and 293T-GIPZ 7 days post-GIPZ 
transduction. Equivalent loading of total protein was verified by western blotting of GAPDH (10 
µg of total protein of cell lysates per lane). Negative control was 293T cells without transduced 
GIPZ-LV (‘no shRNA’). Protein molecular seizes are indicated.  
 
For transient LV production GIPZ-293Ts were co-transfected with p8.91 and pMDG as well as 
the vector genome plasmid pHV using Fugene transfection reagent. The same master mix was 
used for each GIPZ-293T sample (AHNAK, ALIX, TSG101, scramble and ‘no shRNA’ control) to 
avoid variation in transfection efficiencies. Transfection efficiency could not be determined by 
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counting the percentage of GFP positive cell using FACS analysis as 293T cells already express 
GFP from pGIPZ. 293T cells that were only transiently transfected to produce LVs, referred to 
as ‘no shRNA control sample’ were analysed by FACS for percentage of GFP positive cells to 
assess transfection efficiency. Transient transfection of 293T cells was carried out in three 
independent experiments and resulted on average in a relatively low transfection efficiency of 
49.3%±6% (n=3) of GFP positive cells (Figure 28) in the ‘no shRNA’ sample. This means that 
only a fraction of 293T cells produced vector particles. An efficient transfection should result in 
>90% of transfected, GFP positive cells. All GIPZ-293T cells of one set were transfected with 
the same transfection mix resulting in comparable transfection efficiency for each sample and 
the percentage of transfected cells in the ‘no shRNA’ was used to estimate the percentage of 
transfected cells in GIPZ-293T cells. If the transfection efficiency in all samples was comparable 
and knock-down of the selected cellular host protein affected transfection efficiency, the 
proportion of transfected cells would be similar and any differences in production levels due to 
effects of protein knock-down.  
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Figure 30: Assessment of transfection efficiency of 293T cells with GIPZ-LVs. FACS analysis of 
transiently transfected 293T cells expressing GIPZ-scramble (top) or no shRNA (bottom); 
representative example shows cells of one well of samples of set II day 12.  top panel: after 
transduction with GIPZ-LV-scramble and transient transfection of plasmids for LV production 
95.8 % cells express GFP, this is the sum of GFP expression from GIPZ-GFP expression cassette 
and transiently transfected vector genome, bottom panel: 293T cells that were only transiently 
transfected to produce LVs (without GIPZ-LV transduction) also referred to as ‘no shRNA’ 
control sample, contain 58.5% of transfected, GFP positive cells.  
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Host cell protein expression knock-down effects on vector production were also analysed in 
293T-GIPZ cell lysates. Results for western blotting of viral protein p24 in producer cell lysate 
of each set of samples are shown in Figure 28. P24 levels are below the detection limit for all 
samples even when 30 µg total proteins were loaded (three times more compared to STAR-
GIPZ cell lysates, Figure 25). Gag precursor levels of set I day 13 and day 20 are too weak to be 
detected. Low levels of vector proteins in producer cells are possibly due to low transfection 
efficiency of 293T-GIPZ (as described in section 5.3.2). 
 
Figure 31: p24 levels in 293T-GIPZ cell lysates are below detection limit; gag precursor was 
detected only in samples of set II day 12 suggesting they contain highest levels of vector 
proteins and produced highest levels of LVs; equivalent loading of total protein was verified by 
western blotting of GAPDH (30 µg of total protein of cell lysates were loaded) 
 
As in the experiments with STAR-GIPZ cells the fold change of vector genome RNA copies was 
quantified in 293T-GIPZ-AHNAK, 293T-GIPZ-TSG101 as well as 293T-GIPZ-ALIX producer cell 
lysates compared to 293T-GIPZ-scramble using Q-RT-PCR, normalised to human beta-actin 
copies per cell. Vector genome HV RNA copies in 293T-GIPZ-AHNAK and 293T-GIPZ-TSG101 
producer cells analysed in three repeat-experiments were 0.63 to 1.39 fold of the vector 
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genome RNA copies in 293T-GIPZ scramble. 293T-GIPZ-ALIX producer cells of the first set 
contained 0.63 fold vector RNA copies compared to the scramble control. 293T-GIPZ-AHNAK 
producer cells of set I day 20 contained 0.6 fold vector RNA copies compared to the scramble 
control but these results did not repeat in subsequent sets (Figure 30). Overall there is no 
consistent difference to vector RNA copies in the scramble control. 
 
 
Figure 32: No consistent effect of shRNA mediated knock-down of AHNAK, ALIX and TSG101 on 
the number of vector genome RNA copies (HV) in 293T-GIPZ cells compared to 293T-GIPZ-
scramble. Comparative quantification of HV RNA fold difference in cell lysates using Q-RT-PCR 
is shown. Results of vector genome RNA copy levels in three sets of samples; normalised to ß-
actin copies per cell; negative control 293T-GIPZ-scramble and ‘no shRNA’ are comparable. 
SFFV fold change in 
host cell KD samples 
compared to scramble
set day GIPZ
Ct beta 
actin Ct SFFV 2^-deltadeltaCt
I 13 AHNAK 29.5 29.3 0.99
I 13 TSG101 30.5 30.3 1.04
I 13 scramble 29.4 29.2 1.00
I 13 no shRNA 31.6 31.6 0.87
I 13 ALIX 35.1 35.8 0.63
I 20 AHNAK 17.1 23.6 0.60
I 20 TSG101 17.3 23.4 0.84
I 20 scramble 16.9 22.7 1.00
I 20 no shRNA 16.7 22.5 0.97
I 20 ALIX 17.7 24.0 0.74
II 12 AHNAK 27.2 27.2 1.13
II 12 TSG101 27.8 27.8 1.15
II 12 scramble 26.9 27.0 1.00
II 12 no shRNA 26.1 25.7 1.39
II 12 ALIX 27.7 27.6 1.12
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5.3.3. Analysis of Vectors Produced by GIPZ-Producer Cells 
 
5.3.3.1. STAR-GIPZ Lentiviral Vector Analysis 
 
Vector particle production after shRNA knock-down was analysed using several assays. First, 
the number of infectious vector particles was measured. 293T cells were transduced with 
vector from triplicate wells of samples of each set followed by FACS analysis of GFP expression 
of infected cells (Figure 30). Comparison of infectious titers of LVs produced by STAR-GIPZ-
TSG101 showed that these are significantly lower than those of STAR-GIPZ-AHNAK produced 
vectors (p-value 0.0314, Figure 31). Statistical analysis was carried out using the two way 
analysis of variants, ANOVA. The two variants are 1) set of samples (set I and set II) and 2) days 
of analysis post-puromycin selection start. The average titer of vectors produced by STAR-
GIPZ-TSG101 was 7.35x105 TU/ml (±1.91x105) and 1.14x106 (±1.33x105) produced by STAR-
GIPZ-AHNAK. Overall the average titer difference of LVs produced by STAR-GIPZ-TSG101 and -
AHNAK in four sets of samples is only 0.19 fold (Figure 31). Titers of vectors produced by STAR-
GIPZ-AHNAK and STAR-GIPZ-TSG101 were between 0.7-2.1 fold and 0.6-1.0 fold the titer of the 
scramble control, respectively. STAR-GIPZ-ALIX produced vectors had an infectious titer of 1.1-
2.4 fold compared to the scramble control (Figure 32). Overall no significant difference in 
infectious vector production compared to the scramble control was observed. Statistical 
analysis also showed that variation of titer over time is random and does not follow a specific 
trend (no significant interaction between set and time). No further analysis of vector 
production in STAR-GIPZ-ALIX cells was undertaken. 
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Figure 33: No significant effect of shRNA mediated knock-down of AHNAK and TSG101 on 
infectious particle production from STAR-GIPZ cells was seen. Infectious particle production 
from STAR-GIPZ cells from four sets of samples (transducing units/ml vector harvest) are 
shown and are the average of 3 wells/ sample per set. Bars on columns indicate SD. 
 
 
Figure 34: No significant effect of shRNA mediated knock-down of AHNAK and TSG101 on 
infectious particle production in STAR-GIPZ cells. Individual value plot of STAR-GIPZ produced 
vectors (log10 TU/ml). Mean values are displayed. Overall no significant difference in infectious 
titers compared to the scramble control (p-values >0.05). Variation of titer over time is random 
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and does not follow a specific trend (no significant interaction between set and time, p-value 
>0.05). Infectious titers of STAR-GIPZ AHNAK produced vectors were significantly higher 
compared to STAR-GIPZ-TSG101 produced vectors (p-value 0.0314) however are on average 
only 0.19 fold higher. Log TU/ml = log10 TU/ml. 
 
 
 
Figure 35: No significant effect of shRNA mediated knock-down of ALIX (and AHNAK) on 
infectious particle production from STAR-GIPZ cells was seen. Infectious particle number in 
STAR-GIPZ vectors (transducing units/ml vector harvest), duplicate or triplicate wells measured 
(A, B and C). Vector titers in ALIX knock-down produced samples on day 20 (10 cm) dishes are 
considered results of variable.  
 
Further analysis of vector produced by STAR-GIPZ-AHNAK and STAR-GIPZ-TSG101 cells was 
carried out to assess if other aspects of vector production are affected. Q-RT-PCR showed that 
reduced levels of protein expression after knock-down, did not affect levels of viral genome 
RNA in producer cells (Figure 24). In order to investigate if knock-down of protein expression in 
producer cells influences the incorporation of viral genome RNA into vector particles, vectors 
were produced by the same number of STAR-GIPZ-AHNAK, STAR-GIPZ-TSG101 and STAR-GIPZ-
scramble cells followed by measuring viral reverse transcribed RNA copy numbers in the 
vectors by Q-RT-PCR. Vectors of duplicate wells were analysed (duplicate wells: well A and B). 
The number of reverse transcribed vector RNA copies was calculated relative to a pHV plasmid 
standard at a known concentration. STAR-GIPZ-AHANK produced vectors were 0.6-1.8 fold of 
control RNA level (scramble) with one result of variable, 5.6 fold RNA copies compared to 
scramble control, in set I on day 16. STAR-GIPZ-TSG101 cells produced titers of 0.3-2.0 fold 
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compared to the control (Figure 34). Overall no significant changes in viral RNA levels were 
observed compared to scramble control or between different GIPZ producer vectors 
confirming results of quantification of RNA copies in producer cells where no significant 
difference between samples was detected either (Figure 24). These results suggest packaging 
of vector genome RNA is not affected by AHNAK or TSG101 knock-down in producer cells.  
 
  
Figure 36: No effect on vector genome copy numbers in STAR-GIPZ vectors (reverse 
transcribed pHV RNA copies/ml vector harvest); four sets of samples were analysed. 
Quantification of reverse transcribed HV RNA copies in vector harvests and HV DNA plasmid 
standard using Q-RT-PCR is shown. Duplicate wells A and B for each sample; vector genome 
copies in vectors produced by STAR-GIPZ-AHNAK in well A of set I day 16 are 0.5 log higher 
compared to other samples, however this result did not repeat and was considered to be a 
result of variable. 
 
P24 levels of vectors were measured by enzyme-linked immunosorbant assay (ELISA) in order 
to assess any differences in physical titre of vectors after knock-down of AHNAK or TSG101 
expression. Quantities of p24 protein can be converted into physical vector particle numbers 
based on the assumption that one lentiviral vector particle contains 2000 molecules of p24 
protein. The calculation is explained in Figure 34. The Particle number calculated based on p24 
ELISA is later compared to particle numbers calculated based on assays measuring infectious 
titers and vector genome RNA copies in vectors. 
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2000 p24 molecules per lentiviral particle (LP) 
1 p24 protein = 24 000 Dalton (Da) 
1 Da = 1.66 x10 -24 grams (g) 
Î 2000 x 24 000 / (1.66 x10 -24) = 2.89x10-5 pg p24 / LP 
or 1 ng p24 = 3.33 x107 LP 
Figure 37: Calculation of lentiviral particle number based on p24 protein measured in p24 
ELISA. Based on the assumption that 1 ng p24 = 3.33 x107 LP. 
 
P24 levels in vectors of one well per sample per set were measured. Vector p24 levels of STAR-
GIPZ-TSG101 producers were 0.7-1.1 fold of p24 levels of vectors produced by the scramble 
control representing no significant difference. However STAR-GIPZ-AHNAK produced vectors 
contained significantly higher p24 levels compared to the scramble control (1.1-2.5 fold of 
scramble control) and compared to STAR-GIPZ-TSG101 produced vector p24 levels (p-value 
0.0151 and 0.0035, respectively). P24 levels in LVs from STAR-GIPZ producer cells from four 
sets are grouped to illustrate this more clearly (Figure 36). Increased p24 levels in vectors from 
STAR-GIPZ-AHNAK producers were seen in three out of four sets of experiments but levels are 
comparable in set II day 17, which becomes clear when fold changes relative to STAR-GIPZ-
scramble control are visualised (Figure 37).  P24 levels in vectors from ‘no shRNA’ controls 
ranged between 110 and 180 ng/ml and in vectors from STAR-GIPZ-AHNAK between 218 to 
144 ng/ml. Compared to the ‘no shRNA’ control, p24 levels in LVs produced by STAR-GIPZ-
AHNAK are not significantly higher (p-value >0.05). These data and previously shown results of 
p24 levels in vector STAR producer cells (Figure 25) suggests that knock-down of AHNAK 
expression may only have a small or no significant effect on p24 expression and packaging into 
produced vectors. 
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Figure 38: No consistent effect on viral protein p24 levels in STAR-GIPZ vectors; p24 in STAR-
GIPZ vectors are shown grouped by STAR-GIPZ producer cells, p24 ng/ml of one well of vector 
harvests for each set was measured; in three out of four sets STAR-GIPZ-AHNAK vectors 
contained significantly higher numbers of vector particles compared to STAR-GIPZ-TSG101 and 
scramble produced vectors (p-value 0.0151 and 0.0035, respectively), this did not repeat in the 
fourth set of samples; no significant difference between STAR-GIPZ-AHNAK and ‘no shRNA’ 
control was measured. 
 
 
Figure 39: p24 levels in vectors of STAR-GIPZ-AHNAK, STAR-GIPZ-TSG101 and ‘no shRNA’ 
control relative to STAR-GIPZ-scramble (=1); fold p24 ng/ml of scramble p24 levels; in three out 
of four sets of samples p24 levels of STAR-GIPZ-AHNAK produced cells were at least 1.5 fold of 
p24 levels of scramble control; however p24 levels of all samples are comparable in the fourth 
set. 
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Protein p24 levels in vectors were further analysed by western blotting to assess the effect of 
AHNAK and TSG101 knock-down on vector production. Results for western blotting of vectors 
collected after selection in puromycin on day 16 and 22 (set I) as well as on day 10 and 17 (set 
II) are shown in Figure 38. No considerable difference between p24 values among LVs made by 
the different producer cells was detected. Based on densitometry readings of p24 signals in 
vectors STAR-GIPZ-AHNAK and STAR-GIPZ-TSG101 p24 levels varied between 0.8-1.9 fold and 
0.6-1.3 fold of scramble p24 values, respectively (Figure 39). This method is not as sensitive as 
the p24 ELISA however can be used to confirm the relative p24 levels among different vector 
samples of the p24 ELISA. Western blotting showed that p24 levels of STAR-GIPZ-AHNAK 
vectors are comparable to the ‘no shRNA’ control (the ‘no shRNA’ control was only analysed 
for the fourth set of samples, set II day 17). Like in p24 ELISA, levels of p24 in STAR-GIPZ-
AHNAK produced vectors are increased compared to STAR-GIPZ-scramble in three out of four 
sets of samples, however this difference is not significant. STAR-GIPZ-AHNAK and STAR-GIPZ-
TSG101 produced p24 levels in vectors are comparable to each other, unlike results of p24 
ELISA where p24 levels were higher in vectors produced from STAR-GIPZ-AHNAK than those 
from STAR-GIPZ-TSG101. 
Interestingly the p55 Gag protein levels in vectors of STAR-GIPZ-TSG101 cells are 15 to 31 fold 
higher in three out of four experiments (Figure 40) compared to scramble control and STAR-
GIPZ-AHNAK Gag precursor levels. This data suggests that Gag precursor processing to p24 is 
disturbed when TSG101 protein expression is reduced. This might only be a minor effect as 
elevated Gag precursor levels in vectors of STAR-GIPZ-TSG101 producer cells were not 
detected consistently in all sets of harvested vectors. Gag precursor levels in STAR-GIPZ-
TSG101 are comparable to STAR-GIPZ-AHNAK and scramble in set II day 17 (Figure 38). 
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Figure 40: No effect of shRNA mediated knock-down of host protein AHNAK and TSG101 on 
p24 levels in STAR-GIPZ vectors; western blot using anti-p24 monoclonal antibody, proteins 
p24 and pre-cursor were detected; Gag precursor levels in STAR-GIPZ-TSG101 cells are 
significantly higher in three out of four sets of samples compared to STAR-GIPZ-AHNAK and 
scramble control (15 to 31 fold compared to scramble) however comparable in the fourth set; 
45 µl of vector harvest per lane. 
 
 
 
Figure 41: No effect of shRNA mediated knock-down of host protein AHNAK and TSG101 on 
p24 levels in STAR-GIPZ vectors; densitometry readings of p24 signal of western blots relative 
the scramble control (=1) is shown to visualise the minor differences between STAR-GIPZ 
samples and scramble control from Figure 38. 
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Figure 42: Effect of shRNA mediated knock-down of host proteins on Gag precursor levels in 
STAR-GIPZ vectors. Densitometry readings of Gag precursor signal of western blots relative to 
the scramble control (=1). Vectors from TSG101 knock-down STAR cells show a 15 to 31 fold 
increase of Gag precursor levels, however this effect was not observed consistently in all 
repeat experiments. STAR-GIPZ-AHNAK Gag precursor levels in vectors are comparable to 
those of controls. 
 
5.3.3.2. 293T-GIPZ Lentiviral Vector Analysis 
 
Vector particle production from 293T-GIPZ cells was also measured using several assays. After 
transduction of 293T cells with vectors produced by 293T-GIPZ cells, GFP positive cells were 
analysed for infectious particle production by FACS analysis. Supernatant of triplicate wells for 
samples of three repeat-experiments were measured. The number of infectious particles of 
samples from the first experiment showed about 10 fold lower transducing units per ml vector 
harvest compared to titers of the other two sets of experiments (Figure 41). This is most likely 
due to a less efficient transient transfection of cells in the first set of samples (set I day 13) 
with only 43% vector producing cells compared to about 55% in subsequent sets. Infectious 
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particles in vector harvests produced by 293T-GIPZ-TSG101 of set I are about five-fold higher 
compared to the control, but this was not seen in the following sets. In the other two sets of 
vector samples titers of 293T-GIPZ-AHNAK and 293T-GIPZ-TSG101 produced cells were 1.2 fold 
and between 0.9-2.1 fold of the titer of vectors produced by 293T-GIPZ-scramble, respectively. 
293T-GIPZ-ALIX produced particles had an infectious titer of 0.6-0.8 fold compared to the 
control titer. Overall no significant difference in infectious titers compared to the scramble 
control was observed (p>0.05) (Figure 41).  
 
 
Figure 43:  No significant effect of shRNA mediated knock-down of AHNAK, ALIX and TSG101 
on infectious particle production in 293T-GIPZ cells (p>0.05). Infectious particle numbers in 
293T-GIPZ vectors of three sets of samples (transducing units/ml vector harvest), shown is the 
average of 3 wells/sample per set. 
 
Q-RT-PCR of vector genome RNA copies of 293T-GIPZ cells showed that production of vector 
genome RNA was unaffected by AHNAK, ALIX and TSG101 protein knock-down (Figure 30). The 
measurement of vector genome RNA copies in vectors from 293T-GIPZ producers was also 
carried out by Q-RT-PCR to investigate if packaging of viral RNA into particles was affected 
after gene knock-down. Vectors of duplicate wells were measured (well A and B). The number 
of reverse transcribed HV vector RNA copies was calculated using plasmid DNA pHV as the 
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standard. In some vector samples no vector RNA could be detected (for example well A, set I 
day 13 AHNAK, TSG101 and ALIX). This could be due to very low levels of vector genome RNA 
in these samples caused by low transfection efficiency (section 5.3.2). 293T-GIPZ-AHANK and 
293T-GIPZ-TSG101 produced vectors were 0.4-1.9 and 0.9-1.6 fold of the scramble control 
titers. 293T-GIPZ-ALIX cells produced vectors with titers of 0.5-0.9 fold compared to the 
control. Overall no considerable titer changes were observed compared to scramble control or 
between different GIPZ producer vectors. In summary no effect on vector genome RNA 
packaging into vector particles could be detected.  
 
 
Figure 44: No considerable effect on vector genome copy numbers in 293T-GIPZ vectors 
(reverse transcribed pHV RNA copies/ml vector harvest); three sets of samples were analysed. 
Comparative quantification of reverse transcribed HV RNA copies in vector harvests and HV 
DNA plasmid standard using Q-RT-PCR is shown. Duplicate wells A and B for each sample; 
vector genome copy numbers of some of the vector samples of the first set of samples (set I 
day 13) were below the detection limit; however vector genome copy numbers in vectors of 
the other two sets were comparable to controls and showed no significant difference. 
 
In order to assess any effect of host protein knock-down on vector capsid protein p24 its levels 
were measured in 293T-GIPZ vectors by enzyme-linked immunosorbant assay (ELISA). P24 
levels can be converted into physical particle numbers by assuming 1 ng p24 equals 3.33x107 
LP physical particles. In a p24 ELISA vector harvests of one well per day were measured. P24 
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levels of vectors from 293T-GIPZ-AHNAK cells were 0.04 to 1.0 fold of the p24 levels in vectors 
produced by scramble. This included the result of the first set of samples when transfection 
efficiency was lowest resulting in about 10 fold lower levels of p24 compared to the other two 
sets confirming titration data of RNA copies and infectious particles of this set of samples 
compared to the other two sets. Differences in p24 levels of samples of set I day 20 and set II 
day 12 are not significant. 293T-GIPZ-TSG101 and 293T-GIPZ-ALIX produced vectors contained 
p24 levels 0.6 to 1.6 fold and 0.5 to 0.9 of p24 levels produced by the scramble control, 
respectively, representing no significant difference (Figure 43) (p>0.05). 
 
 
 
Figure 45: No significant effect on viral protein p24 levels in 293T-GIPZ vectors (p>0.05); p24 in 
293T-GIPZ vectors are shown for three sets of samples, p24 ng/ml vector harvest of one well of 
vectors for each set was measured; the first set of samples contained about 10 fold lower 
levels of p24 compared to the other two sets, confirming results of previous assays presented. 
 
Results for western blotting of p24 in vectors after AHNAK, ALIX or TSG101 knock-down in 
producer cells on different days are shown in Figure 44. P24 levels are below the detection 
limit for all samples. Hence based on this assay no conclusions about differences in p24 levels 
in vectors could be drawn. Gag levels of set I day 13 and day 20 are too weak to be quantified. 
Strongest Gag precursor signals could be recorded for samples of set II day 12, confirming 
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results of p24 ELISA and vector genome RNA copy number assay and titers of infectious 
particles, measuring highest vector particle levels in this set of samples.  
 
 
Figure 46: p24 levels in 293T-GIPZ vectors are below the detection limit, Gag precursor levels 
highest in the third set of samples confirming previous titration assays; western blot using anti-
p24 monoclonal antibody is shown; 45 µl of vector harvest per lane 
 
A general assessment of vector production levels in STAR-GIPZ and 293T-GIPZ based on various 
characteristics of harvested particles was undertaken in order to elucidate any potential 
differences between both producer cells. The ratio of infectious particles over physical 
particles based on vector genome RNA copy numbers and p24 levels (TU:RNA:p24) was 
calculated. Physical particle numbers are based on the assumption that one particle contains 
two copies of viral RNA genomes and 1 ng p24 equals 3.33x107 vector particles. The ratios of 
TU:RNA:p24 in STAR-GIPZ and 293T-GIPZ produced vectors show an interesting difference. 
RNA copies of STAR-GIPZ produced particles are on average 43 fold higher and corresponding 
physical particles based on p24 levels are on average 1000 fold higher compared to infectious 
particles. In contrast, vectors from 293T-GIPZ cells contain 3 fold higher physical particles 
based on RNA copies and 100 fold higher physical particles based on p24 levels compared to 
infectious particles meaning they are 10 times more infectious compared to STAR produced 
vectors (Figure 46 and 47). This has been shown in other experiments in this project as well as 
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by others (Bell et al., 2010, Strang et al., 2004) and is most likely due to a lower infection 
efficiency of RDpro compared to VSV-G envelope. 
Overall none of the titration assays showed that protein knock-down of AHNAK, TSG101 or 
ALIX had a significant, consistent impact in replicate sets of samples on vector particle 
production regarding infectious or physical particle numbers. In all assays the titer of the 
control ‘no shRNA’ varied between 0.5 to 2.0 fold of the titer of the scramble control with no 
significant difference in any of the experiments.  
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Figure 47: STAR-GIPZ - ratio of RNA copies and p24 in vectors relative to infectious particles per ml of vector harvest.  
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Figure 48: 293T-GIPZ - ratio of RNA copies and p24 in vectors relative to infectious particles per ml of vector harvests, samples, ND: not detected. 
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5.4. Discussion 
 
In the experiments presented in this chapter host cell proteins that had been identified in size 
exclusion chromatography (SEC) purified lentiviral vectors by mass spectrometry (MS) are 
further analysed for their role in vector formation. Potentially MS detected host proteins might 
interact with viral proteins or RNA during vector assembly and budding from cells, which 
resulted in binding to or incorporation of the host proteins into secreted vector particles. The 
aim of the experiments presented in this chapter was to assess if knock-down of the selected 
MS-detected host proteins enhances or reduces LV production by quantifying vector particles.  
Initially, several shRNA sequences targeting different parts of the mRNA of a selected protein 
were screened and the shRNA with the highest knock-down efficiency for each protein was 
chosen for further analysis. For the proteins AHNAK and ALIX a high level of knock-down of 
protein expression was achieved.  The experiments performed showed no relation between 
the position of the shRNA target site within the mRNA sequence and the knock-down 
efficiency. The position of the binding site in the mRNA sequence of the shRNA sequence, that 
could efficiently knock-down protein expression, differed between the different proteins. 
Good knock-down efficiency was achieved by a shRNA targeting the 5’end of the mRNA of ALIX 
whereas high knock-down of AHNAK was achieved by a shRNA targeting the 3’end or middle 
part of the mRNA.  
Selected proteins for further knock-down studies included AHNAK, ALIX and TSG101. AHNAK 
was identified by MS only in RD-pseudotyped LVs produced by STAR cells, hence studying the 
effect of AHNAK expression levels on vector production in the two different producer cell 
systems was of interest. ALIX was detected in all vector samples. ALIX is known to be an early-
acting ESCRT factor (Katoh et al., 2003) and involved in HIV-1 budding (Votteler and Sundquist, 
2013). TSG101 was not detected in SEC purified samples however is part of ESCRT-III host 
protein complex and recruits HIV-1 Gag via p6 to the budding site (Garrus et al., 2001, 
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VerPlank et al., 2001). Infectivity of HIV-1 secreted virions produced by TSG101 siRNA depleted 
293T cells was reduced up to 10 fold (Martin-Serrano et al., 2003) thus it was thought to be 
suitable to be included in the study as a positive control. Significant knock-down of the 
candidate proteins EEF1A, ENO1 and MARCKSL1, identified by MS in all purified vector 
samples, was not successful and alternative shRNAs need to be screened. Hence these 
proteins were not further studied at this stage in the interest of time. 
Assessment of vector infectivity is the most informative assay to characterise effects of 
protein-protein or protein-RNA interaction between host and vectors on vector formation. The 
production of infectious particles was not significantly affected after knocking down protein 
expression of AHNAK, ALIX or TSG101. Overall the infectivity of RDpro-pseudotyped vectors 
was 10 fold lower than that of VSV-G pseudotypes transiently produced (Figure 46 and 47) 
which has previously been shown to be caused by properties of the envelope protein used to 
pseudotype vectors. Ikeda et al. (2003) had reported a lower infectivity of stably produced 
gamma-retroviral pseudotyped vectors and observed that transiently produced vectors with 
gamma-retroviral envelopes were still equally less infectious compared to transiently 
produced VSV-G pseudotypes. Others produced LVs from STAR cells reported a 4-5 higher level 
of p24 ng/ml in vector harvests compared to VSV-G pseudotyped vectors when comparing LVs 
with similar transduction titer (Strang et al., 2004), confirming the results presented here. 
Other characteristics of vector particles were also analysed. No significant difference in RNA 
copy numbers was detected in vectors produced by knock-down cells. P24 levels of STAR-GIPZ 
produced vectors were unchanged compared to the negative control, whereas p24 levels in all 
293T-GIPZ produced vector samples, including knock-down control scramble, were below the 
detection limit which may have been caused by low transfection efficiency of vector packaging 
plasmids. 
The presence of an ALIX binding site in p6 of HIV-1 and its ability to recruit Gag to the vector 
assembly site (Strack et al., 2003) suggests that ALIX is relevant for HIV-1 budding from 
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infected cells. ALIX interacts with the C-terminal region the HIV-1 Gag p6 domain (Strack et al., 
2003) that is required for HIV-1 particle release from the host cell membrane (Huang et al., 
1995, Strack et al., 2003) and is classed as an early-acting ESCRT factor (Votteler and 
Sundquist, 2013). It was also found to be incorporated in HIV-1 virions produced by HeLa cells 
and HIV-1 virions with mutations in p6-Gag contained reduced levels of incorporated ALIX. 
Furthermore an interaction of ALIX and the p9 domain of Equine Immunodeficiency Virus 
(EIAV)-Gag was documented (Strack et al., 2003). Martin-Serrano et al. (2003) showed that 
ALIX interacts with proteins of the ESCRT-III complex hypothesising that ALIX recruits the 
ESCRT-III complex to the budding site. Based on these publications it was initially thought that 
knock-down of ALIX expression in producer cells would reduce LV production hence serve as a 
positive control when comparing to knock-down effects of AHNAK. However it was also shown 
that siRNA mediated depletion of ALIX in HIV-1 infected cells had only a minor effect on virus 
infectivity compared to relatively high titer reduction after knock-down of ALIX in EIAV 
infected cells. Consequently during EIAV budding ALIX is thought to be recruiting the ESCRT 
complex  to the budding site (Martin-Serrano et al., 2003) which may explain the unchanged 
number of HIV-1 based infectious particles produced after ALIX knock-down in the 
experiments shown here and further analysis of knock-down effects of this protein was not 
undertaken.  
TSG101 have been previously linked to retroviral budding from infected cells as a cellular 
partner for the p6 PTAP motif (Garrus et al., 2001, VerPlank et al., 2001). TSG101 has also been 
detected in MDM- and 293T-derived HIV-1 virions (Chertova et al., 2006, Saphire et al., 2006). 
Requirement of the interaction of TSG101 and p6 for HIV-1 release was demonstrated after 
mutation of the p6 PTAP motif lead to decreased TSG101 binding and infectivity of produced 
particles (Martin-Serrano et al., 2001) and supported by showing that infectivity after siRNA 
depletion of TSG101 in HIV-1 producing 293T cells is significantly reduced (Garrus et al., 2001, 
Martin-Serrano et al., 2003). Garrus et al. (2001) also showed that capsid (p24) and matrix 
(p17) levels are reduced in released virions after knock-down of TSG101.  
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Garrus et al. (2001) documented that TSG101 siRNA mediated depletion in 293T cells followed 
by transfection with proviral HIV-1, lead to reduced infectivity of produced virions of up to 14 
fold, however in our experiments TSG101 knock-down in vector producing 293T cells or 293T 
derived STAR cells did not change the infectivity of the secreted vectors. In the results 
presented here p24 levels in 293T secreted vectors could not be detected even in control 
samples. In vectors produced by STAR-GIPZ-TSG101 no significant reduction could be seen in 
p24 levels compared to the scramble control. Martin-Serrano et al. (2003) did not specify the 
level of knock-down of TSG101 expression they achieved whereas Garrus et al. (2001) could 
only detect traces of TSG101 in cell lysates using an optimised knock-down system by 
transfecting siRNA twice at 24 hours intervals documented by western blotting after an 
additional 24 hours. Western blotting of TSG101 knock-down producer cells presented here 
showed that TSG101 expression was achieved efficiently, but does not result in complete 
protein depletion. Vector budding from producer cells might only require minimal levels of 
TSG101 and therefore need an even higher knock-down of TSG101. Differences in infectious or 
physical particle numbers could potentially be seen when TSG101 expression is even further 
reduced by using a higher dose of shRNA, by transducing producer cells with GIPZ-LVs at a 
higher MOI.  
It is hypothesised that ALIX can bind p6-Gag and compensate for any functional loss regarding 
virus release when TSG101 expression levels are reduced (Fujii et al., 2007). Each protein binds 
a different HIV-1 p6 late domain (L-domain). TSG101, as part of ESCRT-I, is recruited to the 
budding site by binding the PTAP motif of HIV-1 p6 (Garrus et al., 2001) whereas ALIX binds the 
motif YPXL of p6 (Strack et al., 2003) as well as CHMP4 (Katoh et al., 2003) connecting ESCRT-III 
and HIV-1 Gag at the plasma membrane. Alternatively to the individual knock-down of either 
TSG101 or ALIX, TSG101 and ALIX could be knocked-down simultaneously to achieve reduced 
vector release from producer cells. Another approach would be to overexpress host cell 
proteins and study the effect on vector packaging. Usami et al. (2007) also showed that ALIX 
can bind via its C- terminal domain to TSG101. Overexpression of ALIX rescues HIV-1 release by 
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providing an alternative route for virus release after TSG101 interaction with PTAP is 
eliminated by PTAP domain mutation (Usami et al., 2007). Hence, knock-down of ALIX and 
TSG101 in the same producer cell might result in significant reduction of vector titer. 
Whereas p24 levels among vectors were comparable in all STAR-GIPZ produced vectors, in 
consistence with the results of the infectivity and vector genome copy numbers, interestingly 
Gag-precursor levels in vectors, produced by STAR-GIPZ-TSG101 were 15 to 31 fold higher 
compared to any other samples. However, this effect might only be minor as it could not be 
seen in one out of four repeated experiments. As mentioned before, TSG101 binds Gag 
precursor, Pr55Gag, via the PTAP late domain of p6 of Gag (VerPlank et al., 2001). 
Furthermore, TSG101 depletion in 293T cells mediated by siRNA showed an increase of 
cytoplasmic levels of the Gag intermediate CA-p2 (CA-SP1) but not in released virions (Garrus 
et al., 2001). Nevertheless, raised levels of unprocessed Gag in vectors produced from STAR-
TSG101 cells may be due to a vector maturation defect caused by TSG101 knock-down. A 
comparison to Gag precursor levels in 293T-GIPZ cells and vectors was not possible as protein 
levels were too low to be analysed by western blotting. 
 
Knock-down of candidate proteins did not show effects on vector titers. In order to analyse 
viral protein expression from the producer cells after knock-down, viral protein levels within 
the producer cells were analysed. Producer cell analysis in all experiments showed that after 
knock-down the host cell proteins AHNAK, ALIX or TSG101 viral protein p24 levels or vector 
genome RNA copy numbers in producer cells were not considerably different compared to the 
scramble control. In transiently transfected 293T-GIPZ cells viral RNA and protein levels varied 
between different sets. In set I 5 to 10 fold lower levels of viral RNA copies were measured 
compared to producer cells of set II. Accordingly, vectors of this set also contained similarly 
reduced levels of infectious particles, RNA copies and p24 protein compared to the vectors of 
two subsequently produced set of samples and is potentially due to lower transfection 
efficiency when transiently transfected with vector plasmids (section 5.3.2).  
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The assay measuring transducing units of vector samples used in the study presented here 
quantifies vector particles that are secreted from the producer cells investigating only host-
virus interactions in the late stages of the replication cycle, including transcription of viral 
genes to assembly and budding of LVs. The RNAi screen for host factors influencing HIV-1 
infectivity presented by Zhou et al. (2008) investigated host proteins involved in early as well 
as late stages of HIV-1 production, the latter by investigating host factors that affected 
infectivity of secreted virus from knock-down producer cells. In the RNAi screen P4/R5 HeLa 
cells were used, which are modified HeLa cells that express CD4 and encode ß-galactosidase 
(Clavel and Charneau, 1994). The latter is expressed from lacZ under the control of a truncated 
HIV-1 LTR that upon infection of the cells with HXB2 virus is transactivated by Tat binding to 
the TAR sequence, therefore expression levels of ß-galactosidase are directly related to viral 
expression levels (Kimpton and Emerman, 1992). In a staged assay HeLa P4/R5 cells were 
transfected with siRNAs followed by HIV-1 infection (Zhou et al., 2008). Supernatant was 
harvested and added to HeLa P4/R5 cells that had not been treated with siRNA. They reported 
that virions produced by TSG101-depleted 293T cells were 20% less infectious compared to the 
negative control luciferase siRNA. The infectivity of 293T-GIPZ-TSG101 produced vectors in the 
experiments presented here was not reduced when compared to vectors produced by the 
scramble control. 293T-GIPZ-TSG101 produced vectors had a comparable infectivity to the 
scramble control, as seen when TU/ml levels were compared to p24 protein levels in 293T-
GIPZ-TSG101 produced vectors and scramble control, which were comparable (Figure 46). 
Both vector populations have a similar amount of transducing particles per physical particle. 
This could be due to lower TSG101 knock-down levels in our experiments compared to the 
ones presented by Zhou et al. However, results of mRNA knock-down presented by Zhou et al. 
do not include mRNA knock-down levels of TSG101. Direct comparison of results is also 
difficult due to differences in several conditions in the experiment conducted by Zhou et al. 
and the conditions used in this study. Zhou et al. used HeLa cells (versus 293T or 293T based 
STAR cells in this study) and siRNAs were transiently transfected twice (versus transduction 
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with LVs delivering shRNA). Zhou et al. infected cells with HXB2 HIV-1 virus. An alignment of 
HXB2 gag-pol (GenBank K03455.1) and the sequence of p8.91 gag-pol in 293T transiently 
produced vectors showed they are 97% identical and STAR cells express codon-optimised gag-
pol gene based on HXB2 gag-pol. However LVs produced here are pseudotyped with VSV-G or 
RDpro envelope and not the wild type glycoprotein envelope (gp120), potentially causing 
interaction with different host proteins during budding.  
Apart from the study by Zhou et al. (2008), RNAi has also been used in two other genome wide 
screens to identify host cell factors in HIV-1 replication (Brass et al., 2008, König et al., 2008, 
Zhou et al., 2008). Brass et al. 2008 also investigated late stages of HIV-1 replication and 
infected P4/R5 indicator cells with virus produced by siRNA depleted cell, however in that and 
the other two screens neither AHNAK, ALIX, TSG101, MARCKSL1, EEF1A nor ENO1 were 
identified as a host factor in HIV-1 replication. Out of 842 genes identified in all three screens 
only 34 genes were identified as factors with potential roles in HIV replication in more than 
one screen (König et al., 2008, Brass et al., 2008, Zhou et al., 2008, Bushman et al., 2009).  A 
total of 11 were previously reported in the NCBI HIV-1 interaction database and have been 
reported to play a role in the HIV-1 replication cycle. These include for instance T cell surface 
receptors cluster of differentiation 4 (CD4) and C-X-C chemokine receptor type 4 (CXCR4) 
which are HIV-1 target cell receptors providing host cell entry (Maddon et al., 1986, Feng et al., 
1996) as well as the nuclear basket protein nucleoporin 153kDa (NUP153) involved in several 
steps of the HIV-1 life cycle for example the nuclear entry by binding HIV-1 integrase 
(Woodward et al., 2009). Only three genes were found to diminish HIV-1 replication in all three 
screens (mediator complex subunit 6 [MED6] and 7 [MED7] as well as RELA, also known as 
NfKB3 and only RELA has been linked to the NCBI HIV interaction database before. The little 
overlap in these siRNA screens was hypothesised to be due to variations in cell lines used, 
timing of sampling and filtration criteria (Bushman et al., 2009) and shows that the data 
presented in this project cannot be simply compared to these knock-down screens.  
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AHNAK could be a potential host factor during HIV-1 entry as its knock-down in CD4+ T cells 
reduced HIV-1 ability to infect these cells (Wojcechowskyj et al., 2013), but apart from this 
study AHNAK has not been associated with retroviral replication or detected in 293T-produced 
LV particles. The more intriguing it was to investigate why of all analysed purified vector 
samples only STAR cell produced vector particles seem to be associated with this protein. If 
AHNAK is however expressed in higher amounts in STAR cells then this protein could 
potentially be secreted at higher levels into the cell culture medium compared to 293T cells 
and, if several proteins agglomerate could co-purify with vector particles instead of being 
directly associated to them. Semi-quantitative analysis of AHNAK protein however showed 
comparable levels in STAR and 293T cells. AHNAK has been localised to the plasma membrane 
in several cell types such as keratinocytes (Hashimoto et al., 1995) and in mouse embryonic 
fibroblasts (MEF) after binding to protein kinase C-α (PKC-α) (Lee et al., 2008). It is 
hypothesised that host cell proteins can be acquired by viruses through different mechanisms, 
such as positive selection caused by direct binding of the host protein to a viral protein in 
assembly and budding from the producer cell or through passive inclusion (for example 
tetraspannins) due to egress of the virus from sites expressing high levels of the protein (Ott, 
2008).  AHNAK could be packaged into vectors because of its localisation close to the vector 
assembly site at the plasma membrane.  
 
Further analysis of host cell proteins needs to be undertaken to fully understand why they are 
identified in some but not all vector samples. Certain host cell proteins might be associated 
with vectors due to interaction with a viral protein or purely due to their abundant presence at 
the budding site and are not influencing production of LVs for that reason. It is unclear why 
AHNAK was only found in STAR derived RDpro pseudotyped vectors but not in VSV-G 
pseudotyped vector samples produced by transient production from 293T. However, absence 
of AHNAK in purified transiently produced vector samples needs to be confirmed by western 
blot analysis in order to confidently rule-out its association with VSV-G Env. AHNAK might not 
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have been detected in VSV-G pseudotyped transiently produced samples by MS due to high 
abundance of other proteins in the sample that may have masked detection of low levels of 
AHNAK. 
Vector treatment with subtilisin has been used to eliminate host proteins that are not 
encapsulated within the particles (Segura et al., 2008) allowing the distinction between host 
proteins associated with the surface (or co-purified proteins) and vector incorporated proteins. 
Knock-down effects in other cell lines could also be investigated, for example T cell lines, as 
knock-down effects on vector production and infectivity could vary in different cell lines. 
Overexpression of host proteins in HIV-1 producer cells can lead to increased incorporation 
into virions due to its interaction with viral proteins or RNA. The latter has been shown for host 
cell protein Staufen. Higher incorporation levels of Staufen correlated with higher vector 
genome RNA levels in virions (Mouland et al., 2000). 
The analysis of the selected vector associated host cell proteins AHNAK, ALIX and TSG101 did 
not identify host proteins whose expression levels are directly influencing vector production by 
improving or decreasing vector titers when reduced. Before further study of other host 
proteins such as EFF1A, ENO1 and MARCKSL1 is undertaken, knock-down efficiency needs to 
be improved. This could be either achieved by using a higher MOI during producer cell 
transduction with GIPZ-LVs. Alternative shRNA vectors could be used such as pSIREN, encoding 
a shRNA driven from the human U6 small nuclear promoter which is a RNA polymerase III 
promoter of one of the human RNA polymerases driving RNA transcription.  
For complete elimination of protein expression knock-out methods can be used. During recent 
years naturally occurring DNA recognition codes have been engineered for example 
transcription activator-like effector nucleases (TALENs) (Boch et al., 2009) or clustered 
regularly interspaced short palindromic repeats (CRISRP) (Jinek et al., 2012). These systems can 
be used to induce double-strand breaks (DSB) in the DNA encoding the target protein. Through 
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cell induced repair of the DSB non-homologous end joining reconnects the DNA strands. This 
repair mechanism commonly induces errors leaving the expressed protein dysfunctional.  
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6. General Discussion 
Lentiviral Vectors are being used for the treatment of a range of monogenic disorders, such as 
neurological diseases and haematopoietic disorders. Recently started clinical trials replace 
gamma-retroviral vectors with LVs due to their safer integration profile into the host cell 
genome, their ability to transduce non-proliferating cells as well as their larger transgene 
capacity. In addition, a recent publication of the outcome of a clinical trial shows that LVs are 
also suitable for cancer immunotherapy treating patients with acute lymphoblastic leukaemia 
(ALL). These developments show that the demand for LV supply is increasing. Large scale 
lentiviral vector production for example in the form of a stable producer cell line is required. 
Generally, vector production would benefit from a better understanding of vector particle 
formation within the producer cells, specifically interactions between host and viral proteins 
during particle assembly and budding. In this thesis cellular proteins associated with LVs 
produced by a transient and stable production system were identified by mass spectrometry 
(MS) and compared. Furthermore the effect of expression levels of selected proteins on vector 
titers was analysed.  
Lentiviral vectors were prepared by the commonly used transient transfection method using 
VSV-G Env as well as by the packaging cell line STAR, continuously producing RDpro-
pseudotyped vectors. It was noted that the transduction titer of crude samples was 10 fold 
higher in transiently compared to stably prepared samples, confirming lower titers of STAR-
RDpro produced vectors compared to transiently produced VSV-G-vectors in previous 
publications (Ikeda et al., 2003, Strang et al., 2004, Bell et al., 2010). Increasing the 
concentration factor of RDpro-vectors six fold compared to VSV-G-vectors resulted in a 
comparable number of physical particles in purified samples produced by both methods for 
cellular protein analysis. 
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6.1. Discussion of Vector Purification 
Size exclusion chromatography applying sephacryl 500-HR medium effectively purifies LV. It 
was shown that dominant proteins in purified samples are viral proteins and that viral vectors 
are separated from smaller, non-associated proteins. One limitation of this method was the 
relatively low recovery of infectious particles suggesting that TEN buffer may be affecting 
vector infectivity. An alternative elution buffer such as PBS or cell culture medium could 
increase recovery of infectious particles. Serum free Cell Gro® medium has been used as the 
buffer in size exclusion chromatography in vector preparation in a recently published clinical 
trial report (Aiuti et al., 2013). The use of TEN buffer is however suitable for the purpose of 
vector purification for a comparative MS analysis of vector particles. 
The study presented here shows that SEC can be applied for small scale vector preparation in 
the context of in vitro research experiments and has been used in protocols in small scale 
clinical trials for vector purification (Levine et al., 2006). Anion-exchange chromatography 
(AEx), through resin or a membrane, has been used to purify HIV-1 derived (Schweizer and 
Merten, 2010, Merten et al., 2011, Aiuti et al., 2013, Biffi et al., 2013) and EIAV derived LVs 
(Stewart et al., 2010) in clinical trials and could be used to purify vector particles for a  
comparative analysis with SEC purified samples. 
Purified VSV-G containing samples in this study could potentially contain tubulovesicular 
structures whose presence has been reported in sucrose-gradient concentrated LVs 
pseudotyped with VSV-G (Pichlmair et al., 2007). Proteins eluting in the void peak during SEC 
of VSV-G-only showed that this control sample, free of viral proteins, potentially contains 
protein complexes of similar size to vector particles, such as microvesicles. Their presence in 
purified VSV-G vector samples produced in this study would need to be confirmed for example 
by electron microscopy (Pichlmair et al., 2007). An additional control sample of VSV-G vectors 
treated with a protease, such as subtilisin, could be included in the mass spectrometry analysis 
to identify cellular proteins inside vector particles.  
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Lentiviral vectors purification from producer cell derived proteins in cell supernatants can 
reduce cytotoxicity and increases transduction efficiency. Current protocols used for vector 
production in clinical trials include steps that eliminate contaminants including DNA, derived 
from transfected DNA plasmids or lysed producer cells, using benzonase (Sastry et al., 2004) as 
well as purification steps such as anion-exchange chromatography for the removal of serum 
proteins derived from cell culture medium or proteins derived from producer cells (Yamada et 
al., 2003). However these methods are not able to remove potentially present impurities that 
have similar physical properties to those of vector particles. Anion-exchange chromatography 
is used to separate vector particles from impurities based on the negative charge of vectors 
binding to the positively charged chromatographic supports such as diethylaminoethanol 
(DEAE) anion-exchangers (Merten et al., 2011, Aiuti et al., 2013, Biffi et al., 2013), suggesting 
that protein complexes of similar charge could co-purify with vectors during AExc. Electron 
microscopy can be performed (Transfiguracion et al., 2003, Pichlmair et al., 2007) to visualise 
the presence of potential microvesicles in purified vectors. To analyse if specific proteins are 
located on the surface or inside purified vector particles, immunogold staining of vectors can 
be used (Segura et al., 2008).  
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6.2. Discussion of MS results and Identified Protein Functions 
Vector samples of transiently produced VSV-G-vectors and stably-produced RD-vectors were 
prepared for mass spectrometry (MS) analysis. The protein composition of comparable 
numbers of viral particles based on p24 levels was analysed in several sets of each vector 
sample as well as controls as described in chapter 4.  
The aim of this study was the identification of any true differences in vector associated host 
proteins among vector samples which can only be ensured if possible co-purification of 
comparable sized proteins or protein aggregates is excluded as they could be identified as 
false-positive vector associated proteins. The most striking difference was that STAR-RDpro-
produced vectors contained substantially fewer protein species than transiently prepared VSV-
G pseudotypes, hence in comparison stably produced RDpro pseudotyped vectors are of 
higher purity. Less different cellular proteins than in VSV-G pseudotyped vectors were also 
detected in envelope free Gag-Pol samples similar to RDpro-pseudotyped stably produced 
samples. In the samples analysed here detected cellular proteins that are exclusive to SEC-
purified samples containing VSV-G protein could be derived from potential VSV-G vesicles of 
similar size to vectors that could have co-eluted in the SEC void peak fraction as they have 
been shown to be present in VSV-G pseudotyped lentiviral vectors (Pichlmair et al., 2007).  The 
results presented here suggest that vesicles closely related in size to vectors are present at 
much lower levels or not at all in SEC-purified vectors pseudotyped with the gammaretroviral 
envelope RDpro. Proteins of VSV-G vesicles could be eliminated by protease digest for example 
using subtilisin, of vectors which has been used for protein digestion on the surface but not 
inside the HIV-1 virions (Ott et al., 1995) followed by sucrose-gradient centrifugation 
microvesicles in vector particle samples were reduced (Ott et al., 1996). Comparing the protein 
composition of transiently produced protease-treated VSV-G vector samples with untreated 
vectors could discriminate co-purifying, VSV-G vesicle derived, cellular proteins or proteins 
associated to the vector surface from vector incorporated proteins. In order to analyse if 
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differences in cellular protein composition are due to differences due to the packaging system 
used or due to the envelope protein of vectors MS analysis of SEC-purified vectors 
pseudotyped with other envelope proteins such as amphotropic murine leukaemia virus (MLV-
A) Env, modified gibbon ape leukaemia virus Env (GALV+) or Rabies virus glycoprotein (RVG) 
would be interesting. Finally, a complete comparison would include the MS analysis of 
transiently produced RDpro-pseudotypes.  
The predominant functions of MS-identified cellular proteins are cytoskeleton organisation, 
vesicular transport but also cell death. Some of the identified proteins are known to assist in 
trafficking of viral proteins to assembly site for example actin, tubulin as well as budding from 
cell for example ALIX, clathrin. This shows that other proteins we detected, such as MARCKSL1 
and ENO1, that have not been shown to function in HIV-1 assembly, could be associated with 
purified vectors due to a role in vector assembly and budding. The presence of proteins 
functioning in necrosis and apoptosis could be due to induced stress of vector production in 
the cells. Many of the proteins, such as proteins of the cytoskeleton or cytoskeleton regulators 
as well as proteins associated with vesicular trafficking and transmembrane proteins, that 
were identified in our study have been found in mass spectrometry analysis of various sucrose 
gradient purified enveloped viruses in other publications (Chertova et al., 2006, Zhu et al., 
2005, Varnum et al., 2004, Johannsen et al., 2004, Shaw et al., 2008, Moerdyk-Schauwecker et 
al., 2009) suggesting similarities in assembly and budding processes of different enveloped 
viruses resulting in the association of similar cellular proteins, for example secretory pathway 
trafficking of envelope proteins. Overlapping MS-results of our study with a study on HIV-1 
virions produced in a different cell type, MDMs, compared to 293T cells used here, suggests 
that at least a subset of these host cell proteins is not randomly incorporated (Chertova et al., 
2006). Analysis of vector titers after reducing gene expression levels of these proteins could 
elucidate which of them affect vector formation.   
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Generally, results of this study show that MS analysis is a suitable method for characterisation 
of viral vectors and could be applied for the comparison of other vector designs. 
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6.3. Discussion of Protein Knock-Down 
Specific proteins that had been identified by mass spectrometry were selected for further 
analysis by knock down of gene expression in producer cells. Out of the selected proteins 
efficient knock-down was achieved for AHNAK, ALIX and TSG101 expression in STAR-RDpro as 
well as 293T cells. Analysis of vectors produced in cells after knock-down of expression of ALIX, 
AHNAK or TSG101 showed that infectious titers as well as physical titers of vectors were 
comparable to cells in which gene expression was not knocked-down; hence reduced protein 
levels did not have a measurable effect on LV production. One explanation could be that these 
cellular proteins do not influence LV assembly or budding in producer cells. Depletion of ALIX 
in HIV-1 infected cells by siRNA resulted only in a titer reduction of approximately 5 fold  
compared to about 15 fold reduction in titer after knock-down of ALIX in EIAV infected cells 
(Martin-Serrano et al., 2003). ALIX may only play a minor role in HIV-1 budding and may be 
more important in EIAV budding.  
Infectivity of HIV-1 was significantly reduced after siRNA depletion of TSG101 in HIV-1 
producing 293T cells (Garrus et al., 2001, Martin-Serrano et al., 2003). Martin-Serrano et al. 
(2003) did not specify the level of knock-down of TSG101 expression they achieved when using 
siRNA. Garrus et al. (2001), however, optimised their knock-down system by transfecting siRNA 
twice at 24 hours intervals to achieve almost complete depletion of protein expression as they 
could only detect traces of TSG101 proteins in cell lysates by Western blotting after an 
additional 24 hours. Increasing the efficiency of TSG101 knock-down in 293T or STAR-RDpro 
cells used in our study could potentially result in a better knock-down reducing residual 
TSG101 mRNA levels. For complete elimination of a specific protein, gene expression can be 
knocked out by using sequence specific nucleases such as transcription activator-like effector 
nucleases (TALENs) (Boch et al., 2009), clustered regularly interspaced short palindromic 
repeats (CRISRP) (Jinek et al., 2012) or zinc finger nucleases (ZFNs) which can be delivered by 
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viral vectors or directly by transfection (Gaj et al., 2012), disrupting gene expression or 
resulting in dysfunctional protein expression.  
Both Garrus (et al. 2001) and Martin-Serrano (et al. 2003) were studying knock-down effects in 
wild type HIV-1 with the gp120 envelope protein. Knock-down of ALIX and TSG101 could 
potentially affect assembly and budding of VSV-G and RDpro-pseudotypes differently 
compared to wild type HIV-1 virions with the gp120 envelope protein. Both, ALIX and TSG101 
bind HIV-1 Gag L-domains suggesting that they recruit the viral protein to the assembly side 
suggesting that binding of ALIX to p6-Gag compensates for any functional loss regarding virus 
release when TSG101 expression levels are reduced. This could also be the case vice versa. 
TSG101 could compensate for  ALIX in ALIX knock-down cells vector particle budding. 
AHNAK could be a potential host factor during HIV-1 entry as its knock-down in CD4+ T cells 
reduced HIV-1 ability to infect these cells (Wojcechowskyj et al., 2013), but apart from this 
study AHNAK has not been associated with retroviral replication or detected in 293T-produced 
LV particles. AHNAK could associate with vector particles due to its location at the plasma 
membrane, hence close location to the assembly site. Why AHNAK was only detected in STAR 
cells is unknown, as cell lines, 293T as well as STAR cells express similar levels of AHNAK. It 
could specifically associate with RDpro Env. To investigate this possibility, an additional vector 
sample, transiently produced RDpro-pseudotyped vectors, would need to be included in this 
study. 
RNAi screens in producer cells can be carried out for analysing the influence of cellular protein 
expression on vector production as presented by Zhou et al. (2008) for HIV-1 viruses. These 
RNAi screens could be applied for investigation of the involvement of cellular proteins in 
vector assembly and budding by investigating the transduction ability of vectors produced in 
knock-down producer cells.  
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6.4. Concluding Remarks  
In conclusion, this project has characterised the cellular protein composition of SEC-purified 
LVs stably produced from the STAR cells pseudotyped with RDpro envelope and from 
transiently produced from 293T cells pseudotyped with VSV-G. Vector particles from both 
production systems were purified and directly compared regarding their cellular protein 
composition. Stably produced RDpro-pseudotyped vectors contained substantially less cellular 
proteins than transiently produced VSV-G pseudotyped vectors. Overall, mass spectrometry 
detected proteins include proteins, such as actin, tubulin, ALIX and clathrin that are known to 
function in HIV-1 virion assembly and budding. The characterisation of the identified cellular 
proteins, potentially associated with vectors through their interaction with viral proteins, 
provides a starting point for further studies on vector particle formation within the producer 
cells, specifically at the stages of vector assembly and budding. 
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7. Future Work 
The following aspects can be included in future experiments: 
Vector Samples. A transiently produced RDpro-pseudotyped vector sample should be included 
to distinguish proteins associated with the envelope protein from proteins that are associated 
with the viral core. This additional sample would also allow determining if, like in stably 
produced RDpro-pseudotypes, less host proteins are associated with transiently RDpro-
pseudotypes compared to VSV-G pseudotyped vector samples. Further control samples, such 
as harvests from untransfected 293T cells or from cells transfected with DNA plasmids devoid 
of HIV-1 or VSV-G sequences, can be included. To prevent contamination with bovine proteins, 
vectors could be produced in serum free medium; replacing complete DMEM 24 hours post-
transfection (see section 2.3.1). 
Vector Purification. For the removal of non-viral membrane vesicles and other potential 
impurities closely related to the size and shape of functional LVs, rate zonal ultracentrifugation 
using iodixanol, a density gradient medium, could be employed (Segura et al., 2006a). An 
alternative or additional vector purification method can be tested, such as anion-exchange 
chromatography (AExc) which has been used to purify vector samples for their use in clinical 
trials. AExc could then be followed by SEC to remove smaller proteins that are of similar charge 
to vector particles. During SEC, an alternative buffer could be used such as PBS or serum free 
cell culture medium, similar to the gel filtration step in vector preparation for clinical trials 
(Aiuti et al., 2013).  
Vector Sample Protein Analysis. For a complete analysis by MS, the same conditions of data 
acquisition should be used for all vector samples, such as the rejection method of transiently 
produced samples as well as setting the threshold to the same minimum of peptides that is 
required for the confident detection of a protein (see section 2.3.3.2.). This would potentially 
detect low abundance peptides in VSV-G pseudotypes that were not detected using the 
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normal acquisition method, allowing a more accurate estimation of the number of proteins 
detected in VSV-G-pseudotypes compared to RDpro-pseudotypes. 
Purified vector particles could be visualised by electron microscopy of crude and purified 
vector particles in order to assess if any contaminating vesicles are present (Transfiguracion et 
al., 2003, Pichlmair et al., 2007). Subtilisin treatment of vector samples has been used to 
eliminate host proteins that are on the surface of vector particles (or co-purified along vector 
samples) (Segura et al., 2008) allowing the distinction between vector encapsulated host 
proteins. Alternatively the localisation of a host protein either on the surface or inside of 
purified vector particles can be investigated using immunogold staining of vectors (Segura et 
al., 2008). A co-immunoprecipitation assay of cell lysates might allow identifying interactions 
of host and viral proteins. 
Analysis of Effect of Expression Levels of Specific Host Proteins on Vector Titers. TSG101 and 
ALIX might need to be knocked-down simultaneously to achieve reduced vector release from 
producer cells as they are binding different L-domains, PTAP (Garrus et al., 2001) and YPXL 
(Strack et al., 2003), respectively. An increase in knock-down efficiency might be necessary 
which could be achieved by using a higher dose of shRNA, by transducing producer cells with 
GIPZ-LVs at a higher MOI. In addition, for increased knock-down efficiency, an alternative 
shRNA vector could be tested such as pSIREN, encoding a shRNA driven from a promoter of a 
human RNA polymerase. Alternatively knock-out techniques could be used such as CRIPRS or 
TALENs (see section 5.4.). 
The knock-down effect on vector production of other proteins that are common to all vector 
samples and are less well characterised in terms of viral vector assembly, should be 
investigated next, including EEF1A, MARCKSL1 and ENO1 (see Table 15). On the other hand 
overexpression of candidate host cell proteins might allow the identification of proteins that 
increase vector titers and hence could be beneficial for vector production and to further study 
their effect on vector assembly and budding. 
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